NZ624945B2 - Uracil derivatives as axl and c-met kinase inhibitors - Google Patents
Uracil derivatives as axl and c-met kinase inhibitors Download PDFInfo
- Publication number
- NZ624945B2 NZ624945B2 NZ624945A NZ62494512A NZ624945B2 NZ 624945 B2 NZ624945 B2 NZ 624945B2 NZ 624945 A NZ624945 A NZ 624945A NZ 62494512 A NZ62494512 A NZ 62494512A NZ 624945 B2 NZ624945 B2 NZ 624945B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- lcms
- acid
- nmr
- dioxo
- dmso
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Provided are uracil derivative compounds of the general formula I, where the variables are as defined in the specification. Examples of the compounds include 1-Ethyl-3-( 4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylicacid [4-(6,7-dimethoxyquinolin-4-yloxy)-3-fluorophenyl]amide and 4-(4-Fluoro-phenyl)-2-isopropyl-3,S-dioxo-2,3,4,S-tetrahydro-1,2,4-triazine-6-carboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methoxy-phenyl]-amide. The compounds are AXL and c-MET inhibitors. The compounds may be useful in the treatment of cancer. d 4-(4-Fluoro-phenyl)-2-isopropyl-3,S-dioxo-2,3,4,S-tetrahydro-1,2,4-triazine-6-carboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-2-methoxy-phenyl]-amide. The compounds are AXL and c-MET inhibitors. The compounds may be useful in the treatment of cancer.
Description
URACIL DERIVATIVES AS AXL AND
C-MET KINASE INHIBITORS
BACKGROUND OF THE INVENTION
The present invention relates to novel compounds that are inhibitors of the receptor
ne kinases AXL and c-MET. The compounds are suitable for treatment ofAXL or c-
MET-mediated disorders such as cancer, and the development of resistance to cancer
therapies.
Receptor tyrosine kinases (RTKs) are transmembrane proteins that transduce
signals from the extracellular environment to the cytoplasm and nucleus to regulate
normal cellular processes, including survival, growth, differentiation, adhesion, and
mobility. Abnormal expression or activation of RTKs has been implicated in the
pathogenesis of various human cancers, linked with cell ormation, tumor formation
and asis. These ations have led to intense interest in the development of
tyrosine kinase inhibitors as cancer therapeutics (Rosti et al, Crit. Rev. Oncol. Hematol.
2011. [Epub ahead of print]; Gorden et al, J. Oncol. Pharm. Pract. 2011. [Epub ahead of
print]; Grande et al, Mol. Cancer Ther. 2011, 10, 569).
AXL is a member of the TAM (TYRO3, AXL, MER) receptor ne kinase
(RTK) family originally identified as a transforming gene expressed in cells from patients
with chronic myelogenous leukemia (O'Bryan et. al Mol. Cell Biol. 1991, 11, 5016) or
chronic myeloproliferative disorder en et. al ne, 1991, 6, 2113). AXL
activation occurs by g of its cognate protein ligand, growth arrest specific 6 (Gas6),
homotypic dimerization through its extracellular domain or cross-talk via the interleukin
(IL)-15 receptor or HER2. AXL signaling stimulates cellular ses, including
activation phoinositide 3-kinase—Akt, extracellular signal-regulated kinase (ERK)
and p38 mitogen-activated protein kinase cascades, the NF-KB pathway, and signal
transducer and activator of transcription (STAT) signaling (Hafizi et. al Cytokine Growth
Factor Rev., 2006, 17, 295). Numerous biological consequences ofAXL signaling,
including invasion, migration, survival signaling, angiogenesis, resistance to
chemotherapeutic and targeted drugs, cell transformation, and proliferation, represent
rable traits associated with cancer (Linger et al. Adv. Cancer Res., 2008, 100, 35;
Hafizi et. al Cytokine Growth Factor Rev., 2006, 17, 295; Holland et al, Cancer Res. 2005,
65, 9294).
AXL receptors regulate vascular smooth muscle homeostasis (Korshunov et al,
Circ. Res. 2006, 98, 1446) and are implicated in the control of oligodendrocyte cell
survival (Shankar et al, J. Neurosci. 2003, 23, 4208). Studies in knockout mice have
revealed that TAM ors play pivotal roles in innate immunity by inhibiting
inflammation in macrophages and dendritic cells (Sharif et al, J. Exp. Med. 2006, 203,
1891; Rothlin et al, Cell. 2007, 131, 1124), promoting the phagocytosis of apoptotic cells
(Lu et al, Nature. 1999, 398, 723; Lu & Lemke, Science. 2001, 293, 306; Prasad et al,
Mol. Cell Neurosci. 2006, 3, 96) and stimulating the differentiation of natural killer cells
(Park et al, Blood 2009, 113, 2470).
AXL has been found to be constitutively activated due to gene amplification
and/or altered protein expression (O’Bryan et al, J. Biol. Chem. 1995, 270, 551; Linger et
al, Expert Opin. Ther. Targets. 2010, 14, 1073; Mudduluru et al, Oncogene, 2011, 30,
2888). Altered expression ofAXL has been reported in a variety of human cancers
(Crosier et al, Leuk. ma. 1995, 18, 443; Challier et al, ia, 1996, 10, 781;
Ito et al, d. 1999, 9, 563; Sun et al, Oncology. 2004, 66, 450; Green et al, Br. J.
Cancer. 2006, 94, 1446; Liu et al, Blood. 2010, 116, 297) and is associated with
invasiveness and metastasis in lung cancer (Shieh et al, Neoplasia. 2005, 7, 1058), prostate
cancer (Shiozawa et al, Neoplasia. 2010, 12, 116), breast cancer (Zhang et al, Cancer Res.
2008, 68, 1905), geal cancer (Hector et al, Cancer Biol. Ther. 2010, 10, 1009),
ovarian cancer (Rankin et al, Cancer Res. 2010, 70, 7570), pancreatic cancer (Koorstra et
al, Cancer Biol. Ther. 2009, 8, 618; Song et al, Cancer, 2011, 117, 734), liver cancer (He
et al, Mol. Carcinog. 2010, 49, 882), gastric cancer (Wu et al, Anticancer Res. 2002, 22,
1071; Sawabu et al, Mol Carcinog. 2007, 46, 155), thyroid cancer (Avilla et al, Cancer
Res. 2011, 71, 1792), renal cell oma (Chung et al, DNA Cell Biol. 2003, 22, 533;
Gustafsson et al, Clin. Cancer Res. 2009, 15, 4742) and glioblastoma (Hutterer et al, Clin.
Cancer Res. 2008, 14, 130).
Indeed, AXL overexpression is associated with late stage and poor l survival
in many of those human s (Rochlitz et al, Leukemia, 1999, 13, 1352; Vajkoczy et al,
Proc Natl. Acad. Sci.. 2006, 103, 5799). AXL contributes to at least three of the six
fundamental mechanisms of malignancy in human, by promoting cancer cell migration
and invasion, involving in tumor angiogenesis, and facilitating cancer cell survival and
tumor growth (Holland et al, Cancer Res. 2005, 65, 9294; Tai et al, Oncogene. 2008, 27,
4044; Li et al, Oncogene, 2009, 28, 3442; Mudduluru et al, Mol. Cancer Res. 2010, 8,
159). AXL is strongly induced by epithelial-to-mesenchymal transitions (EMT) in
immortalized mammary epithelial cells and AXL knockdown completely prevented the
spread of highly metastatic breast carcinoma cells from the mammary gland to lymph
nodes and l major organs and increases overall survival rum et al, Proc. Natl.
Acad. Sci. U S A. 2010, 107, 1124; Vuoriluoto et al, Oncogene. 2011, 30, 1436),
indicating AXL represents a critical downstream effector of tumor cell EMT requiring for
cancer metastasis.
AXL is also induced during progression of resistance to therapies including
imatinib in intestinal stromal tumors (Mahadevan et al, Oncogene. 2007, 26, 3909)
and Herceptin and EGFR inhibitor therapy (e.g. lapatinib) in breast cancer (Liu et al,
Cancer Res. 2009, 69, 6871) via a “tyrosine kinase switch”, and after chemotherapy in
acute myeloid leukemia (Hong et al, Cancer Lett. 2008, 268, 314). AXL knockdown was
also reported to lead to a significant increase in chemosensitivity of astrocytoma cells in
response to herapy treatment (Keating et al, Mol. Cancer Ther. 2010, 9, 1298).
These data te AXL as an important mediator for tumor resistance to conventional
chemotherapy and molecular-based cancer therapeutics.
The c-MET receptor was initially identified as the TPR—MET oncogene in an
osteosarcoma cell line treated with a chemical carcinogen. The TPR—Met protein is able to
orm and confer invasive and metastatic ties to non-tumorigenic cells (Sattler
et. al, Current Oncology Rep., 2007, 9, 102). The oncogenic potential is a result of
spontaneous dimerization and constitutive activation of TPR—MET. Aberrant expression
ofHGF and c-MET is associated with the development and poor prognosis of a wide
range of solid tumors, ing , prostate, thyroid, lung, stomach, colorectal,
pancreatic, kidney, ovarian, and e carcinoma, malignant glioma, uveal ma,
and osteo-and soft-tissue sarcoma (Jaing et. al Critical Rev. Oncol/Hematol., 2005, 53,
). Gastric tumors with an amplification of the wt-c-MET gene are more susceptible to
MET tion, thereby making c-MET an attractive target (Smolen et. al Proc. Natl.
Acad. Sci. USA, 2006, 103, 2316).
In vitro and in vivo s have shown that increased and ulated c-MET
activation leads to a wide range of biological responses associated with the malignant
phenotype. These responses include increased motility/invasion, increased tumorigenicity,
enhanced angiogenesis, protection of carcinoma cells from apoptosis induced by DNA-
damaging agents such as adriamycin, iolet light, and ionizing radiation, and
enhanced rate of repair ofDNA strand breaks [Comoglio et. al J. Clin. Invest., 2002, 109,
857, Sattler et. al Current gy Rep., 2007, 9, 102; Fan et. al, Mol. Cell Biol., 2001,
21, 4968). Based upon these data, HGF may enhance mutagenicity following DNA
damage, ng tumor cells with genetic damage to survive, and thus leading to
resistance to chemo- and radiotherapeutic treatment regimens (Fan et. al, Mol. Cell Biol.,
2001, 21, 4968; Hiscox et. al Endocrine-Related Cancer, 2004, 13, 1085).
MET amplification plays a unique critical role in mediating resistance of non-small
cell lung cancer to EGFR inhibitors (e.g. TarcevaTM, TM the resistance of
, TykerbTM)
HER2 positive breast cancer to trastuzumab (Sattler et. al, Update Cancer Ther., 2009, 3,
109; Engleman et. al, Science, 2007, 316, 1039, Shattuck et. al Cancer Res., 2008, 68,
1471, Agarwal et. al, Br. J. Cancer, 2009, 100, 941; Kubo et. al, Int. J. Cancer 2009, 124,
1778). Inhibition of c-MET in TarcevaTM or IressaTM resistant cells using shRNA or small
molecules alone or in combination with an EGFR inhibitor overcame diated
ance to EGFR inhibitors [Agarwal et. al, Br. J. Cancer, 2009, 100, 941; Bachleitner-
Hoffman et. al, Mol. Cancer Ther., 2008, 7, 3499, Tang et. al, Br. J. Cancer, 2008, 99,
911; Bean et. al, Proc. Natl. Acad. Sci. USA, 2007, 104, 20932). Due to the pleiotropic,
pro-tumorigenic activities of the HGF-c-MET axis, inhibiting this pathway would be
predicted to have potent anti-tumor effects in many common cancers through multiple
complimentary mechanisms.
A need exists for AXL and c-MET inhibitors for use as pharmaceutical agents.
SUMMARY OF THE INVENTION
The present ion provides a compound of Formula I
a. T3 x/“YO
R1b /
\IY NWME Rd o o
R161
Rb N
Formula I
or a pharmaceutically acceptable salt form thereof, wherein Ra, Rb, RC, Rd, D, W, Y, Rla,
Rlb, R10, R3, X, G and E are as defined herein.
The compound of Formula I has AXL and c-MET inhibitory activity, and may be
used to treat AXL-, or c-MET- ed ers or ions.
The present ion fiarther provides a pharmaceutical composition comprising at
least one compound of the present invention together with at least one pharmaceutically
able carrier, diluent, or excipient therefor.
In another aspect, the present ion provides a method of treating a subject
suffering from an AXL- or c-MET- mediated disorder or condition comprising
administering to the subject a therapeutically effective amount the pharmaceutical
composition of the t invention.
The present invention fiarther provides a method of treating a proliferative disorder
in a subject, comprising administering to the subject a therapeutically effective amount of
a compound of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
As used herein, the following terms have the meanings ascribed to them unless
specified otherwise.
“Alkylamino” or an “alkylamino group” refers to an —NH-alkyl group.
“Alkoxy” or “alkoxy group” refers to an —O-alkyl group.
ycarbonyl” refers to an all<yl-O-C(=O)- group.
"Alkyl" or “alkyl group” refers to a branched or unbranched saturated arbon
chain. Examples include, but are not limited to, , ethyl, n-propyl, l, n-pentyl,
n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, isopropyl, tert-butyl, isobutyl, etc. Alkyl
groups typically contain l-lO carbon atoms, such as 1-6 carbon atoms.
“Substituted alkyl” tes that one or more hydrogen atoms on an alkyl group
has been replaced with a different atom or group of atoms and the atom or group of atoms
replacing the hydrogen atom is a “substituent”. Representative substituents include, but
are not limited to, halogen, (C1-C8)alkyl, (Cl-Cg)alkoxy, (Cl-Cg)alkoxy(C1-C4)alkyl,
carboxyl, formyl, (C1-C6)acyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy, hydroxyl, nitro, cyano,
amino, trifluoromethyl, mono- or di-(C1-C6)alkylamino, oxo, (C6-C10)aryl, (C5-
C9)heteroaryl, (C1-C6)alkoxycarbonyl, (Cg-Clo)cycloalkyl, (Cg-Clo)cycloalkyloxy, (C3-
cloalkyl(C1-C6)alkoxy, (C2-C9)heterocyclyl, (C2-C9)heterocyclyloxy, (C2-
C9)heterocyclyl(C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(C1-C4)alkyl, (C1-C6)alkoxycarbonyl,
(C1-C6)alkylsulf1nyl, (C1-C6)alkylsulfonyl, mono- and di-(C1-C6)alkylaminocarbonyl, (C1-
C6)acylthio, and (C1-C6)acyloxy.
“Alkenyl” refers to an alkyl group containing the requisite number of carbon atoms
as described herein for “alkyl”, and which contains at least one double bond. Representative
examples of alkenyl groups include, but are not limited to l, allyl, isopropenyl, and 2-
methyl- 1 nyl.
“Substituted l” indicates that one or more hydrogen atoms on an alkenyl group
has been replaced with a different atom or group of atoms and the and the atom or group of
atoms replacing the hydrogen atom is a “substituent”. Representative substituents include,
but are not limited to, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, )alkoxy(C1-C4)alkyl,
carboxyl, formyl, (C1-C6)acyl, halo(C1-C4)alkyl, 1-C4)alkoxy, hydroxyl, nitro, cyano,
amino, trifluoromethyl, mono- or di-(C1-C6)alkylamino, oxo, (C6-C10)aryl, (C5-
C9)heteroaryl, (C1-C6)alkoxycarbonyl, (Cg-C10)cycloalkyl, (Cg-C10)cycloalkyloxy, (C3-
C10)cycloalkyl(C1-C6)alkoxy, (C2-C9)heterocyclyl, (C2-C9)heterocyclyloxy, (C2-
C9)heterocyclyl(C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(C1-C4)alkyl, (C1-C6)alkoxycarbonyl,
)alkylsulf1nyl, (C1-C6)alkylsulfonyl, mono- and di-(C1-C6)alkylaminocarbonyl, (C1-
C6)acylthio, and (C1-C6)acyloxy.
“Alkynyl” refers to an alkyl group containing the requisite number of carbon atoms
as described herein for “alkyl”, and which ns at least one triple bond. Representative
examples of alkenyl groups include, but are not limited to l, propargyl, and l- and 2-
“Substituted alkynyl” indicates that one or more hydrogen atoms on an alkynyl
group has been replaced with a different atom or group of atoms and the and the atom or
group of atoms replacing the hydrogen atom is a “substituent”. Representative tuents
include, but are not limited to, halogen, (Cl-Cg)alkyl, (C1-C8)alkoxy, (C1-C8)alkoxy(C1-
C4)alkyl, yl, formyl, (C1-C6)acyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy, hydroxyl,
nitro, cyano, amino, trifluoromethyl, mono- or di-(Cl-C6)alkylamino, oxo, (C6-C10)aryl, (C5-
C9)heteroaryl, (C1-C6)alkoxycarbonyl, (Cg-C10)cycloalkyl, (Cg-C10)cycloalkyloxy, (C3-
C10)cycloalkyl(C1-C6)alkoxy, (C2-C9)heterocyclyl, (C2-C9)heterocyclyloxy, (C2-
C9)heterocyclyl(C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(C1-C4)alkyl, (C1-C6)alkoxycarbonyl,
(C1-C6)alkylsulf1nyl, (C1-C6)alkylsulfonyl, mono- and di-(C1-C6)alkylaminocarbonyl, (C1-
C6)acylthio, and (C1-C6)acyloxy.
“Alkanoyl” refers to an C(=O)— group.
The term “CH” indicates the number of carbon atoms in a group. For example, a
“C1_6-alkyl” is an alkyl group haVing from one (1) to six (6) carbon atoms.
The term “cyano” refers to a CN group.
“Cycloalkyl” refers to a non-aromatic, saturated carbocyclic ring system, and may
be monocyclic, bicyclic or tricyclic, and may be bridged, spiro and/or fiJsed. Preferably
the cycloalkyl group contains from 3 to 10 ring atoms. Examples include, but are not
limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and norbomyl.
“Cycloalkoxyalkyl” refers to a cycloalkyl-O-alkyl- group.
“Cycloalkylalkyl” refers to a lkyl-alkyl- group.
“Carbamoyl” refers to a NH2C(=O)- group.
“N-alkylcarbamoyl” or “alkyl carbamoyl” refers to an alkyl-NH-C(=O)— group.
“N,N—dialkylcarbamoyl” or “dialkylcarbamoyl” refers to an (alkyl)(alkyl)N—
C(=O)- group. On such a group the alkyl groups may be the same or different.
“Aryl” or “aryl group” refers to phenyl and 7-15 membered monoradical bicyclic
or tricyclic hydrocarbon ring systems, ing bridged, spiro, and/or fused ring s,
in which at least one of the rings is aromatic. Aryl groups can be substituted or
unsubstituted. Examples include, but are not limited to, phenyl, naphthyl, indanyl, l,2,3,4-
ydronaphthalenyl, 9-tetrahydro-5H-benzocycloheptenyl, and 6,7,8,9-
tetrahydro-5H-benzocycloheptenyl. Preferably, the aryl group contains 6 (i.e., phenyl) or
9 to 15 ring atoms. More preferably, the aryl group contains 6 (i.e., phenyl), 9 or 10 ring
atoms.
“Substituted aryl indicates that one or more hydrogen atoms on an aryl group has
been replaced with a different atom or group of atoms and the and the atom or group of
atoms replacing the hydrogen atom is a ituent”. Representative substituents include,
but are not d to, halogen, (C1-C8)alkyl, (C1-C8)alkoxy, (Cl-Cg)alkoxy(C1-C4)alkyl,
carboxyl, formyl, (C1-C6)acyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy, hydroxyl, nitro, cyano,
amino, romethyl, mono- or -C6)alkylamino, oxo, (C6-C10)aryl, (C5-
C9)heteroaryl, (C1-C6)alkoxycarbonyl, (Cg-C10)cycloalkyl, (Cg-C10)cycloalkyloxy, (C3-
C10)cycloalkyl(C1-C6)alkoxy, (C2-C9)heterocyclyl, (C2-C9)heterocyclyloxy, (C2-
C9)heterocyclyl(C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(C1-C4)alkyl, (C1-C6)alkoxycarbonyl,
(C1-C6)alkylsulf1nyl, (C1-C6)alkylsulfonyl, mono- and di-(C1-C6)alkylaminocarbonyl, (C1-
C6)acylthio, and (C1-C6)acyloxy.
“Arylalkyl” refers to an lkyl- group.
“Arylalkoxy” refers to an aryl-alkyl-O- group.
“Arylalkoxyalkyl” refers to an aryl-alkyl-O-alkyl- group.
“Aryloxy” refers to an aryl-O- group.
“Heterocyclyl” or “heterocyclyl group” refers to 3-15 membered monocyclic,
bicyclic, and lic non-aromatic rings, which may be saturated or unsaturated, can be
substituted or unsubstituted, may be d, spiro, and/or fused, and which contain, in
addition to carbon ), at least one heteroatom, such as nitrogen, oxygen or sulfilr.
Examples include, but are not limited to, tetrahydrofuranyl, pyrrolidinyl, pyrrolinyl,
imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl,
isoindolinyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidyl,
homopiperazinyl, thiomorpholinyl, ydropyranyl, piperidinyl, tetrahydrothienyl,
homopiperidinyl, oxazolidinonyl, dihydropyrazolyl, opyrrolyl, dihydropyrazinyl,
dihydropyridinyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, quinuclidinyl, 2-oxa-
-azabicyclo[2.2. l]heptane, 8-oxaaza-bicyclo[3 .2. l ]octane, 3 ,8-diazabicyclo
[3.2. l]octane, 2,5-diaza-bicyclo[2.2. l]heptane, 3,8-diaza-bicyclo[3.2.l]octane, 3,9-
diaza-bicyclo[4.2. l]nonane and 2,6-diaza-bicyclo[3.2.2]nonane. Preferably, the
heterocyclyl group contains from 3 to 10 ring atoms. More preferably, the heterocycyl
group contains from 3 to 7 ring atoms. More preferably, the heterocyclyl group contains
from 5 to 7 ring atoms, such as 5 ring atoms, 6 ring atoms, or 7 ring atoms. Unless
otherwise indicated, the ing heterocyclyl groups can be C- attached or N-attached
where such is possible and results in the creation of a stable structure. For example,
piperidinyl can be piperidin-l-yl (N-attached) or piperidinyl (C-attached). A
heterocyclyl group can also include ring systems substituted on ring carbons with one or
more —OH functional groups (which may fiarther tautomerize to give a ring C=O group)
and/or substituted on a ring sulfur atom by one (1) or two (2) oxygen atoms to give S=O or
802 groups, tively.
“Substituted heterocyclyl” indicates that one or more hydrogen atoms on a
heterocyclyl group has been replaced with a different atom or group of atoms and the and
the atom or group of atoms replacing the hydrogen atom is a ituent”. entative
substituents include, but are not limited to, n, (C1-C8)alkyl, )alkoxy, (C1-
oxy(C1-C4)alkyl, carboxyl, formyl, (C1-C6)acyl, halo(C1-C4)alkyl, halo(C1-C4)alkoxy,
hydroxyl, nitro, cyano, amino, trifluoromethyl, mono- or di-(Cl-C6)alkylamino, oxo, (C6-
yl, (C5-C9)heteroaryl, (C1-C6)alkoxycarbonyl, (C3-C10)cycloalkyl, (C3-
C10)cycloalkyloxy, (Cg-C10)cycloalkyl(C1-C6)alkoxy, (C2-C9)heterocyclyl, (C2-
C9)heterocyclyloxy, (C2-C9)heterocyclyl(C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(C1-C4)alkyl,
(C1-C6)alkoxycarbonyl, (C1-C6)alkylsulf1nyl, (C1-C6)alkylsulfonyl, mono- and di-(Cl-
ylaminocarbonyl, (C1-C6)acylthio, and )acyloxy.
ocyclylalkoxyalkyl" refers to a heterocylylalkyl-O-alkyl- group.
“Heterocyclylcarbonyl” refers to a heterocyclyl-(C=O)- group.
“Heteroaryl” or “heteroaryl group” refers to (a) 5 and 6 membered monocyclic
aromatic rings, which contain, in addition to carbon atom(s), at least one heteroatom, such
as nitrogen, oxygen or sulfur, and (b) 7-15 membered bicyclic and tricyclic rings, which
contain, in addition to carbon atom(s), at least one heteroatom, such as nitrogen, oxygen or
sulfur, and in which at least one of the rings is aromatic. Heteroaryl groups can be
substituted or unsubstituted, and may be bridged, spiro, and/or fused. Examples include,
but are not limited to, 2,3-dihydrobenzofuranyl, l,2-dihydroquinolinyl, 3,4-
dihydroisoquinolinyl, l ,2,3 ,4-tetrahydroisoquinolinyl, l ,2,3 ,4-tetrahydroquinolinyl,
benzoxazinyl, benzthiazinyl, chromanyl, filranyl, 2-fi1ranyl, 3-furanyl, imidazolyl,
isoxazolyl, azolyl, oxadiazolyl, oxazolyl, pyridinyl, 2-, 3-, or 4-pyridinyl,
pyrimidinyl, 2-, 4-, or 5-pyrimidinyl, pyrazolyl, pyrrolyl, 2- or 3-pyrrolyl, pyrazinyl,
zinyl, 3- or 4-pyridazinyl, zinyl, thienyl, 2-thienyl, 3- thienyl, tetrazolyl,
thiazolyl, thiadiazolyl, triazinyl, lyl, pyridinyl, pyridinyl, pyrimidinyl,
pyridazinyl, pyrazinyl, naphthyridinyl, pteridinyl, phthalazinyl, purinyl, alloxazinyl,
benzimidazolyl, benzofuranyl, benzofilrazanyl, 2H-l-benzopyranyl, benzothiadiazine,
hiazinyl, hiazolyl, hiophenyl, benzoxazolyl, cinnolinyl, furopyridinyl,
nyl, zinyl, indolyl, or 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 3H-indolyl, quinazolinyl,
quinoxalinyl, isoindolyl, isoquinolinyl, lO-aza-tricyclo [6.3 . l .0*2,7*]dodeca-2(7),3 ,5-
trienyl, l2-oxa-lO-aza-tricyclo[6.3. l *]dodeca-2(7),3,5-trienyl, l2-azatricyclo
[7.2.l.0*2,7*]dodeca-2(7),3,5-trienyl, l0-aza-tricyclo[6.3.2.0*2,7*]trideca-
2(7),3,5-trienyl, 2,3,4,5-tetrahydro-lH-benzo[d]azepinyl, l,3,4,5-tetrahydro-
benzo[d]azepinonyl, l ,3 ,4,5-tetrahydro-benzo[b]azepinonyl, 2,3 ,4,5-tetrahydrobenzo
[c]azepin-l-onyl, l,2,3,4-tetrahydro-benzo[e][l,4]diazepinonyl, 2,3,4,5-
tetrahydro- l H-benzo [e] [l ,4] diazepinyl, 5 ,6, 8 ,9-tetrahydrooxa-benzocycloheptenyl,
2,3 ,4,5 hydro- l H-benzo [b] azepinyl, l,2,4,5 -tetrahydro-benzo [e] [ l ,3 ] diazepin-3 -onyl,
3 ,4-dihydro-2H-benzo [b] [l ,4]dioxepinyl, 3 ,4-dihydro-2H-benzo[f] [ l ,4]oxazepin-5 -onyl,
6,7,8,9-tetrahydro-5 -thiaaza-benzocycloheptenyl, 5,5-dioxo-6,7,8,9-tetrahydrothia
aza-benzocycloheptenyl, and 2,3,4,5-tetrahydro-benzo[f][l,4]oxazepinyl. Preferably, the
heteroaryl group contains 5, 6, or 8-15 ring atoms. More preferably, the heteroaryl group
contains 5 to 10 ring atoms, such as 5, 6, 9, or 10 ring atoms. A heteroaryl group can also
include ring systems substituted on ring carbons with one or more —OH or C=O fianctional
groups and/or substituted on a ring sulfur atom by one (1) or two (2) oxygen atoms to give
S=O or 802 groups, respectively.
“Substituted heteroaryl” indicates that one or more hydrogen atoms on a heteroaryl
group has been replaced with a ent atom or group of atoms and the and the atom or
group of atoms replacing the hydrogen atom is a “substituent”. Representative substituents
include, but are not limited to, halogen, (Cl-Cg)alkyl, (C1-C8)alkoxy, (C1-C8)alkoxy(C1-
C4)alkyl, carboxyl, formyl, (C1-C6)acyl, halo(C1-C4)alkyl, 1-C4)alkoxy, hydroxyl,
nitro, cyano, amino, trifluoromethyl, mono- or di-(C1-C6)alkylamino, oxo, (C6-C10)aryl, (C5-
eroaryl, (C1-C6)alkoxycarbonyl, (Cg-Clo)cycloalkyl, (Cg-Clo)cycloalkyloxy, (C3-
C10)cycloalkyl(C1-C6)alkoxy, (C2-C9)heterocyclyl, (C2-C9)heterocyclyloxy, (C2-
C9)heterocyclyl(C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(C1-C4)alkyl, (C1-C6)alkoxycarbonyl,
(C1-C6)alkylsulf1nyl, (C1-C6)alkylsulfonyl, mono- and di-(C1-C6)alkylaminocarbonyl, (C1-
C6)acylthio, and (C1-C6)acyloxy.
oarylalkyl” refers to a heteroaryl-alkyl- group.
“Halo” and “halogen” include fluoro, chloro, bromo and iodo, and fluorine,
chlorine, bromine and iodine atoms.
“Trihalomethyl” refers to a —CH3 group, the hydrogens of which have been
substituted with halogen atoms, which may be the same or different. Representative
trihalomethyl groups include CF3, CClg, CBrg or C13. A preferred trihalomethyl group is
CF3.
“Trihaloalkyl” refers to an alkyl group substituted by three halogen atoms, which
may be the same or different.
“Alkoxyalkyl” or “alkoxyalkyl group” refers to an alkyl group containing an
alkoxy group substituent.
“Hydroxyl”, “hydroxy”, “hydroxyl group” or “hydroxyl group” refers to an —OH
group.
“Amino” or “amino group” refers to an —NH2 group.
“Alkylamino” or “alkylamino group” refers to an alkyl-N(H)- group.
“Dialkylamino” or “dialkylamino” group refers to an (alkyl)(alkyl)N— group. In
such a group the alkyl groups substituting the nitrogen may be the same or different.
“Carboxy3, “
, carboxyl”, “carboxy group” or “carboxyl group” refers to a —COOH
group.
“Oxo” refers to a =0 group.
“Pseudohalogen” refers to —OCN, —SCN, —CF3, and —CN.
“Chemically stable” or “stable” refers to a compound that is ently robust to
be isolated to a useful degree of purity from a reaction mixture. The present invention is
directed only to ally stable nds.
“Pharmaceutical composition” refers to a composition suitable for administration
in medical or veterinary use.
When lists of ative substituents include members which, owing to valency
requirements, chemical stability, or other reasons, cannot be used to substitute a particular
group, the list is ed to be read in context to include those members of the list that are
suitable for substituting the particular group.
“Pharmaceutically acceptable” refers to physiologically tolerable materials, which
do not typically produce an allergic or other untoward reaction, such as gastric upset,
dizziness and the like, when administered to a mammal.
“Therapeutically effective amount” refers to an amount of a nd, or a
ceutically acceptable salt thereof, sufficient to t, halt, or cause an
improvement in a disorder or condition being treated in a particular subject or subject
population. For example in a human or other , a therapeutically effective amount
can be determined mentally in a laboratory or al setting, or may be the amount
2012/065019
required by the guidelines of the United States Food and Drug Administration, or
equivalent foreign , for the particular disease and subject being treated.
It should be appreciated that ination of proper dosage forms, dosage
amounts, and routes of administration is within the level of ordinary skill in the
ceutical and medical arts, and is described below.
“Subject” refers to a member of the class Mammalia. Examples ofmammals
include, without limitation, , primates, chimpanzees, rodents, mice, rats, rabbits,
horses, livestock, dogs, cats, sheep, and cows.
“Treatment” refers to the acute or prophylactic diminishment or alleviation of at
least one symptom or characteristic associated or caused by a disorder being treated. For
example, treatment can include diminishment of several symptoms of a disorder or
complete eradication of a disorder.
“Administering” refers to the method of contacting a nd with a subject.
Modes of “administering” include, but are not limited to, methods that involve contacting
the compound intravenously, intraperitoneally, intranasally, transdermally, topically, via
implantation, aneously, parentally, intramuscularly, orally, systemically, and via
adsorption.
II. Compounds
The present invention provides a compound of a I or a salt form thereof,
| I
R1b /
| NWBKE
Rd \ Y o 0
R3 R13
Rb NJ
Formula I
wherein:
E and G are independently chosen from H, C1_6alkyl optionally substituted by l-6
R19, C2_6alkenyl optionally substituted by l-6 R19, C2_6alkynyl optionally
substituted by 1-6 R19, C6_11aryl optionally substituted by 1-6 R19, c3-
11cycloalkyl optionally substituted by 1-6 R19, 3—15 membered heterocyclyl
optionally tuted by l-6 R19, 5-15 membered heteroaryl ally
substituted by 1-6 R19, —C(=O)R20, —C(=O)OR2°, NR22R23, —
S(=O)2R2°, and —S(=O)2NR22R23;
X is N or C-R4;
Y is N or C-Rld;
R3 is H or C1_6alkyl;
D is O S SO SOZ C(—O) CHOH CH2 NH or
, , , , , , , NC1_6alkyl—;
W is CH or N;
Ra, Rb, RC, Rd, Rla, Rlb, R10, Rld, and R4 are independently chosen from H, C1-
6alkyl optionally substituted by l-6 R119 tuted by
, C2_6alkenyl optionally
l-6 R119, C2_6alkynyl optionally substituted by l-6 R
, C6_11aryl optionally
substituted by l-6 R119, C3_11cycloalkyl optionally substituted by 1-6 R119, 3-15
membered heterocyclyl optionally substituted by 1-6 R119, 5-15 membered
heteroaryl optionally substituted by l-6 R119, halogen, —CN, —C(=O)R110, —
C(=O)OR110,—C(=O)NR112R113,—NC, —N02, —NR112R113, C(=O)R110, _
NR114C(=O)OR1“, C(=O)NR112R113, S(:O)2R111’ _
NR114S(=O)2NR“2R“3, —0R“°, —OCN, —0C(=0)R“°, —OC(=O)NR“2R“3, —
OC(=O)OR“°, —S(=O)nR“0, and —S(=O)2NR“2R“3;
or any of Ra and Rb, Ra and Rd, and Rb and RC can, together with the atoms
linking them, form a C6_11aryl optionally substituted by l-6 R119, C3-
11cycloalkyl optionally substituted by 1-6 R119, 3—15 membered heterocyclyl
optionally substituted by l-6 R119 or a 5-15 membered heteroaryl optionally
substituted by 1-6 R119;
R19 at each occurrence is independently chosen from kyl optionally
substituted by l-6 R39, C2_6alkenyl ally substituted by l-6 R39, C2_
6alkynyl optionally substituted by l-6 R39, C6_11aryl optionally substituted by
1-6 R39, C3_11cycloalkyl optionally substituted by l-6 R39, 3-15 membered
cyclyl optionally substituted by l-6 R39, 5-15 membered heteroaryl
optionally substituted by 1-6 R39, halogen, —CN, —C(=O)R3°, —C(=O)OR3°, —
C(=O)NR32R33, —N02, —NR32R33, —NR34C(=0)R3°, —NR34C(=O)OR31, —
=O)NR32R33, —NR34S(=O)2R31,—NR34S(=O)2NR32R33, —0R3°, =0, —
OC(=O)R3°, —OC(=O)NR32R33, —OC(=O)OR30, —S(=O)HR30, and —
S(=O)2NR32R33;
R20, R30, R31, and R34 at each occurrence is independently chosen from H, C1_6alkyl
optionally substituted by 1-6 R49, C2_6alkenyl optionally substituted by 1-6 R49,
C2_6alkynyl optionally substituted by 1-6 R49, C6_11aryl optionally substituted
by 1-6 R49, C3_11cycloalkyl optionally substituted by 1-6 R49, 3-15 ed
heterocyclyl optionally substituted by 1-6 R49, and 5-15 ed heteroaryl
optionally substituted by 1-6 R49;
R22, R23, R32 and R33 at each occurrence is independently chosen from H, C1_6alkyl
optionally substituted by 1-6 R59, C2_6alkenyl optionally substituted by 1-6 R59,
C2_6alkynyl optionally substituted by 1-6 R59, C6_11aryl optionally substituted
by 1-6 R59, C3_11cycloalkyl optionally substituted by 1-6 R59, 3-15 membered
heterocyclyl optionally tuted by 1-6 R59, and 5-15 membered heteroaryl
optionally substituted by 1-6 R59;
or any R22 and R23 and/or R32 and R33 may form, together with the nitrogen
atom to which they are attached, a 3-15 membered cyclyl optionally
substituted by 1-6 R69 or a 5-15 membered heteroaryl ally substituted
by 1-6 R69;
R39, R49, R59 and R69 at each occurrence is independently chosen from C1_6all<yl
optionally substituted by 1-6 R79, C2_6alkenyl optionally substituted by 1-6 R79,
C2_6alkynyl optionally substituted by 1-6 R79, C6_11aryl ally substituted
by 1-6 R79, C3_11cycloalkyl optionally substituted by 1-6 R79, 3-15 membered
heterocyclyl optionally substituted by 1-6 R79, 5-15 membered aryl
optionally substituted by 1-6 R79, halogen, —CN, —C(=O)R7°, —C(=O)OR7°, —
C(=O)NR72R73, —N02, —NR72R73, —NR74C(=O)R7°, —NR74C(=O)OR71, —
=O)NR72R73, —NR74S(=O)2R71,—NR74S(=O)2NR72R73, —0R7°, =o, —
R7°, —OC(=O)NR72R73, —S(=O)nR7°, and —S(=O)2NR72R73;
R70, R71, R72, R73, and R74 at each ence is independently chosen from H, C1-
6alkyl and aloalkyl;
R79 at each occurrence is independently chosen from C1_6alkyl, C1_6-haloalkyl,
benzyl, halogen, —CN, —C(=O)(C1_6alkyl), —C(=O)O(C1_6alkyl), —C(=O)N(C1_
6alkyl)2, —C(=O)OH, —C(=O)NH2, —C(=O)NHC1_6alkyl, —N02, —NH2, —NHC1_
6alkyl, —N(C1_6alkyl)2, —NHC(=O)C1_6alkyl, —NHS(=O)2C1_6alkyl, —OH, —OC1_
6alkyl, =0, —OC(=O)C1_6alkyl, —OS(=O)2C1_6alkyl, —S(=O)2C1_6alkyl, and —
S(=O)2N(C1_6alkyl)2;
R110, R111, and R114 at each occurrence is independently chosen from H, C1_6alkyl
optionally substituted by 1-6 R129 substituted by 1-6
, C2_6alkenyl optionally
R129, kynyl optionally substituted by 1-6 R129, ryl optionally
substituted by 1-6 R129, C3_11cycloalkyl optionally substituted by 1-6 R129, 3-15
membered heterocyclyl optionally substituted by 1-6 R129 and 5-15 membered
aryl optionally substituted by 1-6 R129;
R112 and R113 at each occurrence is independently chosen from H, C1_6alkyl
optionally substituted by 1-6 R139 substituted by 1-6
, C2_6alkenyl optionally
R139, C2_6alkynyl optionally substituted by 1-6 R139, C6_11aryl optionally
substituted by 1-6 R139, ycloalkyl optionally substituted by 1-6 R139, 3-15
membered heterocyclyl optionally substituted by 1-6 R139 and 5-15 membered
heteroaryl optionally substituted by 1-6 R139;
or any R112 and R113 may form, together with the nitrogen atom to which they
are attached, a 3-15 membered heterocyclyl optionally substituted by 1-6 R149
or a 5-15 membered heteroaryl optionally substituted by 1-6 R149;
R119 at each ence is ndently chosen from C1_6alkyl optionally
substituted by 1-6 R159, C2_6alkenyl optionally tuted by 1-6 R159, C2-
6alkynyl optionally substituted by 1-6 R substituted by
, ryl optionally
1-6 R159, C3_11cycloalkyl ally substituted by 1-6 R159, 3-15 membered
heterocyclyl optionally substituted by 1-6 R159 5 -15 membered heteroaryl
optionally tuted by 1-6 R159, halogen, —CN, —C(=O)R15°, —C(=O)OR150, —
C(=O)NR152R153, —NC, —N02, —NR152R153, —NR154C(=O)R150, _
NR154C(:O)OR151, —NR154C(:O)NR152R153, —NR154S(:O)2R151, _
NR154S(=O)2NR152R153, —OR150, :0, —OC(=O)R150, —OC(=O)NR152R153, _
S(=O)nR15°, and —S(=O)2NR152R153;
R150, R151, R152, R153 and R154 at each occurrence is independently chosen from H,
C1_6alkyl, benzyl, and aloalkyl;
R129, R139, R149, and R159 at each occurrence is independently chosen from C1-
6alkyl, C1_6-haloalkyl, benzyl, halogen, —CN, (C1_6alkyl), —C(=O)O(C1_
6alkyl), —C(=O)N(C1_6alkyl)2, —C(=O)OH, —C(=O)NH2, —C(=O)NHC1_6alkyl,
N02, —NH2, —NHC1_6alkyl, —N(C1_6alkyl)2, —NHC(=O)C1_6alkyl, —
WO 74633
NHS(=O)2C1_6alkyl, —OH, —OC1_6alkyl, =0, —OC(=O)C1_6alkyl, —OS(=O)2C1_
6alkyl, —S(=O)2C1_6alkyl, and —S(=O)2N(C1_6alkyl)2; and
n at each occurrence is independently chosen from 0, l, and 2.
In one embodiment, E and G are independently chosen from H, C1_6alkyl
optionally substituted by 1-6 R19, C2_6alkenyl optionally substituted by 1-6 R19, C2_6alkynyl
optionally substituted by 1-6 R19, phenyl optionally tuted by 1-5 R19, C3_6cycloalkyl
optionally substituted by 1-6 R19, 3-6 ed heterocyclyl optionally substituted by 1-5
R19, 5-6 membered heteroaryl optionally substituted by 1-3 R19, —C(=O)R20, —C(=O)OR20,
—C(=O)NR22R23, —S(=O)2R2°, and —S(=O)2NR22R23.
In one embodiment, E is chosen from H, C1_6alkyl optionally tuted by 1-6
R19, C2_6alkenyl ally substituted by 1-6 R19, C2_6alkynyl optionally substituted by 1-6
R19, C6_11aryl optionally substituted by 1-6 R19, and C3_11cycloalkyl optionally substituted
by 1-6 R”.
In one embodiment, E is chosen from H, C1_6alkyl optionally substituted by 1-6
R19, C2_6alkenyl optionally substituted by 1-6 R19, C2_6alkynyl optionally substituted by 1-6
R19, phenyl optionally substituted by 1-6 R19, and C3_6cycloalkyl ally substituted by
1-6 R19.
In one embodiment, E is chosen from H, kyl optionally substituted by 1-3
R19, C2_6alkenyl optionally substituted by 1-3 R19, C2_6alkynyl optionally substituted by 1-3
R19, phenyl optionally substituted by 1-3 R19, and cloalkyl optionally substituted by
1—3 R19.
In one embodiment, E is chosen from H, C1_6alkyl optionally substituted by 1-3
R19, C2_6alkenyl, C2_6alkynyl optionally substituted by —OH, phenyl optionally substituted
by halogen, and C3_6cycloalkyl.
In one embodiment, E is chosen from H, C1_6alkyl optionally substituted by 1-3
R19, C2_6alkenyl, C2_6alkynyl optionally substituted by —OH, phenyl optionally tuted
by halogen, and cyclohexyl.
In one embodiment, E is chosen from H, C1_6alkyl optionally substituted by 1-3
R19, C2_6alkenyl, kynyl optionally substituted by —OH, phenyl optionally substituted
by fluoro, and cyclohexyl.
In one embodiment, E is chosen from C1_6alkyl ally substituted by R19,
phenyl, and ophenyl.
In one embodiment, E is phenyl optionally substituted by 1-5 halogen.
In one embodiment, E is C1_6alkyl optionally substituted by R19.
-l6-
2012/065019
In one embodiment, E is p-fluorophenyl.
In one embodiment, G is chosen from H, C1_6alkyl optionally substituted by 1-6
R19, C2_6alkenyl optionally tuted by 1-6 R19, kynyl optionally tuted by 1-6
R19, C6_11aryl optionally substituted by 1-6 R19, C3_11cycloalkyl optionally substituted by l-
6 R19, and 3-15 membered heterocyclyl optionally substituted by 1-6 R19.
In one ment, G is chosen from H, C1_6alkyl optionally substituted by 1-3
R19, kenyl optionally substituted by 1-3 R19, C2_6alkynyl optionally substituted by 1-3
R19, phenyl optionally substituted by 1-3 R19, cloalkyl optionally substituted by 1-3
R19, and 3-6 membered heterocyclyl optionally substituted by 1-3 R19.
In one embodiment, G is chosen from H, C1_6alkyl ally substituted by 1-3
R19, C2_6alkenyl ally substituted by 1-3 halogen, C2_6alkynyl, phenyl optionally
substituted by 1-3 halogen, C3_6cycloalkyl, and 3-6 membered heterocyclyl.
In one embodiment, G is chosen from H, C1_6alkyl optionally substituted by 1-3
R19, C2_6alkenyl optionally substituted by 1-3 halogen, C2_6alkynyl, phenyl optionally
substituted by 1-3 halogen, C3_6cycloalkyl, and 6 membered heterocyclyl.
In one embodiment, G is chosen from H, C1_6alkyl ally substituted by 1-3
R19, C3_6alkenyl optionally substituted by 1-3 fluoro, C3_6alkynyl, phenyl optionally
substituted by 1-3 fluoro, C3_6cycloalkyl, and 6 membered heterocyclyl.
In one embodiment, G is chosen from H, C1_6alkyl optionally substituted by 1-3
R19, C3_6alkenyl optionally substituted by 1-3 fluoro, C3_6alkynyl, phenyl optionally
substituted by 1-3 fluoro, C3_6cycloalkyl, and 6 membered heterocyclyl.
In one embodiment, G is chosen from H, C1_6alkyl optionally substituted by R19,
C3_6alkenyl optionally substituted by 2 fluoro, C3_6alkynyl, phenyl optionally substituted
by fluoro, C3_6cycloalkyl, and tetrahydropyranyl.
In one embodiment, G is H.
In one embodiment, G is C1_6alkyl optionally substituted by R19.
In one embodiment, G is C1_6alkyl.
In one embodiment, G is C3_6alkenyl optionally substituted by 2 .
In one embodiment, G is C3_6alkynyl.
In one embodiment, G is phenyl optionally tuted by fluoro.
In one embodment, G is p-fluorophenyl.
In one embodiment, G is C3_6cycloalkyl.
In one embodiment, G is tetrahydropyranyl.
In one embodiment, X is N.
In one embodiment, X is C-R4.
In one embodiment, Y is N.
In one embodiment, Y is CH.
In one ment, Y is C-Rld.
In one embodiment, R3 is H.
In one embodiment, R3 is C1_6alkyl.
In one embodiment, D is —O—, —S—, —C(=O)—, —CHOH—, —CH2—, —NH— or —NC1_
6alkyl—.
In one embodiment, D is —O—, —S—, —C(=O)—, , —CH2—, or —NH—.
In one embodiment, D is —O—, —S—, —C(=O)—, —CHOH—, or —CH2—.
In one embodiment, D is —O—, —C(=O)—, , or —CH2—.
In one embodiment, D is —O—, —C(=O)—, —CHOH—, or —CH2—.
In one ment, D is —O—.
In one embodiment, D is —C(=O)—.
In one embodiment, D is .
In one ment, D is —CH2—.
In one embodiment, W is CH.
In one embodiment, W is N.
In one embodiment, Ra, Rb, RC, and Rd are independently chosen from H, C1_6alkyl
optionally substituted by l-6 R substituted by l-6 R119, C2-
, C2_6alkenyl optionally
6alkynyl optionally substituted by l-6 R119 substituted by l-6 R119, C3-
, C6_11aryl optionally
llcycloalkyl optionally substituted by l-6 R119, 3-15 ed heterocyclyl optionally
substituted by l-6 R119, 5-15 membered heteroaryl optionally substituted by 1-6 R119,
halogen, —CN, —C(=0)R“°, —C(=O)NR“2R“3, —N02,—NR112R113, —NR“4C(=0)R“°, —
NR114C(=O)OR111, _NR114C(:O)NR1 12R113, —NR114S(=O)2R111, —OR110, —S(=O)2R110, and
—S =0 ZNRmRm; or any of Ra and Rb, Ra and Rd, and Rb and RC can, together with the
atoms linking them, form a C6_11aryl optionally substituted by l-6 R
, C3_1lcycloalkyl
optionally substituted by 1-6 R119, 3-15 membered cyclyl optionally substituted by
l-6 R119 or a 5-15 membered heteroaryl optionally substituted by l-6 R119.
In one embodiment, Ra, Rb, RC, and Rd are independently chosen from H, C1_6alkyl
optionally substituted by l-6 R119, —CN, and —OR110; or Ra and Rb can, together with the
atoms linking them, form a 3-6 membered heterocyclyl optionally substituted by l-6 R119.
In one embodiment, Ra, Rb, RC, and Rd are independently chosen from H, C1_6alkyl
ally substituted by 1-6 R119, —CN, and —OR110; or Ra and Rb can, er with the
atoms linking them, form a 5-6 membered heterocyclyl ally substituted by 1-6 R119.
In one embodiment, Ra, Rb, RC, and Rd are independently chosen from H, C1_6alkyl
optionally tuted by 1-6 R119, —CN, and ; or Ra and Rb can, er with the
atoms linking them, form a 5-6 ed heterocyclyl.
In one embodiment, Ra is chosen from H, —CN, and —OC1_6alkyl; Rb is chosen from
H, C1_6alkyl ally substituted by 1-6 R119, and —OR110; Rc is chosen from H and —
OC1_6alkyl; and Rd is chosen from H and —OC1_6alkyl; or Ra and Rb can, together with the
atoms g them, form a 5-6 membered heterocyclyl.
In one embodiment, Ra is chosen from H, —CN, and —OC1_6alkyl; Rb is chosen from
H, C1_6alkyl optionally substituted by 6-membered heterocyclyl, and —OR110; RC is chosen
from H and —OC1_6alkyl; and Rd is chosen from H and —OC1_6alkyl; or Ra and Rb can,
together with the atoms linking them, form a 5-6 membered heterocyclyl.
In one embodiment, Ra is chosen from H, —CN, and —OC1_6alkyl; Rb is chosen from
H, C1_6alkyl optionally substituted by 6-membered heterocyclyl, —OH, —OC1_6alkyl, —
OCnghenyl, —OC1_6alkyl-O-C1_6alkyl; RC is chosen from H and —OC1_6alkyl; and Rd is
chosen from H and —OC1_6alkyl; or Ra and Rb can, together with the atoms linking them,
form a 5-6 membered heterocyclyl.
In one embodiment, Ra is chosen from H, —CN, and —OC1_6alkyl; Rb is chosen from
H, C1_6alkyl optionally substituted by morpholinyl, —OH, —OC1_6alkyl, —OCH2phenyl, —
OC1_6alkyl-O-C1_6alkyl; RC is chosen from H and —OC1_6alkyl; and Rd is chosen from H
O O
< E
and —OC1_6alkyl; or Ra and Rb together form 0or O.
In one embodiment, Ra is chosen from H and —OC1_6alkyl; Rb is chosen from H,
C1_6alkyl optionally substituted by morpholinyl, —OH, —OC1_6alkyl, —OCH2phenyl, —OC1_
6alkyl-O-C1_6alkyl; RC is H; and Rd is chosen from H and —OC1_6alkyl; or Ra and Rb
O O
< E
together form 0or O.
In one embodiment, Ra is chosen from H and —OC1_6alkyl; Rb is chosen from C1-
6alkyl optionally substituted by morpholinyl, —OH, —OC1_6alkyl, —OCH2phenyl, —OC1_
2012/065019
6alkyl-O-C1_6alkyl; RC is H; and Rd is chosen from H and —OC1_6alkyl; or Ra and Rb
<0 [0
O O
together form or .
In one embodiment, Ra is —OC1_6alkyl; Rb is chosen from H, C1_6alkyl optionally
substituted by morpholinyl, —OH, —OC1_6alkyl, henyl, —OC1_6alkyl-O-C1_6alkyl; RC
0 O
< E
is H; and Rd is chosen from H and —OC1_6alkyl; or Ra and Rb together form 0or O.
In one embodiment, Ra is chosen from H and —OC1_6alkyl; Rb is chosen from H and
—OC1_6alkyl; RC is H; and Rd is chosen from H and —OC1_6alkyl; or Ra and Rb together
<0 [0
O O
form or .
In one embodiment, Ra, Rb, RC, and Rd are independently chosen from H and —OC1_
<0 E0
0 O
6alkyl; or Ra and Rb together form or .
In one embodiment, Ra is chosen from H and —OC1_6alkyl; Rb is chosen from H and
<0 [0
O O
—OC1_6alkyl; RC is H; and Rd is H; or Ra and Rb together form or .
In one embodiment, Ra is chosen from H and —OC1_6alkyl; Rb is chosen from H and
—OC1_6alkyl; RC is H; and Rd is H.
In one ment, Ra is chosen from H and —OC1_3alkyl; Rb is chosen from H and
alkyl; Rc is H; and Rd is H.
<0 E0
0 O
In one embodiment, RC is H; Rd is H; and Ra and Rb together form or .
In one embodiment, R4 is chosen from H. C1_6alkyl, and C1_6haloalkyl.
In one embodiment, R4 is chosen from H and C1_6alkyl.
In one embodiment, R4 is chosen from H and C1_3alkyl.
In one embodiment, R4 is chosen from H and methyl.
In one embodiment, R4 is H.
In one embodiment, R4 is kyl.
In one embodiment, R4 is methyl.
In one ment, Rla, Rlb, R10, and Rld are independently chosen from H, C1-
6alkyl optionally substituted by l-6 R119 substituted by l-6 R119
, C3_6cycloalkyl optionally ,
3-6 membered heterocyclyl optionally substituted by 1-6 R119, halogen, —CN, —NR112R113,
and —OR110.
In one embodiment, Rla, Rlb, R10, and Rld are independently chosen from H, C1-
6alkyl ally substituted by l-6 R119 substituted by l-6 R119
, C3_6cycloalkyl optionally ,
halogen, —NR112R113, and —OR110.
In one ment, Rla, Rlb, R10, and Rld are independently chosen from H, C1-
6alkyl, C1_6haloalkyl, C3_6cycloalkyl, halogen, —NH2, —NHC1_6alkylg, —N(C1_6alkyl)2, —OH,
and —OC1_6alkyl.
In one embodiment, Rla, Rlb, R10, and Rld are independently chosen from H, C1-
6alkyl, C1_6haloalkyl, C3_6cycloalkyl, halogen, —N(C1_6alkyl)2, —OC1_6alkyl.
In one embodiment, Rla, Rlb, R10, and Rld are independently chosen from H, C1-
galkyl, C1_3haloalkyl, C3_6cycloalkyl, halogen, and alkyl.
In one embodiment, Rla, Rlb, R10, and Rld are ndently chosen from H, C1-
galkyl, C1_3haloalkyl, cyclopropyl, halogen, and —OC1_3alkyl.
In one embodiment, Rla, Rlb, R10, and Rld are independently chosen from H,
halogen, and —OC1_3alkyl.
In one embodiment, Rla, Rlb, R10, and Rld are independently chosen from H,
halogen, and methoxy.
In one embodiment, Rla, Rlb, R10, and Rld are independently chosen from H and
halogen.
In one embodiment, Rla, Rlb, R10, and Rld are independently chosen from H and
fluoro .
In one embodiment, Rla and Rlb are independently chosen from H, C1_6alkyl
optionally substituted by l-6 R119 substituted by l-6 R119
, C3_6cycloalkyl optionally ,
halogen, and —OR110; and R10 and Rld are independently chosen from H, C1_6alkyl
optionally substituted by l-6 R119, n, R113, and —OR110.
In one embodiment, Rla and Rlb are independently chosen from H, C1_6alkyl, C1-
6haloalkyl, C3_6cycloalkyl, halogen, and alkyl; and R10 and Rld are ndently
chosen from H, C1_6alkyl, halogen, —N(C1_6alkyl)2, and —OC1_6alkyl.
In one embodiment, Rla and Rlb are ndently chosen from H, C1_3alkyl, C1-
3haloalkyl, C3_6cycloalkyl, halogen, and —OC1_3alkyl; and R10 and Rld are independently
chosen from H, C1_3alkyl, halogen, 3alkyl)2, and —OC1_3alkyl.
In one embodiment, Rla and Rlb are independently chosen from H, C1_3alkyl, C1_
3haloalkyl, ropyl, halogen, and —OC1_3alkyl; and R10 and Rld are independently
chosen from H, C1_3alkyl, halogen, 3alkyl)2, and —OC1_3alkyl.
In one embodiment, Rla and Rlb are independently chosen from H, C1_3alkyl, C1-
3haloalkyl, cyclopropyl, halogen, and —OC1_3alkyl; and R10 and Rld are independently
chosen from H, C1_3alkyl, halogen, and —OC1_3alkyl.
In one embodiment, Rla, R10, and Rld are H and Rlb is chosen from H, C1_3alkyl,
C1_3haloalkyl, cyclopropyl, halogen, and —OC1_3alkyl.
In one embodiment, Rla, R10, and Rld are H and Rlb is chosen from H, halogen, and
—OC1_3alkyl.
In one embodiment, Rla, R10, and Rld are H and Rlb is chosen from H and halogen.
In one embodiment, Rla, R10, and Rld are H and Rlb is chosen from H and fluoro.
In one ment, Rla, R10, and Rld are H and Rlb is halogen.
In one ment, Rla, R10, and Rld are H and Rlb is fluoro.
In one embodiment, R19 at each occurrence is independently chosen from C1_6alkyl
optionally substituted by 1-6 R39, C6_11aryl optionally substituted by 1-6 R39, C3-
11cycloalkyl optionally tuted by 1-6 R39, 3-15 membered heterocyclyl optionally
substituted by 1-6 R39, 5-15 membered heteroaryl optionally substituted by 1-6 R39,
n, —CN, —C(=O)OR3°, —C(=O)NR32R33, —NR32R33, —0R3°, and :0.
In one embodiment, R19 at each occurrence is independently chosen from C1_6alkyl
optionally substituted by 1-6 R39, phenyl ally substituted by 1-6 R39, C3_6cycloalkyl
optionally tuted by 1-6 R39, 3-6 membered heterocyclyl optionally substituted by 1-6
R39, 5-6 membered aryl optionally substituted by 1-6 R39, halogen, —CN, —
C(=O)OR30, —C(=O)NR32R33, —NR32R33, —0R3°, and :0.
In one embodiment, R19 at each occurrence is independently chosen from C1_6alkyl,
phenyl optionally tuted by 1-3 halogen, cloalkyl, 3-6 membered heterocyclyl,
5-6 membered heteroaryl optionally substituted by 1-3 C1_6alkyl, halogen, —CN, —
C(=O)OH, —C(=O)OC1_6alkyl, —C(=O)N(C1_6alkyl)2, —N(C1_6alkyl)2, —OH, —OC1_6alkyl, —
Obenzyl, and =0.
In one embodiment, R19 at each occurrence is independently chosen from C1_6alkyl,
phenyl optionally substituted by 1-3 halogen, C3_6cycloalkyl, 5-6 membered heterocyclyl,
-6 membered heteroaryl optionally substituted by 1-3 kyl, halogen, —CN, —
C(=O)OH, —C(=O)OC1_6alkyl, N(C1_6alkyl)2, —C(=O)pyrrolidinyl, —
C(=O)morpholinyl, —N(C1_6alkyl)2, —OH, alkyl, —Obenzyl, and =0.
In one embodiment, R19 at each occurrence is independently chosen from C3-
6cycloalkyl and —OH.
In one embodiment, R19 at each occurrence is ndently chosen from
cyclopropyl and —OH.
In one embodiment, R20, R30, R31, R34, R22, R23, R32 and R33 at each occurrence is
independently chosen from H, C1_6alkyl, C1_6halolkyl, phenyl, benzyl, C5_6cycloalkyl, 5-6
membered heterocyclyl, and 5-6 membered heteroaryl; or R32 and R33 may form, together
with the nitrogen atom to which they are ed, a 5-6 membered cyclyl or a 5-6
membered heteroaryl.
In one embodiment, R20, R30, R31, R34, R22, R23, R32 and R33 at each occurrence is
independently chosen from H, C1_6alkyl, C1_6halolkyl, phenyl, benzyl, C5_6cycloalkyl, 5-6
membered heterocyclyl, and 5-6 membered heteroaryl.
In one ment, R20, R30, R31, R34, R22, R23, R32 and R33 at each ence is
independently chosen from H and C1_6alkyl.
In one embodiment, R39, R49, R59 and R69 at each occurrence is independently
chosen from C1_6alkyl, C1_6haloalkyl, and benzyl.
In one embodiment, R39, R49, R59 and R69 at each occurrence is independently
chosen from C1_6alkyl and C1_6haloalkyl.
In one embodiment, R39, R49, R59 and R69 at each occurrence is independently
chosen from C1_6alkyl.
In one embodiment, R70, R71, R72, R73, and R74 at each occurrence is independently
chosen from H and C1_6alkyl.
In one embodiment, R70, R71, R72, R73, and R74 at each occurrence is H.
In one embodiment, R79 at each occurrence is independently chosen from C1_6alkyl,
C1_6-haloalkyl, benzyl, and halogen.
In one embodiment, R79 at each occurrence is independently chosen from C1_6alkyl
and C1_6-haloalkyl.
In one embodiment, R79 at each occurrence is independently chosen from C1_6alkyl.
In one embodiment, R110, R111, R112, R113, and R114 at each occurrence is
independently chosen from H and C1_6alkyl optionally substituted by 1-3 R129.
- 110 111 112 113 and R114 In one embod1ment, R R R R -
at each occurrence 1s
, , , ,
ndently chosen from H and C1_3alkyl optionally substituted by 1-3 R129.
In one ment, R110, R111, R112, R113, and R114 at each occurrence is
independently chosen from H, benzyl, and C1_6alkyl optionally substituted by —OC1_3alkyl.
In one embodiment, R110, R111, R112, R113, and R114 at each occurrence is
independently chosen from H and C1_3alkyl optionally substituted by —OC1_3alkyl.
In one ment, R110, R111, R112, R113, and R114 at each ence is
independently chosen from H and C1_3alkyl.
In one embodiment, R110, R111, R112, R113, and R114 at each occurrence is H.
In one embodiment, R at each occurrence is independently chosen from C1-
6alkyl optionally substituted by 1-6 R159, 3-15 membered heterocyclyl ally
substituted by 1-6 R159, and halogen.
In one embodiment, R at each occurrence is independently chosen from C1-
6alkyl optionally substituted by 1-3 R159 5-6 membered heterocyclyl optionally substituted
by 1-3 R159, and halogen.
In one embodiment, R at each occurrence is independently chosen from C1-
6alkyl, loalkyl, 5-6 membered heterocyclyl, and halogen.
In one embodiment, R at each occurrence is independently chosen from 5-6
membered heterocyclyl and halogen.
In one embodiment, R at each occurrence is independently chosen from 6
membered heterocyclyl and halogen.
In one embodiment, R at each occurrence is independently chosen from
morpholinyl and halogen.
In one embodiment, R119 at each occurrence is independently chosen from
morpholinyl and fluoro.
In one embodiment, R150, R151, R152, R153 and R154 at each occurrence is
independently chosen from H and C1_6alkyl.
In one embodiment, R150, R151, R152, R153 and R154 at each occurrence is H.
In one embodiment, R129, R139, R149, and R159 at each occurrence is independently
chosen from C1_6alkyl, C1_6-haloalkyl, , and n.
In one embodiment, R129, R139, R149, and R159 at each occurrence is independently
chosen from C1_6alkyl and halogen.
In one ment, R129, R139, R149, and R159 at each occurrence is halogen.
In one embodiment, R129, R139, R149, and R159 at each occurrence is C1_6alkyl.
In one embodiment, n at each occurrence is 0 or 2.
In one ment, n at each ence is 0.
In one embodiment, n at each occurrence is 2.
The present invention also provides compounds of Formula II
R2 T3 XI/NYO
| NWME
Rd \ Y o o
Ra R1
Rb N/J
a II
wherein:
Ra is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, dialkylamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, N—alkylcarbamoyl,
N,N—diall<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
ent, trihalomethyl, or Ra is OA;
Rb is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, lamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, N—alkylcarbamoyl,
N,N—diall<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
different, trihalomethyl, or Rb is OB;
RC is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, dialkylamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, N—alkylcarbamoyl,
N,N—diall<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
different, trihalomethyl, or RC is OJ;
Rd is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, dialkylamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, N—alkylcarbamoyl,
N,N—diall<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
different, trihalomethyl, or Rd is 0L;
where A, B, J and L, are, independently, H, alkyl, alkoxyalkyl, cycloalkyl,
cycloalkoxyalkyl, heterocyclylalkyl, heterocyclylalkoxyalkyl, arylalkyl or arylalkoxyalkyl,
or A and B together with the oxygen atoms to which they are attached form or
D is O, S, SO, SOZ, C=O, C(H)OH, CH2, NH or N-alkyl;
E is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl,
or heteroarylalkyl, where the heteroaryl group of heteroarylalkyl may be substituted or
unsubstituted;
G is H, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl, alkyl
or cycloalkyl, cycloalkylalkyl, alkenyl or alkynyl, where alkyl, alkenyl or cycloalkyl may
be substituted by one, two or three groups selected from the group consisting of alkanoyl,
cycloalkyl, alkenyl, l, halo, yl, alkoxy, alkoxycarbonyl, heterocyclyl, aryl,
tuted aryl, aryloxy, koxy, amino, alkylamino, dialkylamino, where the alkyl
groups of dialkylamino may be the same or different, heteroaryl, carboxyl, oxo,
carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, where the alkyl groups of dialkylcarbamoyl
may be the same or different, and cycyclylcarbonyl;
W is CH or N;
X is C-R4 or N, where R4 is H, OH or alkyl, where the alkyl group may be
substituted by hydroxyl, alkoxy, alkylamino, or dialkyl amino, where the alkyl groups of
dialkylamino may be the same or different;
Y is N, CH or C where C may be substituted with one of the groups R1 or R2; and
R1 and R2 are, independently, H, alkyl, cycloalkyl, halo, alkoxy, trihaloalkyl,
amino, alkylamino, dialkylamino, where the alkyl groups on dialkylamino may be the
same or different, or heterocyclyl; and
R3 is H, or alkyl; or
a ceutically acceptable salt thereof.
A red embodiment of the t invention provides compounds of a
11 wherein W is CH.
Another preferred embodiment of the present ion provides compounds of
Formula 11 wherein W is N.
Another preferred embodiment of the present invention provides compounds of
Formula III.
N 0
R2 x/ Y
H '
\ Y O O
A_O R1
8—0 N
Formula 111
n:
A and B are, independently, H, alkyl, alkoxyalkyl, cycloalkyl,
cycloalkoxyalkyl, heterocyclylalkyl, heterocyclylalkoxyalkyl, arylalkyl or
arylalkoxyalkyl, or A and B together with the oxygen atoms to which they are
C: [0
attached form or ;
D is O, S, NH, or C=O;
E is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, cycloalkyl, aryl, tuted aryl, heteroaryl, heterocyclyl,
substituted heteroaryl, or heteroarylalkyl, where the heteroaryl group of
arylalkyl may be substituted or unsubstituted;
G is H, aryl, substituted aryl, heteroaryl, substituted aryl,
heterocyclyl, alkyl or cycloalkyl, cycloalkylalkyl, alkenyl or alkynyl, where alkyl,
alkenyl or cycloalkyl may be substituted by one, two or three groups selected from
the group ting of alkanoyl, cycloalkyl, alkenyl, alkynyl, halo, hydroxyl,
alkoxy, carbonyl, heterocyclyl, aryl, substituted aryl, aryloxy, koxy,
amino, alkylamino, dialkylamino, where the alkyl groups of dialkylamino may be
the same or different, heteroaryl, carboxyl, oxo, carbamoyl, alkylcarbamoyl,
dialkylcarbamoyl, where the alkyl groups of dialkylcarbamoyl may be the same or
different, and heterocycyclylcarbonyl;
X is C-R4 or N, where R4 is H or alkyl;
Y is N, CH or C where C may be substituted with one of the groups R1 or
R2; and
R1 and R2 are, ndently, H, alkyl, halo, alkoxy, trihaloalkyl, amino,
alkylamino, dialkylamino, where the alkyl groups on dialkylamino may be the
same or different; or
a pharmaceutically acceptable salt thereof.
Another preferred embodiment of the t invention provides compounds of
Formula 111 wherein A and B are, independently, alkyl, cyclylalkyl or
heterocyclylalkoxyalkyl.
Another preferred embodiment of the present invention provides compounds of
Formula 111 wherein A and B are, independently, alkyl.
Another preferred ment of the present invention provides compounds of
Formula 111 wherein D is O, S or NH.
Another preferred embodiment of the present invention provides nds of
Formula 111 wherein D is 0.
Another preferred embodiment of the present invention provides nds of
Formula 111 wherein R1 and R2 are, independently, halo, alkoxy, alkyl or H.
Another preferred embodiment of the present invention provides compounds of
Formula 111 n R1 and R2 are, independently, halo or alkoxy.
Another preferred ment of the present invention provides compounds of
Formula 111 wherein R1 and R2 are, independently, methoxy or fluoro.
Another preferred ment of the t invention provides compounds of
Formula 111 n X is N or CH.
Another preferred embodiment of the present invention provides compounds of
Formula 111 wherein X is CH.
r preferred embodiment of the present invention provides compounds of
Formula 111 wherein G is alkyl where alkyl may be substituted by one, two or three groups
selected from the group consisting of alkanoyl, cycloalkyl, alkenyl, alkynyl, halo,
hydroxyl, alkoxy, alkoxycarbonyl, heterocyclyl, aryl, substituted aryl, aryloxy, arylalkoxy,
amino, alkylamino, dialkylamino, where the alkyl groups of lamino may be the
same or different, heteroaryl, carboxyl, oxo, carbamoyl, alkylcarbamoyl,
dialkylcarbamoyl, where the alkyl groups of dialkylcarbamoyl may be the same or
different, and cycyclylcarbonyl.
Another preferred embodiment of the present invention provides compounds of
Formula 111 wherein E is aryl, substituted aryl or lkyl.
Another preferred embodiment of the present invention provides compounds of
Formula 111 wherein E is substituted aryl.
r preferred embodiment of the present ion provides nds of
Formula 111 wherein A and B are, independently, alkyl; D is O, S or NH; R1 and R2 are,
independently, halo, alkoxy, alkyl or H; X is N or CH; G is alkyl where alkyl may be
substituted by one, two or three groups selected from the group consisting of alkanoyl,
cycloalkyl, alkenyl, alkynyl, halo, hydroxyl, alkoxy, alkoxycarbonyl, heterocyclyl, aryl,
substituted aryl, aryloxy, arylalkoxy, amino, alkylamino, dialkylamino, where the alkyl
groups of dialkylamino may be the same or different, heteroaryl, carboxyl, oxo,
carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, where the alkyl groups of dialkylcarbamoyl
may be the same or ent, and heterocycyclylcarbonyl; and E is aryl, substituted aryl or
cycloalkyl.
WO 74633
In other preferred embodiments, the present invention provides any of the
nds as described in the Examples.
The present invention provides salts of the AXL and c-MET inhibitory compounds
described herein. ably, the salts are pharmaceutically acceptable. Pharmaceutically
acceptable acid addition salts of the compounds described herein include, but are not
limited to, salts derived from inorganic acids such as hydrochloric, nitric, phosphoric,
sulfuric, hydrobromic, hydriodic, and phosphorus, as well as the salts d from
organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic
acids, hydroxy ic acids, alkanedioic acids, aromatic acids, and aliphatic and
aromatic sulfonic acids. Such salts thus include, but are not limited to, sulfate,
pyrosulfate, bisulfate, sulf1te, bisulf1te, nitrate, ate, monohydrogenphosphate,
dihydrogenphosphate, metaphosphate, osphate, chloride, bromide, iodide, acetate,
racetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate,
sebacate, fumarate, mandelate, te, chlorobenzoate, methylbenzoate,
obenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate,
lactate, ate, pyroglutamate, maleate, tartrate, and methanesulfonate. Also
contemplated are the salts of amino acids such as arginate, gluconate, galacturonate, and
the like; see, for example, Berge et al., "Pharmaceutical Salts," J. of Pharmaceutical
Science, 1977;66:1-19.
The acid addition salts of basic compounds described herein may be prepared by
contacting the free base form with a sufficient amount of the d acid to produce the
salt in the conventional manner. The free base form may be regenerated by contacting the
salt form with a base and isolating the free base in the tional manner. The free base
forms differ from their respective salt forms somewhat in certain physical properties such
as solubility in polar solvents, but otherwise the salts are in general equivalent to their
respective free base for purposes of the present invention.
Pharmaceutically acceptable base addition salts of compounds described herein are
formed with metals or amines, such as alkali and alkaline earth metal hydroxides, or of
organic amines. Examples of metals used as cations include, but are not limited to,
sodium, potassium, magnesium, and m. Examples of suitable amines include, but
are not limited to, N,N'- dibenzylethylenediamine, chloroprocaine, choline,
diethanolamine, ethylenediamine (ethane-l,2-diamine), N—methylglucamine, and ne;
see, for e, Berge et al., supra., 1977.
WO 74633
The base addition salts of acidic compounds may be prepared by ting the
free acid form with a sufficient amount of the desired base to produce the salt in the
conventional manner. The free acid form may be regenerated by contacting the salt form
with an acid and isolating the free acid in a conventional manner. The free acid forms
differ from their respective salt forms somewhat in certain physical properties such as
solubility in polar solvents, but otherwise the salts are in general lent to their
respective free acid for es of the present invention.
Some of the compounds in the present invention may exist as stereoisomers,
including enantiomers, diastereomers, and geometric isomers. Geometric isomers include
compounds of the present invention that have alkenyl groups, which may exist as entgegen
or zusammen conformations, in which case all geometric forms thereof, both entgegen and
zusammen, cis and trans, and mixtures thereof, are within the scope of the present
invention. Some compounds of the present invention have carbocyclyl groups, which may
be substituted at more than one carbon atom, in which case all geometric forms thereof,
both cis and trans, and mixtures f, are within the scope of the present invention. All
of these forms, including (R), (S), epimers, diastereomers, cis, trans, syn, anti, (E), (Z),
tautomers, and es thereof, are contemplated in the compounds of the present
invention.
The compounds to be used in the present ion can exist in unsolvated forms
as well as solvated forms, including hydrated forms. In general, the solvated forms,
including hydrated forms, are equivalent to unsolvated forms and are ed to be
encompassed within the scope of the present invention.
III. Pharmaceutical Compositions
The present invention r provides pharmaceutical compositions comprising a
compound of the present invention, or a pharmaceutically acceptable salt thereof, together
with a pharmaceutically acceptable carrier, diluent, or excipient therefor. The
pharmaceutical composition may n two or more compounds of the present invention
(i.e., two or more compounds of the present invention may be used together in the
pharmaceutical composition). Preferably, the pharmaceutical ition contains a
therapeutically effective amount of at least one compound of the present invention. In
another embodiment, these itions are useful in the treatment of an AXL- or c-
MET- mediated disorder or condition. The compounds of the invention can also be
ed in a pharmaceutical composition that also comprises compounds that are useful
for the ent of cancer or another AXL- or c-MET- mediated disorder.
A compound of the present invention can be formulated as a ceutical
composition in the form of a syrup, an elixir, a suspension, a powder, a granule, a tablet, a
capsule, a lozenge, a troche, an aqueous solution, a cream, an ointment, a lotion, a gel, an
on, etc. ably, a compound of the present invention will cause a decrease in
symptoms or a disease indicia associated with an AXL or c-MET- mediated er as
measured quantitatively or qualitatively.
For preparing a pharmaceutical composition from a compound of the present
invention, pharmaceutically able carriers can be either solid or liquid. Solid form
preparations include powders, tablets, pills, capsules, cachets, suppositories, and
dispersible granules. A solid carrier can be one or more substances which may also act as
ts, flavoring agents, binders, preservatives, tablet disintegrating agents, or an
encapsulating material.
In powders, the carrier is a finely divided solid which is in a mixture with the
finely d active component (i.e., compound of the present invention). In tablets, the
active ent is mixed with the carrier having the necessary binding properties in
suitable proportions and compacted in the shape and size d.
The powders and tablets contain from 1% to 95% (w/w) of the active compound
(i.e., compound of the present invention). In another embodiment, the active compound
ranges from 5% to 70% (w/w). Suitable carriers are magnesium carbonate, magnesium
stearate, talc, sugar, lactose, , dextrin, starch, gelatin, tragacanth, methylcellulose,
sodium ymethylcellulose, a low melting wax, cocoa butter, and the like. The term
"preparation" is intended to include the formulation of the active compound with
encapsulating material as a carrier providing a capsule in which the active component with
or without other carriers, is surrounded by a carrier, which is thus in association with it.
Similarly, cachets and es are included. Tablets, powders, capsules, pills, cachets,
and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid
glycerides or cocoa butter, is first melted and the active component is dispersed
neously therein, as by stirring. The molten homogeneous mixture is then poured
into convenient sized molds, allowed to cool, and thereby to solidify.
Liquid form preparations e solutions, suspensions, and emulsions, for
example, water or water/propylene glycol solutions. For parenteral injection, liquid
preparations can be formulated in solution in aqueous polyethylene glycol on.
Aqueous solutions suitable for oral use can be prepared by dissolving the active
component in water and adding suitable colorants, flavors, stabilizers, and thickening
agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing
the finely divided active component in water with viscous al, such as natural or
tic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-
known suspending agents.
Also included are solid form preparations which are intended to be converted,
y before use, to liquid form preparations for oral administration. Such liquid forms
e solutions, suspensions, and emulsions. These preparations may contain, in
addition to the active component, colorants, flavors, stabilizers, buffers, artificial and
natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The pharmaceutical preparation is ably in unit dosage form. In such form the
preparation is subdivided into unit doses containing appropriate quantities of the active
component. The unit dosage form can be a packaged preparation, the package ning
discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials
or ampoules. Also, the unit dosage form can be a capsule, tablet, , or lozenge itself,
or it can be the appropriate number of any of these in packaged form.
The quantity of active component in a unit dose preparation may be varied or
adjusted from 0.1 mg to 1000 mg, preferably 1.0 mg to 100 mg, or from 1% to 95% (w/w)
of a unit dose, according to the particular application and the potency of the active
component. The composition can, if desired, also contain other compatible therapeutic
agents.
Pharmaceutically acceptable carriers are determined in part by the ular
ition being stered, as well as by the particular method used to administer the
composition. Accordingly, there is a wide variety of suitable formulations of
pharmaceutical compositions of the present invention (see, e.g., Remington: The Science
and Practice ofPharmacy, 20th ed., Gennaro et al. Eds., cott Williams and
Wilkins, 2000).
A compound of the present invention, alone or in combination with other suitable
components, can be made into aerosol formulations (i.e., they can be "nebulized") to be
administered via inhalation. Aerosol formulations can be placed into pressurized
able propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
Formulations suitable for parenteral administration, such as, for example, by
intravenous, intramuscular, intradermal, and subcutaneous , include aqueous and
non-aqueous, ic sterile injection solutions, which can contain antioxidants, buffers,
bacteriostats, and solutes that render the formulation isotonic with the blood of the
intended recipient, and aqueous and nonaqueous e suspensions that can include
suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. In the
practice of this invention, itions can be administered, for example, by intravenous
infusion, orally, topically, intraperitoneally, intravesically or intrathecally. The
formulations of compounds can be presented in unit-dose or multi-dose sealed containers,
such as ampoules and vials. Injection solutions and suspensions can be prepared from
sterile powders, es, and tablets of the kind previously described.
The dose stered to a subject, in the context of the present invention, should
be sufficient to effect a beneficial therapeutic response in the subject over time. The dose
will be determined by the cy of the particular compound employed and the condition
of the subject, as well as the body weight or surface area of the subject to be treated. The
size of the dose also will be determined by the existence, nature, and extent of any e
side-effects that accompany the administration of a particular compound in a particular
subject. In ining the effective amount of the compound to be administered in the
treatment or laxis of the disorder being treated, the physician can evaluate factors
such as the circulating plasma levels of the compound, compound toxicities, and/or the
progression of the disease, etc. In general, the dose equivalent of a compound is from
about 1 ug/kg to 10 mg/kg for a typical subject. Many different administration methods
are known to those of skill in the art.
For administration, compounds of the present invention can be administered at a
rate determined by factors that can include, but are not limited to, the LD50 of the
compound, the pharmacokinetic profile of the compound, contraindicated drugs, and the
side-effects of the nd at various concentrations, as applied to the mass and l
health of the subject. Administration can be accomplished via single or divided doses.
IV. Methods of Treatment
In another aspect, the t invention provides a method of treating a t
suffering from an AXL- or c-MET-mediated disorder or condition comprising
administering to the subject a therapeutically effective amount of a compound of the
present invention or a ceutically acceptable salt form f. In another ,
the present invention provides a nd of the present invention or a pharmaceutically
acceptable salt form thereof for use in treating a subject suffering from an AXL or c-MET-
mediated disorder or condition. Preferably, the compound of the present invention or a
pharmaceutically acceptable salt form thereof is administered to the subject in a
pharmaceutical composition comprising a pharmaceutically acceptable carrier. In another
aspect, the present invention provides a pharmaceutical composition comprising a
compound of the present invention or a ceutically acceptable salt form thereof for
use in treating a subject ing from an AXL- or c-MET- mediated disorder or
condition. In another embodiment, the AXL- or c-MET- mediated ion or disorder is
cancer. In another embodiment, the AXL- or c-MET-mediated disorder or condition is the
development of resistance to cancer ies. In another embodiment, the AXL or c-
MET- mediated condition is selected from chronic myelogenous leukemia, chronic
myeloproliferative disorder, lung cancer, prostate cancer, geal cancer, ovarian
cancer, pancreatic cancer, gastric cancer, liver cancer, thyroid cancer, renal cell carcinoma,
glioblastoma, breast , acute myeloid leukemia, colorectal cancer, uterine cancer,
malignant glioma, uveal melanoma, osteosarcoma and soft tissue sarcoma.
The AXL- or c-MET- mediated disorder or condition can be treated
prophylactically, acutely, and cally using compounds of the present invention,
depending on the nature of the er or ion. Typically, the host or subject in each
of these methods is human, although other mammals can also benefit from the
administration of a compound of the present invention.
In another embodiment, the present ion es a method of treating a
proliferative disorder in a subject in need thereof, sing administering to the subject
a therapeutically ive amount of a compound of the present invention or a
pharmaceutically acceptable salt form thereof. In another aspect, the present invention
provides a compound of the present invention or a ceutically acceptable salt form
thereof for use in treating a proliferative disorder in a t in need thereof. Preferably,
the compound of the present invention or a pharmaceutically acceptable salt form thereof
is administered to the subject in a pharmaceutical ition comprising a
pharmaceutically acceptable carrier. In another aspect, the present invention provides a
pharmaceutical composition comprising a compound of the present invention or a
pharmaceutically acceptable salt form thereof for use in treating a proliferative disorder in
-3 5 _
a subject. In certain embodiments, the proliferative disorder is AXL- or c-MET-
mediated. In certain embodiments, the proliferative disorder is cancer. In certain
embodiments, the proliferative disorder is selected from chronic myelogenous leukemia,
chronic myeloproliferative disorder, lung cancer, prostate cancer, esophageal cancer,
ovarian cancer, pancreatic , gastric cancer, liver , thyroid cancer, renal cell
carcinoma, glioblastoma, breast cancer, acute myeloid leukemia, colorectal cancer, uterine
cancer, malignant glioma, uveal melanoma, osteosarcoma and soft tissue sarcoma.
The proliferative disorder can be treated prophylactically, acutely, and chronically
using compounds of the present ion, depending on the nature of the disorder or
condition. Typically, the host or subject in each of these methods is human, although
other mammals can also benefit from the administration of a nd of the present
invention.
In therapeutic applications, the compounds of the t invention can be
prepared and administered in a wide variety of oral and parenteral dosage forms. Thus,
the compounds of the present ion can be administered by injection, that is,
intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or
intraperitoneally. Also, the compounds described herein can be administered by
tion, for example, intranasally. Additionally, the compounds of the present
invention can be stered transdermally. In another embodiment, the compounds of
the present invention are delivered orally. The compounds can also be delivered rectally,
bucally or by insufflation.
The compounds utilized in the pharmaceutical method of the invention can be
administered at the initial dosage of about 0.001 mg/kg to about 100 mg/kg daily. In
another embodiment, the daily dose range is from about 0.1 mg/kg to about 10 mg/kg.
The dosages, however, may be varied depending upon the requirements of the subject, the
severity of the ion being treated, and the compound being employed. Determination
of the proper dosage for a particular situation is within the skill of the practitioner.
Generally, treatment is initiated with smaller dosages which are less than the optimum
dose of the nd. Thereafter, the dosage is increased by small ents until the
optimum effect under the circumstances is d. For convenience, the total daily
dosage may be divided and administered in ns during the day, if desired.
V. Chemistry
Unless ise indicated, all reagents and solvents were obtained from
commercial sources and used as received. 1H NMRs were obtained on a Bruker Avance
at 400 MHz in the solvent indicated with tetramethylsilane as an internal standard.
Analytical HPLC was run using a Zorbax RX-C8, 5 X 150 mm column eluting with a
mixture of acetonitrile and water containing 0.1% trifluoroacetic acid with a gradient of
-100%. LCMS results were obtained from a Bruker e 2000 Mass Spec with the
Agilent 1100 HPLC equipped with an Agilent Eclipse XDB-C8, 2 X 30 mm 3.5 micron
column. The column was at room temperature, with a run time of five (5) minutes, a flow
rate of 1.0 mL/min, and a solvent mixture of 10% (0.1% formic acid/water) : 100%
(acetonitrile/0.1% formic acid). Automated normal phase column chromatography was
performed on a CombiFlash Companion (ISCO, Inc.). Reverse phase preparative HPLC
was performed on a Gilson GX-28l equipped with Gilson 333 and 334 pumps using a
Phenomenex 00F00-AX Gemini-NX 5 u C18 column. Melting points were taken on
a Mel-Temp apparatus and are uncorrected.
Synthesis
The compounds of the present ion can be synthesized using the methods
described below or by using methods known to one skilled in the art of organic chemistry
or variations thereon as appreciated by those skilled in the art. The preferred s
include, but are not limited to or by, those described below. Unless otherwise stated,
starting compounds are of commercial origin or are readily synthesized by standard
methods well known to one d in the art of c synthesis.
The ons are performed in solvents riate to the reagents, and materials
ed are suitable for the transformations being effected. Also, in the description of
the synthetic methods below, it is to be understood that all proposed reaction conditions,
including choice of solvent, reaction atmosphere, reaction ature, duration of
experiment and workup ures are chosen to be conditions standard for that reaction
which should be readily recognized by one skilled in the art of organic synthesis.
It is understood that the examples and embodiments described herein are for
illustrative purposes only and that various modifications or changes in light f will be
suggested to persons skilled in the art and are to be included within the spirit and purview
of this application and the scope of the appended claims. Specific chemical
transformations are listed in the ensuing schemes and one skilled in the art appreciates that
a variety of different reagents may be used in place of those listed. Common replacements
for such reagents can be found in, but not d to, texts such as “Encyclopedia of
Reagents for Organic Synthesis” Leo A. Paquette John Wiley & Son Ltd (1995) or
“Comprehensive Organic Transformations: A Guide to Functional Group Preparations”
Richard C. Larock. Wiley-VCH and “Strategic Applications ofNamed Reactions in
Organic sis” Kurti and Czako, Elsevier, 2005 and references therein.
The examples of the present invention may be produced according to synthesis
routes as depicted in Schemes 1 to 6, and by the synthetic procedures described herein and
within the examples.
Rb' N
Ra .
Scheme 1
In Scheme 1, W and X are as defined herein. T is Br, Cl or I. D’ is OH, SH, NH2,
or NH-alkyl. D is O, S, NH, or N-alkyl. Ra’, Rb’, Rc’, Rd’, R1’ and R2’ are Ra, Rb, RC, Rd,
R1 and R2, respectively, as defined herein, or are synthetic precursors thereto. Y is N, CH
or C, Where C may be tuted by one of the groups R1’ or R2’.
Looking at Scheme 1, substituted 4-chloroquinolines or 4-bromoquinoline
derivatives are known and can be synthesized as bed in the literature from properly
substituted arylamines and m’s acid in the presence of trimethyl orthoformate
(Bioorg. Medchem. Lett., 1997, 7, 789, WO9813350, US20080004273). Alternatively
ly substituted quinolines can be sized from substituted acetophenones by
methods bed in the literature (for example J. Med. Chem. 2005, 48, 1359;
EP1153920; 45084). Quinazolines analogs may be synthesized by literature
methods (described in J. Med. Chem. 2005, 48, 1359; J. Med. Chem. 2006, 49, 2186; J.
Med. Chem. 2010, 53, 8089). The synthesizes of N, O, and S linker quinolines and
quinazolines intermediates are described in J. Med. Chem. 2005, 48, 1359A 4-
(aminophenoxy)quinoline derivative may be produced by ng a henol derivative
with the 4-chloroquinoline derivative in a suitable solvent, for example, chlorobenzene, to
synthesize a 4-(nitrophenoxy)-quinoline derivative or a corresponding quinazoline
derivative and then reacting the 4-(nitrophenoxy)quinoline derivative in a suitable solvent,
for example, N,N—dimethyl formamide, ethanol or ethyl e in the presence of a
catalyst, for example, palladium hydroxide-carbon or palladium-carbon, under a hydrogen
here. The nitro group can also be reduced with zinc or iron. Alternatively, the 4-
phenoxy)quinoline derivative can be produced by reacting an aminophenol
derivative with the 4-chloroquinoline tive in a suitable t, for example,
dimethyl sulfoxide or N,N—dimethyl ide, in the presence of a base, for example,
sodium hydride or potassium t-butoxide. The 4-(aminophenoxy)-quinazoline derivative
can be produced by dissolving an aminophenol derivative in an aqueous sodium hydroxide
solution and subjecting the solution to a two phase reaction with a solution of the 4-
chloroquinazoline derivative in a suitable solvent, DMF, THF, or ethyl methyl ketone, in
the presence of a phase transfer catalyst, for example, tetra-n-butylammonium chloride.
An example of the synthesis of oxo-l,2,3,4-tetrahydro-pyrimidine
carboxylic acids is shown in Scheme 2.
O O
o 0 EtO 05‘ F
DCE, DIEA, 90° | NaOEt/ EtOH, 0 O 0
EC —>
| NH —>
~85°/° J=O 90 /°0
NH LN
2 ONCQ HN N O
2—Aminomethylene—malonate
4-FIuoro-phenyl)-ureidomethy|ene]—
malonic acid diethyl ester
F F
o o o o
R-X, DMF, 60 aC, Method A
EtO N H0 N
| [Tl/KO |
4M HCI, C4H802, water 70 °C N’go
Method B
LiOH, THF, MeOH
Scheme 2
Where, in Scheme 2, DCE is dichloroethane, DIEA is diisopropylethylamine,
NaOEt is sodium ethoxide, EtOH is ethanol, DMF is dimethylformamide, C4H802 is
dioxane, THF is tetrahydrofuran, MeOH is ethanol, and R—X is an alkyl halide.
ng with a 2-aminomethylene malonate and reacting with any appropriate aryl,
heteroaryl or alkyl isocyanate produces ureidomethylene-malonic acid . The
ureidomethylene-malonic acid esters can be cyclized using a base such as KOH, NaOH or
sodium ethoxide in ethanol to produce the Nl-H 2,4-dioxo-l ,2,3,4-tetrahydro-pyrimidine-
-carboxylic acid esters. Starting with an N—substituted omethylene malonate
produces an Nl substituted 2,4-dioxo-l,2,3,4-tetrahydro-pyrimidinecarboxylic acid
ester. Starting with substitution on the methylene malonate, for example 2-(l-
aminoethylidene)-malonic acid ester or 2-(1-aminocyclopropyl-ethylidene)-malonic
acid ester produces the corresponding C6 substituted 2,4-dioxo-l,2,3,4-tetrahydro-
pyrimidinemethylcarboxylic acid ester or 2,4-dioxo-l,2,3,4-tetrahydro-pyrimidine
cyclopropylmethyl-S-carboxylic acid ester. The Nl-H intermediate may be alkylated
under standard conditions using a base, for example K2C03 in a solvent such as
dimethylsulfoxide or dimethylformamide to produce the Nl-substituted-2,4-di0X0-l -
tetrahydro-pyrimidine-S-carboxylic acid ester.
2,4-dioxo-l,2,3,4-tetrahydro-pyrimidinecarboxylic acid esters that are N1 and
N3 unsubstituted may be mono- or dialkylated using standard conditions as outlined in
Scheme 3 or Scheme 4.
o 0 0 o
o NH —>
I HOwN’
2 ”A, NAG
Scheme 3
a. alkyl halide 80 0C. b. lN LiOH, tetrahydrofuran,
, K2C03, dimethylformamide,
methanol, 65 0C, or 4N HCl in aqueous dioxane, 80 0C.
H 1
Ii] I?
EtOZC COZEt a,b (5(ngK Y c, d N o
1/ 2 I T
R HO
H2N \R2
0 O
O 0
Scheme 4
a. RZNCO, DIEA, dichloroethane, 100 0C, 6 hr. b. sodium ethoxide, ethanol, rt, 18
hr. c. thalide, K2C03, dimethylformamide, 80 0C. d. 4N HCl in s dioxane, 80 0C,
Where R1 and R2 are alkyl
Hydrolysis of the 2,4-dioxo-l,2,3,4-tetrahydro-pyrimidinecarboxylic acid esters
may be achieved under standard acid or basic hydrolysis conditions to produce the acids.
a. ethyl isocyanate, tetrahydrofuran, 0 0C. b. diethyl ethoxymethylenemalonate,
sodium ethoxide, ethanol, rt, 48 hr. c. ethyl acetate / s. D. IN LiOH, ol,
tetrahydrofuran, 60 0C, 18hr.
Examples Where 2,4-dioxo-l,2,3,4-tetrahydro-pyrimidinecarboxylic acid amides
are N1 aryl or N1 heteroaryl may be synthesized as outlined in Scheme 5. The synthesis of
N1 4-fluorophenyl is delineated for Example 91. The sequential reaction of 4-fluoroaniline
with ethyl isocyanate then diethyl ethoxymethylenemalonate produces l(4-fluoro-
phenyl)-2,4-dioxo-l ,2,3,4-tetrahydro-pyrimidinecarboxylic acid ethyl ester and 3-ethyll-
ro-phenyl)-2,4-dioxo- l ,2,3 ,4-tetrahydro-pyrimidinecarboxylic acid ethyl ester.
The uorophenyl) isomer is readily separated by crystallization. 3-Ethyl-l-(4-
fluorophenyl)-2,4-dioxo-l,2,3,4-tetrahydro-pyrimidinecarboxylic acid is produced
under basic hydrolysis and can also be sized under acid conditions, then coupled to
(6,7-dimethoxyquinolinyloxy)fluorophenylamine to produce the N1 aryl amide
example 91.
3,5-Dioxo-2,3,4,5-tetrahydro-[l,2,4]triazinecarboxylic acid esters may be
synthesized as outlined in Scheme 6.
0" M0F 000 000
O N,an| —> MNAO|
H H
F F
—>ON|/I\L”M HONI/ILM HOINM
M M
R R
Scheme 6
2-Oxo-malonic acid diethyl ester and 4-fluorophenyl thiosemicarbazide
condensation produced 4-(4-fluorophenyl)oxothioxo-2,3,4,5-tetrahydro-
[1,2,4]triazinecarboxylic acid ethyl ester. Oxidation with, for example hydrogen
peroxide and acetic acid produces 4-(4-fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-
[1,2,4]triazinecarboxylic acid ethyl ester. Alkylation under conditions bed for
2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid esters produced N2-substituted
4-(4-fluorophenyl)-3 xo-2,3 ,4,5 -tetrahydro- [1 ,2,4]triazinecarboxylic acid ethyl
esters. N1 and or N4 unsubstituted 3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine
carboxylic acid ethyl esters may be ted to e the corresponding substituted 3,5-
dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid ethyl esters. Hydrolysis of the
3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid ethyl esters may be
achieved under acidic or basic conditions to produce 3,5-dioxo-2,3,4,5-tetrahydro-
[1,2,4]triazinecarboxylic acids. ng aniline ediates with these acids may be
achieved using known standard procedures HATU, HOBT or EDCI, in an appropriate
solvent such as DMF or THF or by converting the acid to the acid chloride and reacting
with the amine in an inert solvent.
Examples
l synthesis methods for 2,4-di0x0-1,2,3,4-tetrahydropyrimidine-S-carboxylic
acids
Method A: 1-cyclopropylmethyl(4-fluorophenyl)-2,4-dioxo-1,2,3 ,4-
tetrahydropyrimidine- 5-carboxylic acid
a) 2-Aminomethylene-malonic acid diethyl ester (16.7 g, 89.2 mmol) and 4-
fluorophenyl isocyanate (10.6 mL, 93.7 mmol) in 1,2-dichloroethane (25 mL, 320
mmol) was added N,N—diisopropylethylamine (17.1 mL, 98.1 mmol) and heated at
100 0C for 6h. The mixture was cooled on an ice bath and the solid collected and
washed with ether to give the urea (24.5 g, 85%). mp = 198-200 0C; LCMS m/z =
347 (M + 23);1HNMR(DMSO)8: 10.57 (d, 1H, J = 12.3 Hz), 10.41 (s, 1H), J =
12.45 Hz), 8.45 (d, 1H, J = 12.5 Hz), 7.48-7.53 (m, 2H), 7.16-7.21 (m, 2H), 4.24
(q, 2H, J = 7 Hz), 4.15 (q, 2H, J = 7 Hz), 1.22-1.28 (m, 6H).
b) 2-[3-(4-Fluorophenyl)ureidomethylene]malonic acid diethyl ester (24 g; 70 mmol)
was suspended in Ethanol (100 mL) and added 21% NaOEt in EtOH (41.7 mL,
112 mmol) drop wise at rt. The mixture was stirred 4h, upon which time the
mixture became thick slurry. The mixture was concentrated and the residue
partitioned between ethyl acetate (EtOAc) and 1M citric acid. The EtOAc layer
was washed with water and brine, dried over MgSO4 and was concentrated. The
solid was triturated with ether-hexanes (1/3) to give 3-(4-fluorophenyl)-2,4-dioxo-
1,2,3,4-tetrahydropyrimidinecarboxylic acid ethyl ester as a white solid. mp
206-8 c’C; LCMS m/z = 279 (M + 1);1H NMR (DMSO) 8: 12.0 (s, 1H), 8.25 (s,
1H),7.31 (bs, 2H), 7.29 (d, 2H, J = 3 Hz), 4.17 (q, 2H, J = 7 Hz), 1.23 (t, 3H, J = 7
Hz).
luorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid ethyl
ester (3.50 g, 11.6 mmol), potassium carbonate (3.22 g, 23.3 mmol) and
cyclopropylmethyl e (3.39 mL, 35.0 mmol) in N,N—dimethylformamide
(DMF) (10 mL) was heated at 65 0C for 12h. The mixture was cooled to rt,
ioned between EtOAc and 1N Na2C03, water and brine and then dried over
MgSO4. LCMS m/z = 333 (M + 1); 1H NMR (CDCLg): 8.42 (s, 1H), 7.16-7.19 (m,
4H), 4.35 (q, 2H, J = 7 Hz), 3.74 (d, 2H, J: 7 Hz), 1.35 (t, 3H, J =7 Hz), 1.25 (m,
1H), 0.72 (m, 2H), 0.42 (m, 2H).
d) The oil from step c was dissolved in methanol (10 mL) and tetrahydrofuran (10
mL) and 1 M of m hydroxide (10.6 mL) was added. After stirring at rt for 6h
the mixture was concentrated and extracted with 1N N32C03 (2x). The basic layer
was ed with 1N HCl on an ice bath and the product collected and dried to
give 1-cyclopropylmethyl(4-fluorophenyl)-2,4-dioxo- 1 ,2,3 ,4-
tetrahydropyrimidine- 5-carboxylic acid as a white solid. LCMS m/z = 305 (M +
1); 1H NMR (DMSO) 8: 12.62 (s, 1H), 8.82 (s, 1H), 7.30-7.39 (m, 4H), 3.79 (d,
2H, J = 7.2 Hz), 1.20 (m, 1H), 0.50-0.55 (m, 2H), 0.38-0.42 (m, 2H).
Method B: 3-(4-Fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine
carboxylic acid
a) 3-(4-Fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid ethyl
ester (15 g, 54 mmol), potassium carbonate (14.9 g, 108 mmol) and isopropyl
iodide (10.8 mL, 108 mmol) in N,N—dimethylformamide (35 mL) was heated at 70
0C for 12 h. The mixture was concentrated, ved in EtOAc and was filtered.
The EtOAc layer was washed with 1N N32C03, water and brine and was
concentrated. The product was crystallized from EtOAc-ether—hexanes to give [3-
(4-fluorophenyl)isopropyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic
WO 74633
acid ethyl ester as a white solid (15.5 g, 90%). mp 142-4 oC; LCMS m/z = 321 (M
+ 1), 1H NMR(CDC13) 8: 8.35 (s, 1H), 7.14-7.19 (m, 4H), (4.91 (h, 1H, J = 6.8
Hz), 4.35 (q, 2, J = 7.2 Hz), 1.44 (d, 6H, J = 7 Hz), 1.36 (t, 3H, J = 7.2 Hz).
b) [3 -(4-Fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -
carboxylic acid ethyl ester (15 g, 47 mmol) was added 4M HCl in dioxane (18.7
mL, 216 mmol) and water (5 mL) and heated at 70 OC overnight. The product upon
cooling itated, additional water (~ 10 mL) was added and the product
collected and dried to give 3-(4-fluorophenyl)isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidine- 5-carboxylic acid as a white solid. mp 168-9 C’C; LCMS m/z
= 293 (M + 1); 1H NMR (DMSO) 5: 12.67 (s, 1H), 8.58 (s, 1H), 7.29-7.39 (M,
4H), 4.72 (h, 1H, J = 6.8 Hz), 1.38 (d, 6H, J = 6.8 Hz).
Method C. 3-(4-Fluorophenyl)(3-methoxypropyl)-2,4-dioxo-1,2,3 ,4-tetrahydro-
pyrimidine- 5-carboxylic acid
a) 3-(4-Fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid
(0.25 g, 1.0 mmol), and potassium carbonate (0.55 g, 4.0 mmol) in N,N-
dimethylformamide (5 mL, 60 mmol) was heated at 65 CC for 12h. The mixture
was filtered, concentrated and d with EtOAc. The EtOAc solution was
washed with water and brine then dried over MgSO4 and concentrated to give an
oil.
b) This oil was dissolved in methanol/tetrahydrofuran (MeOH/THF) (1 :1; 5 mL) and
added 3 mL 1N LiOH, then heated at 60 0C for 1h. The cooled on was made
acidic with concentrated HCl and the white solid collected to give 125 mg (40%)
of 3-(4-fluorophenyl)(3-methoxy-propyl)-2,4-dioxo-1,2,3 ,4-
tetrahydropyrimidinecarboxylic acid as a white solid. LCMS m/z = 323 (M +
1); 1H NMR (DMSO) 5: 12.6 (s, 1H), 8.7 (s, 1H), 7.30-7.37 (m, 4H), 3.97 (t, 2H, J
= 7.2 Hz), 3.39 (t, 2H, J = 6.3Hz), 3.2 (s, 3H), 1.88 (q, 2H, J = 6.2 Hz).
The following 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acids were
synthesized using methods A, B or C described above.
3 -(4-Fluorophenyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 xylic acid.
LCMS m/z = 251 (M + 1);1H NMR (DMSO) 8: 12.56 (b, 1H), 12.39 (s, 1H), 8.36
(s, 1H), 7.29-7.38 (M, 4H).
1—3-(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid. mp = 166-8 oC; LCMS m/z = 279 (M + 1); 1H NNR (DMSO) 5: 12.6 (bs,
1H), 8.82 (s, 1H), 7.29-7.38 (m, 4H), 3.94 (q, 2H, J = 7.3 Hz), 1.25 t, 3H, J = 7
Hz).
3 -(4-F1uorophcny1)rncthy1—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid LCMS m/z = 265 (M + 1); 1HNMR (DMSO) 5: 12.59 (s, 1H), 8.80 (s, 1H),
7.3 (m, 4H), 3.56 (s, 3H).
1—3-(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid. LCMS m/z = 291 (M + 1); 1H NMR (DMSO) 8: 1H NMR (DMSO) 5: 12.66
(s, 1H), 8.72 (s, 1H), 7.27-7.41 (m, 4H), 5.89-5.99 (m, 1H), 5.24-5.35 (m, 2H),
4.53 (m, 2H).
1-(3 ,3 -Diflu0r0a11y1)—3 -(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 rahydr0pyrirnidinc-5 -
carboxylic acid. LCMS m/z = 327 (M + 1); 1H NMR (DMSO) 5: 12.6 (s, 1H), 8.8
(s, 1H), 7.31-7.34 (m, 4H), 4.90-4.96 (m, 1H), 4.84-4.86 (m, 1H), 4.54 (d, 2H) 4.78
(m, 1H), 4.60-4.68 (M, 1H), 4.56-4.59 (m, 1H), 4.49 (m, 1H), 4.47 (m, 1H).
3 -(4-F1u0r0phcny1)—1-(3 -rncthy1—butcny1)—2,4-diox0- 1 ,2,3 ,4-tctrahydr0-
pyrimidinecarboxy1ic acid. LCMS m/z = 342 (M + 23); 1H NMR (DMSO) 5:
12.6 (s, 1H), 8.7 (s, 1H), 7.30-7.38 (m, 4H), 5.3 (m, 1H), 4.49 (m, 2H), 1.7 (s, 6H).
3 -(4-F1uor0phcny1)-2,4-di0x0pr0py1— 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid. LCMS m/z = 293 (M + 1); 1H NMR (DMSO) 5: 12.62 (s, 1H), 8.78 (s, 1H),
7.30-7.37 (m, 4H), 3.87 (t, 2H, J = 7.5 Hz), 1.67 (q, 2H, J = 7.5 Hz), 0.89 (t, 3H, J
= 7.5 Hz).
3 -(4-F1uorophcny1)- 1 ty1—2,4-di0xo- 1 ,2,3 ,4-tctrahydr0-pyrirnidinc
carboxylic acid. LCMS m/z = 307 (M + 1).
3 -(4-F1uor0phcny1)—2,4-di0x0pcnty1— 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 xy1ic
acid. LCMS m/z = 321 (M +1); 1H NMR (DMSO) 8: 12.62 (s, 1H), 8.78 (s, 1H),
7.30-7.38 (m, 4H), 3.89 (m, 2H), 1.65 (m, 2H), 1.28 (m, 4H), 0.87 (t, 3H, J =7.4
Hz).
1-Ethy1—3-(4-fluor0phcny1)rncthy1—2,4-dioxo-1 ,2,3 ,4-tctrahydropyrirnidinc
carboxylic acid. LCMS m/z = 293 (M + 1); 1H NMR (DMSO) 5: 13.36 (s, 1H),
7.28-7.33 (m, 4H), 3.96 (q, 2H, J = 7H2), 2.57 (s, 3H), 1.21 (t, 3H, J = 7 Hz).
1-(2-Eth0xycthy1)—3-(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -
carboxylic acid. LCMS m/z = 323 (M + 1); 1H NMR (DMSO) 5: 12.509 (5, 1H),
8.66 (s, 1H), 7.39-7.39 (rn, 4H), 4.09 (t, 2H, J = 5 Hz), 3.61 (t, 2H, J = 5 Hz), 3.47
(q, 2H, J = 7.2 Hz), 1.11 (t, 3H, J = 7.2 Hz).
1 -(2-Benzyloxyethyl)—3-(4-fluorophenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrirnidine-
-carboxylic acid. LCMS rn/z = 385 (M + 1); 1H NMR (DMSO) 5: 12.59 (s, 1H),
8.72 (s, 1H), 7.31-7.34 (rn, 9H), 4.52 (s, 2H), 4.15 (t, 2H, J = 5 Hz), 3.68 (t, 2H, J =
5Hz).
3 -(4-Fluorophenyl)—1-(2-isopropoxy-ethyl)-2,4-dioxo-1,2,3 ,4-
tetrahydropyrirnidinecarboxylic acid. LCMS rn/z = 337 (M + 1). 1H NMR
(DMSO) 5: 12.57 (s, 1H), 8.67 (s, 1H), 7.32-7.36 (rn, 4H), 4.06 (br, 2H), 3.6 (hr,
3H), 1.07 (d, 6H, J = 6 Hz).
1-(3 -Benzyloxypropyl)(4-fluorophenyl)—2,4-dioxo- 1 ,2,3 ,4-
ydropyrirnidinecarboxylic acid. LCMS rn/z = 399 (M + 1); 1H NMR
(DMSO) 5: 12.59 (s, 1H), 8.75 (s, 1H), 7.24-7.35 (rn, 9H), 4.43 (s, 2H), 4.01 (rn,
2H), 3.53 (rn, 2H), 1.74 (rn, 2H).
3 -(4-Fluorophenyl)— 1 -(2-rnorpholinyl-ethyl)-2,4-dioxo- 1 ,2,3 rahydro-
pyrimidinecarboxylic acid; hydrochloride. LCMS rn/z = 400 (M + 1). 1H NMR
(DMSO) 8: 11.11 (br, 1H), 10.18 (br, 1H), 7.43 (rn, 2H), 7.35 (rn, 2H), 4.32 (br,
2H), 3.93 (rn, 4H), 3.73-3.79 (rn, 6H).
1-((S)-2,2-Dirnethyl- 1 ,3 -dioxolanylrnethyl)—3 -(4-fluoro-phenyl)-2,4-dioxo-
1,2,3,4-tetrahydropyrirnidinecarboxylic acid. LCMS m/z = 365 (M + 1). 1H
NMR (DMSO) 5:12.60 (5, 1H), 8.66 (s, 1H), 7.34 (rn, 4H), 4.34 (br, 1H),4.12 (rn,
1H),4.01 (rn, 2H),3.72 (rn, 1H), 1.30 (s, 3H), 1.27 (s, 3H).
1-(2-Dirnethylarninoethyl)(4-fluoro-phenyl)-2,4-dioxo-1,2,3 ,4-
ydropyrirnidinecarboxylic acid; hydrochloride. LCMS rn/z = 358 (M + 1);
1H NMR (DMSO) 8: 12.4 (b, 1H), 10.3 (s, 1H), 8.76 (s, 1H), 7.3-7.42 (rn, 4H), 4.3
(t, 2H, J = 7Hz), 3.4 (rn, 2H), 2.8 (d, 6H),
3 -(4-Fluorophenyl)-2,4-dioxo(2-pyrrolidinyl-ethyl)-1 ,2,3 ,4-tetrahydro-
pyrimidinecarboxylic acid; hydrochloride. LCMS rn/z = 384 (M + 1); 1H
NMR(DMSO) 5: 12.63 (br s, 1H), 11.01 (s, 1H), 8.82 (s, 1H), 7.45 (rn, 2H), 7.34
(rn, 2H), 4.29 (t, 2H, J = 5.2 Hz), 3.47 (rn, 4H), 3.05 (rn, 2H), 1.89-2.0 (rn, 4H).
3 -(4-Fluorophenyl)-2,4-dioxo(2-piperidinyl-ethyl)-1,2,3 ,4-
ydropyrirnidinecarboxylic acid; hydrochloride. LCMS rn/z = 398 (M + 1).
3 -Cyclohexylethyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrirnidine-5 -carboxylic acid.
LCMS rn/z = 267 (M + 1); 1H NMR (DMSO) 5: 12.87 (s, 1H), 8.70 (s, 1H), 4.67
(rn, 1H), 3.98 (rn, 2H), 2.26 (rn, 2H), 1.78 (rn, 2H),1.60 (rn, 3H), 1.07-1.33 (rn,
6H).
1-(3 -Dirnethy1arninopropy1)(4-fluoro-pheny1)—2,4-dioxo- 1 ,2,3 ,4-tetrahydro-
pyrimidinecarboxy1ic acid; hydrochloride. LCMS rn/z = 372 (M -- 1).
3 -(4-F1uoropheny1)—1-(3 -rnorpholiny1—propy1)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-
pyrimidinecarboxy1ic acid; hydrochloride. LCMS rn/z = 414 (M -- 1).
3 -(4-F1uoropheny1)-2,4-dioxo(tetrahydropyrany1)-1 ,2,3 ,4-
tetrahydropyrirnidinecarboxy1ic acid. LCMS rn/z = 335 (M + 1); 1H NMR
(DMSO) 5: 12.60 (s, 1H), 8.54 (s, 1H), 7.30-7.38 (rn, 4H), 4.58 (rn, 1H), 3.98 (rn,
2H), 3.39 (rn, 2H), 2.10 (rn, 2H), 1.80 (rn, 2H).
1 -(4-Benzyloxybuty1)(4-fluoropheny1)-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrirnidine-
-carboxy1ic acid. LCMS m/z = 413 (M + 1); 1H NMR (DMSO) 3 (5, 1H),
8/79 (s, 1H), 7.27-7.40 (rn, 4H), 4.46 (rn, 2H), 3.92 (rn, 2H), 3.40 (rn, 2H),1.60-
1.74 (rn, 2H), .48 (rn, 2H).
1-Cyclobuty1(4-fluoropheny1)-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrirnidine
carboxylic acid. LCMS rn/z = 305 (M + 1); 1H NMR(DMSO) 8: 12.64 (s, 1H),
8.82 (s, 0.5H) 8.52 (s, 0.5H), 7.30-7.39 (rn, 4H), 4.74 (rn, 0.5H), 3.78 (rn, 0.5H),
.40 (rn, 2H), 1.75 (rn, 1H), 1.22 (rn, 0.5), .54 (rn, 1.5H) NMR shows
rotarners.
3 -(4-F1uoropheny1)-2,4-dioxopropyny1— 1 ,2,3 ,4-tetrahydropyrirnidine-5 -
carboxylic acid. LCMS m/z = 289 (M + 1).
3 -(4-F1uoropheny1)—1-(2-irnidazoly1—ethy1)-2,4-dioxo-1,2,3 ,4-
tetrahydropyrirnidinecarboxy1ic acid. LCMS rn/z = 345 (M + 1).
3 -(4-F1uoropheny1)-2,4-dioxo(2-pyrazoly1-ethy1)-1,2,3 ,4-
tetrahydropyrirnidinecarboxy1ic acid. LCMS rn/z = 345 (M + 1).
3 -(4-F1uoropheny1)-2,4-dioxophenethy1— 1 ,2,3 ,4-tetrahydropyrirnidine-5 -
carboxylic acid. LCMS m/z = 355 (M + 1).
1-(2-[1,3]Dioxolany1—ethy1)(4-fluoro-pheny1)-2,4-dioxo-1,2,3 ,4-tetrahydropyrimidinecarboxy1ic
acid. LCMS m/z = 351 (M + 1).
1-Diethy1carbarnoylrnethy1(4-fluoropheny1)—2,4-dioxo- 1 ,2,3 ,4-
tetrahydropyrirnidinecarboxy1ic acid arnide. LCMS rn/z = 364 (M + 1).
3 -(4-F1uoro-pheny1)(2-rnorpholiny1—2-oxo-ethy1)-2,4-dioxo-1,2,3 ,4-
ydro-pyrirnidinecarboxy1ic acid arnide. LCMS m/z = 376 (M + 1).
3 -(4-F1u0r0pheny1)-2,4-di0x0[2-(2-0x0-pyrr01idiny1)-ethy1]—1,2,3 ,4-
tetrahydro-pyrimidinecarb0xy1ic acid. LCMS m/z = 362 (M + 1).
1-(2-F1uor0ethy1)(4-flu0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid. LCMS m/z = 397 (M + 1).
1 -tert-Butoxycarbonylmethy1(4-flu0r0phenyl)-2,4-diox0- 1 ,2,3 rahydr0-
dinecarb0xylic acid. LCMS m/z = 365 (M + 1).
3 -(4-F1uor0-phenyl)oxaz01y1methy1-2,4-di0x0-1 ,2,3 ,4-tetrahydr0-pyrimidine-
-carboxylic acid. LCMS m/z = 332 (M + 1).
3 -(4-F1u0r0-phenyl)-2,4-di0x0(tetrahydr0furanylmethyl)- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid. LCMS m/z = 335 (M + 1).
3 -(4-F1u0r0-phenyl)-2,4-di0x0(tetrahydro-pyrany1methy1)- 1 ,2,3 ,4-tetrahydr0-
dinecarb0xylic acid. LCMS m/z = 349 (M + 1).
3 -(4-F1u0r0-pheny1)(2-methy1-thiaz01—4-y1methy1)-2,4-di0xo-1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid. LCMS m/z = 362 (M + 1).
1-Cyc10penty1—3-(4-flu0ro-pheny1)-2,4-di0x0- 1 ,2,3 ,4-tetrahydr0pyrimidine-5 -
carboxylic acid. LCMS m/z = 319 (M + 1).
1-Benzy1—3-(4-flu0ro-pheny1)-2,4-di0x0- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
carboxylic acid amide. LCMS m/z = 340 (M + 1).
3 -(4-F1uor0phenyl)—1-[2-(2-flu0r0pheny1)-ethy1]-2,4-di0x0-1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid amide. LCMS m/z = 372 (M + 1).
3 -(4-F1uoropheny1)[2-(4-fluor0-pheny1)—ethy1] -2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid amide. LCMS m/z = 372 (M + 1).
1 -(2-Cyc10hexy1—ethy1)-3 -(4-flu0r0-pheny1)—2,4-di0x0-1,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid. LCMS m/z = 360 (M + 1).
3 -(4-F1uoropheny1)-2,4-di0x0-1 -(3 -pheny1pr0pyl)-1 ,2,3 rahydro-pyrimidine-5 -
carboxylic acid. LCMS m/z = 369 (M + 1).
3 -(4-F1uoropheny1)-2,4-di0x0-1 -(2-ox0pyrr01idin-1 -y1—ethy1)- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid. LCMS m/z = 362 (M + 1).
1 -Dimethy1carbamoylmethy1(4-flu0ro-pheny1)-2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid. LCMS m/z = 336 (M + 1).
1-(1-Dimethy1carbamoy1—2-0X0-pr0py1)(4-flu0ro-pheny1)-2,4-di0x0- 1 ,2,3 ,4-
tetrahydro-pyrimidinecarb0xy1ic acid. LCMS m/z = 378 (M + 1).
Example 1
2012/065019
OD: .. .
1-Ethyl(4-fluorophenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylicacid [4-
(6,7-dimethoxyquinolinyloxy)fluorophenyl]amide.
Step a. 4-(6,7-Dimethoxyquinolinyloxy)fluorophenylamine.
Sodium hydride (60% disp. in mineral oil; 1.3 g, 33.5 mmol) was added to 4-amino
fluoro-phenol in dry N,N—dimethylformamide (50 mL) and stirred at rt for 30 min under an
here of nitrogen. Then solid 4-chloro-6,7-dimethoxyquinoline (5.0 g, 22.4 mmol)
was added and the reaction stirred at 100°C for 30 h. The mixture was concentrated,
dissolved in EtOAc (100 mL) and washed with 1N Na2C03, water and brine, then dried
over MgSO4. The t was chromatographed on silica gel (5%
methanol/dichloromethane (MeOH/DCM)) to give a tan solid 4.9 g, 70%. mp = 172-5 0C;
LCMS m/z = 315 (M + 1); 1H NMR (DMSO) 8: 8.48 (d, 1H, J = 5.4 Hz), 7.50 (s, 1H),
7.38 (s, 1H), 7.07 (t, 1H, J = 8.6 Hz), 6.53,6.56 (dd, 1H, J = 2.6, 13.4 Hz), 6.45, 6.47 (dd,
1H, J = 2, 8 Hz), 6.38, 6.39 (dd, 1H, J = 1, 5.4 Hz), 5.48 (s, 2H), 3.94 (s, 6H).
Step b. N,N,N',N'-Tetramethyl-O-(7-azabenzotriazolyl)uronium hexafluorophosphate
(HATU) (0.072 g, 0.19 mmol) and 1-ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-
tetrahydropyrimidinecarboxylic acid (0.053 g,0. 19 mmol) in N,N—dimethylformamide
(2 mL) was added N,N—diisopropylethylamine (0.055 mL, 0.32 mmol). After 15 min
stirring at rt, 4-(6,7-dimethoxyquinolinyloxy)fluorophenylamine (0.05 g, 0.2 mmol)
was added. The reaction was stirred at rt for 12 h, diluted with EtOAc , then
washed with 1N Na2C03, water and brine and then dried over MgSO4. The product was
crystallized from MeOH to give 75 mg (68%) as a white solid. mp = 151-4 0C; LCMS m/z
= 575 (M + 1); 1H NMR (DMSO) 8: 11.04 (s, 1H), 8.89 (s, 1H), 8.47 (d, 1H, J = 5.4 Hz),
7.98, 8.01 (dd, 1H, J = 2.3, 12.6 Hz), 7.52-7.56 (m, 2H), 7.33-7.46 (m, 6H), 6.47 (d, 1H, J
= 5.4Hz), 4.01 (q, 2H, J = 7Hz), 3.98 (d, 6H), 13.0 (t, 3H, J = 7Hz).
The following compounds were synthesized using procedures r to those for
Example 1.
Example 2.
OH: .. .
3 -(4-F1uorophcny1)mcthy1—2,4-di0x0- 1 ,2,3 ,4-tctrahydropyrimidinc-5 -carb0xy1ic acid
7-dimcth0xyquin01iny10xy)—3-flu0ro-phcny1]-amidc. mp = 158-60 0C; LCMS m/z
= 561 (M + 1); 1H NMR (DMSO) 5:11.03 (5, 1H), 8.9 (s, 1H), 8.48 (d, 1H, J = 6Hz), 7.99.
8.01 (dd, 1H, J = 3, 12 Hz), 7.52 (m, 2H), 7.36-7.43 (m, 6H), 6.46 (d, 1H, J = 6Hz), 3.92
(s, 3H), 3.94 (s, 3H), 3.54 (s, 3H).
Example 3.
/O N\
I I /]
GE“NOFO O
N’gO
\OMe
3 -(4-F1uorophcny1)(2-mcthoxycthy1)-2,4-di0x0- 1 ,2,3 rahydropyrimidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp = 118-21
0C; LCMS m/z = 605 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.74 (, s, 1H), 8.47(d,
1H, J = 6 Hz), 7.99, 8.01 (dd, 1H, J = 3, 12 Hz), 7.52-7.55 (m, 2H), 7.33-7.46 (m, 6H),
6.48 (d, 1H, J = 6 Hz), 4.17 (t, 2H, J: 5 Hz), 3.94 (s, 3H),3.95 (s, 3H), 3.16 (t, 2H, J = 5
Hz).
Example 4.
/o N\
CaHwNOFO O
1 -(2-Eth0xycthy1)—3-(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydropyrimidinc
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp = 128-30
0C; LCMS m/z = 619 (M +1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.76 (s, 1H), 8.47 (d,
1H, J = 5.4 Hz), 7.98-8.01 (dd, 1H, J = 2.4, 12 Hz), 7.52—7.55 (m, 2H), 7.40-7.46 (m, 4H),
.38 (m, 2H), 6.48 (d, 1H, J = 5 Hz), 4.16 (t, 2H, J = 5 Hz), 3.94, 3.95 (55, 6H), 3.65
(t, 2H, J = 5 Hz), 3.51 (q, 2H, J = 6.6 Hz), 1.13 (t, 3H, J = 6.6 Hz).
Example 5.
/O N\
I I /]
OQWHOFO 0
N’KO
3 -(4-F1uor0pheny1)isopr0py1-2,4-diox0-1 ,2,3 ,4-tetrahydropyrimidinecarb0xy1ic acid
[4-(6,7-dimeth0xyquin01iny10xy)—3-fluor0pheny1]— amide. mp = 146-48 0C; LCMS m/z
= 589 (M +1);1HNMR(DMSO)5: 11.9 (s, 1H), 8.68 (s, 1H), 8.48 (d, 1H, J = 5.2 Hz),
7.99, 8.02 (dd, 1H, J = 2.4, 12.4 Hz), 7.52-7.55 (m, 2H), 7.33-7.46 (m, 6H), 6.47 (d, 1H, J
= 5.2 Hz), 4.78 (m, 1H, J = 7Hz), 3.94 (55, 6H), 1.43 (d, 6H, J = 6.7 Hz).
Example 6
@110?
1 -Cyclopr0py1methy1—3-(4-flu0r0pheny1)—2,4-di0xo- 1 ,2,3 ,4-tetrahydr0pyrimidine
carboxylic acid [4-(6,7-dimethoxyquino1iny10xy)fluor0pheny1]— amide. mp = 146-9
0C; LCMS (m/z = 601 (M + 1); 1H NM (DMSO) 5: 11.0 (s, 1H), 8.9 (s, 1H), 8.47 (d, 1H, J
= 5.2 Hz), 8.0, 8.02 (dd, 1H, J = 2.3, 12 Hz), 7.52-7.55 (m, 2H), 7.34-7.46 (m, 6H), 6.47
(m, 1H, J = 5.2 Hz), (3.94, SS, 6H), 3.86 (d, 1H, J = 7.2 Hz), 1.25 (m, 1H), 0.57 (m, 2H),
0.44 (m, 2H).
Example 7.
/D/Q\ /
3 -(4-F1u0r0phcny1)—1-(3-mcth0xypropy1)-2,4-di0x0-1 ,2,3 ,4-tctrahydropyrimidinc
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)fluor0phcny1]— amide. mp = 126-7
0C; LCMS m/z = 619 (M + 1); 1H NMR (DMSO) 5: 11.0 (S, 1H), 8.8 (S, 1H), 8.47 (d, 1H,
J = 5.6 Hz), 7.99, 8.02 (dd, 1H, J = 3.2, 13 Hz), 7.52-7.55 (m, 2H), .46 (m, 6H),
6.46 (d, 1H, J = 5.2 Hz), 4.40 (t, 2H, J = 7 Hz), 3.94 (SS, 6H), 3.42 (t, 2H, J = 6.6 Hz), 3.24
(S, 3H), 1.191 (m, 2H).
Example 8.
©0000
3 -(4-F1u0r0phcny1)iS0buty1—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0pyrimidinc-5 -carb0xy1ic acid
[4-(6,7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp = 136-40 0C; LCMS m/z
= 603 (M + 1); 1H NMR (DMSO) 5: 11.0 (S, 1H), 8.81 (S, 1H),8.48 (d, 1H, J = 5.2 Hz), 8.0
(dd, 1H, J = 2.2, 12 Hz), 7.52-7.55 (m, 2H), 7.33-7.46 (m, 6H), 6.47 (d, 1H, J = 5.2 Hz),
3.94 (SS, 6H), 3.82 (d, 2H, J = 7 Hz), 2.05 (m, 1H), 0.93 (d, 6H, J = 7Hz).
Example 9.
m“; .
06 .
o o
1—3-(4-flu0rophcny1)-2,4-di0x0-1 ,2,3,4-tctrahydropyrimidinccarb0xy1ic acid [4-
(6,7-dimcthoxyquino1iny10xy)flu0r0phcny1]—amidc. mp 128-30 0C; LCMS m/z = 587
(M +1); 1H NMR (DMSO) 5: 11.0 (S, 1H), 8.80 (S, 1H), 8.48 (d, 1H, = 5.2 Hz), 7.98, 8.02
(dd, 1H, J = 2.5, 13 Hz), 7.53-7.55 (m, 1H), 7.52 (S, 1H), 7.34-7.46 (m, 6H), 6.47 (d, 1H, J
= 4.7 Hz), 5.94-6.02 (m, 1H), 5.36, 5.40 (dd, 1H, J = 1.5. 17 Hz), 5.27, 5.30 (dd, 1H, J =
1.5, 10 Hz), 4.62 (d, 2H, J = 5.5 Hz), 3.94, 3.95 (SS, 6H).
Example 10.
”$10Fo o
N O
\OBn
1 -(2-Bcnzy10xycthy1)—3-(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)flu0r0phcny1]—amidc. mp > 102 0C
(dcc); LCMS m/z = 681 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.83 (s, 1H), 8.48 (d,
1H, J = 5.3 Hz), 7.99, 8.02 (dd, 1H, J = 2.4, 12.8 Hz), 7.54,7.56 (dd, 1H, J = 1.4, 8.8 Hz),
7.52 (s, 1H), 7.44 (t, 1H, J = 8.8 Hz),7.33-7.41 (m, 9H), 7.30 (m, 1H), 6.47 (d, 1H, J = 5
Hz), 4.55 (s,2H), 4.22 (t, 2H, J = 4.7 Hz), 3.94,3.95 (SS, 6H), 3.72 (t, 2H, J = 4.8 Hz).
Example 11.
3 -(4-F1u0r0phcny1)-2,4-di0xopr0py1-1 ,2,3 ,4-tctrahydr0pyrimidinc-5 - ylic acid
[4-(6,7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp = 134-6 0C; LCMS m/z =
589 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.86 (s, 1H), 8.47 (d, 1H, J = 5.3 Hz),
7.98,8.02 (dd, 1H, J = 2.2, 12.6 Hz), 7.52-7.55 m, 2H), 7.40-7.46 (m, 4H), 7.34-7.38 (m,
2H), 6.47 (d, 1H, J = 5.2 Hz), 3.92-3.97 (m, 8H), 1.71 (h, 2H, J = 7.2 Hz), 0.93 (t, 3H, J =
7.2 Hz).
Example 12.
9Q?\ /
NJLIdLNH | f0
OiPr
3 u0r0phcny1)— 1 -(2-isopr0p0xycthy1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp = 138-9
0C; LCMS m/z = 633 (M + 1); 1H NMR (DMSO) 5: 11.00 (s, 1H), 8.78 (s, 1H), 8.47 (d,
1H, J = 4.7 Hz), 7.99 (d, 1H, J = 13 Hz), 7.49-7.56 (m, 2H), 7.38-7.46 (m, 6H), 6.47 (d,
1H, J = 4.6 Hz), 4.12 (m, 2H), 3.94 (d, 6H), 3.65 (m, 3H), 1.10 (d, 6H, J = 6 Hz).
e 13.
/o\OjijiogN\
a”$10FO O
N O
KLOBn
1-(3 -Benzy10xypr0py1)(4-flu0r0pheny1)-2,4-di0xo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xyquino1iny10xy)—3-fluor0 pheny1]-amide. mp = 94-96
0C; LCMS m/z = 695 (M + 1); 1H NMR (DMSO) 5: 11.00 (s, 1H), 8.83 (s, 1H), 8.47 (d,
1H, J = 5Hz),7.98, 8.01 (dd, J = 2.4, 12.6 Hz), 7.53-7.59 (m, 1H), 7.52 (s, 1H), 7.42-7.46
(m, 1H), 7.40 (s, 1H), .34 (m, 8H), 7.25-7.28 (m, 1H), 6.47 (dd, 1H, J = 1, 5.2 Hz),
4.46 (s, 2H), 4.09 (t, 2H, J = 7 Hz), 3.94 (d, 6H), 3.59 (t, 2H, J = 5.8 Hz), 1.99 (t, 2H, J =
6.4 Hz).
Example 14.
/o N\
N O
F F
1-(3 ,3 -Difluor0-a11y1)-3 -(4-flu0r0pheny1)—2,4-di0xo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -
carboxylic acid [4-(6,7-dimethoxyquino1iny10xy)flu0r0pheny1]—amide. mp = 128-30
0C; LCMS m/z = 623 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.9 (s, 1H), 8.48 (d, 1H,
J = 5.5Hz), 8.0, 7.98 (dd, 1H, J = 2, 12.8 Hz), 7.52-7.56 (m, 2H), 7.34-7.46 (m, 6H), 6.46
(d, 1H, J = 5 Hz), 4.88-4.99 (m, 1H),4.62 (d, 2H, J = 8Hz), 3.94 (s, 6H).
Example 15.
WO 74633
@110?
3 -(4-F1u0r0phcny1)—1-(3 -mcthy1—butcny1)—2,4-diox0- 1 ,2,3 ,4-tctrahydr0pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp = 119-
121°C;LCMS m/z = 615 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.78 9 (s, 1H), 8.47
(d, 1H, J = 5.2 Hz), 8.0 (d, 1H, J = 13 Hz), 7.52-7.54 (m, 2H), 7.33-7.45 (m, 6H), 6.47 (d.
1H. J = 5.2 Hz), 5.34 (m, 1H), 4.56 (d, 1H, J = 6.8 Hz), 3.94 (s, 6H), 1.76 (s, 3H), 1.74 (s,
3H).
Example 16.
\O /
HwNOFO O
3 -(4-F1u0r0phcny1)— 1 -(2-m0rph01iny1—cthy1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcth0xyquino1iny10xy)—3-fluor0 phcny1]-amidc. mp = 124-6
0C; LCMS m/z = 660 (M + 1); 1H NMR(CDC13) 5: 10.9 (s, 1H),8.65 (s, 1H), 8.49 (d, 1H,
J = 5.3 Hz), 7.87, 7.90 (dd, 1H, J = 2.4, 12.4 Hz), 7.57 (s, 1H),7.42 (s, 1H), 7.18-7.29 (m,
6H), 6.42 (dd, 1H, J = 0.5, 5.2 Hz), 4.05-4.08 (m, 8H), 3.72 (t, 4H, J = 4.7 Hz), 2.73 (t,
2H, J = 5.7 Hz), 2.56 (m, 4H).
Example 17.
/BQ\ /
NJKELNH | N’kO
1u0r0phcny1)-2,4-di0x0-1,2,3,4-tctrahydropyrimidinccarb0xy1ic acid [4-(6,7-
dimcthoxyquino1iny10xy)—3-fluor0phcny1]—amidc. mp = 276-8 0C; LCMS m/z = 547
(M + 1); 1H NMR (DMSO) 8: 12.4 (bs, 1H), 11.0 (s, 1H), 8.45 (s, 2H), 7.99 (d, 1H, J = 12
Hz), 7.52 (s, 2H), 7.35-7.40 (m, 6H), 6.4 (s, 1H), 3.9 (s, 6H).
Example 18.
Step a. 4-(6,7-Dimethoxyquin01iny10xy)-phenylamine.
/o N\
\ /
4-(6,7-Dimethoxyquino1iny10xy)pheny1amine was synthesized using the methods for
Example 1
step a. LCMS m/z = 297 (M + 1); 1H NMR (DMSO) 8: 8.42 (d, 1H, J = 5.3 Hz), 7.50 (s,
1H), 7.36 (s, 1H), 7.91 (d, 2H, J = 8 Hz), 6.67 (d, 2H, J = 8 Hz), 6.36 (d, 1H, J = 5.3 Hz),
.14 (s, 2H), 3.93 (s, 6H).
Step b. 3 -(4-F1u0r0pheny1)methy1-2,4-di0x0- 1 ,2,3 ,4-tetrahydr0pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xyquinoliny10xy)-phenyl]-amide. mp = 143-5 0C;
LCMS m/z = 543 (M + 1); 1H NMR (DMSO) 5: 10.92 (s, 1H), 8.85 (s, 1H), 8.46 (d, 1H, J
= 5.2 Hz), 7.80 (d, 2H, J = 9 Hz), 7.50 (s, 1H), 7.34-7.42 (m, 5H), 7.25 (d, 2H, J = 9Hz),
6.47 (d, 1H, J: 5.2 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.53 (s, 3H).
e 19.
0Q F
o o
1 nzyloxyethy1)(4-flu0ro-pheny1)-2,4-di0x0- 1 ,2,3 ,4-tetrahydr0pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xyquinoliny10xy)-phenyl]-amide. mp = 163-4 0C;
LCMS m/z = 663 (M +1); 1H NMR (DMSO) 5: 10.89 (s, 1H), 8.81 (s, 1H), 8.47 (d, 1H,
J: 5.6 Hz), 8.80 (d, 2H, J = 9 Hz), 7.50 (s, 1H), 7.25-7.41 (m, 12H), 6.49 (d, 1H, J = 5.8
Hz), 4.56 (s, 2H), 4.21 (t, 2H, J: 5 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.72 (t, 2H, J = 5 Hz).
Example 20.
/o: :\O :N\:/
GEHwNOFO O
1 -(2-Dirnethy1arninoethy1)—3 -(4-flu0r0pheny1)—2,4-di0xo- 1 ,2,3 ,4-tetrahydr0pyrirnidine-5 -
carboxylic acid 7-dimethoxyquino1iny10xy)—3-flu0r0pheny1]—arnide. mp (HC1
salt): 208-10 0C; LCMS m/z = 618 (M + 1); 1H NMR (DMSO) 5:11.18 (5, 1H), 10.77 (s,
1H), 8.94 (s, 1H), 8.81 (d, 1H, J = 6.6 Hz), 8.11, 8.08 (dd, 1H, J = 2,14 Hz), 7.74 (s, 1H),
7.65 (m, 2H), 7.50-7.60 (m, 3H), 7.37 (m, 2H), 6.95 (d, 1H, J = 6.5Hz), 4.39 (t, 1H, J = 5.8
Hz), 4.04 (s, 3H), 4.03 (s, 3H), (2.82 (d, 6H).
e 21.
/O N\
O”$10FO O
N O
KLOBn
1-(3 -Benzy10xypr0py1)(4-flu0r0pheny1)-2,4-di0xo- 1 ,2,3 ,4-tetrahydr0pyrirnidine-5 -
carboxylic acid [4-(6,7-dimethoxyquino1iny10xy)pheny1]-arnide. mp = 100-104 0C;
LCMS m/z = 677 (M + 1);1H NMR (DMSO) 5: 10.90 (s, 1H), 8.81 (s, 1H), 8.47 (d, 1H, J
= 5 Hz), 7.80 (d, 2H, J = 8.8 Hz), 7.50 (s, 1H), 7.40 (s, 1H), 7.25-7.33 (m, 11H), 6.49 (d,
1H, J = 5.6 Hz), 4.45 (s, 2H), 4.08 (t, 2H, J = 6.4 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.56 (t,
2H, J = 5.6Hz), 1.98 (m, 2H).
Example 22.
/o N\
\ /
01911310
1-(3 -Bcnzy10xypr0py1)(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)fluorophcny1]-amidc. mp 93-96 0C;
LCMS m/z = 695 (M + 1); 1H NMR (DMSO) 8: 11.13 (s, 1H), 8.85 (s, 1H), 7.46-8.51 (m,
2H), 7.47 (s, 1H), .42 (m, 2H), 7.25-7.34 (m, 9H), 7.18 (d, 1H, J = 10 Hz), 6.59 (d,
1H, J = 5.3 Hz), 4.50 (s, 2H), 4.09 (t, 2H, J = 6.5 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.56 (t,
2H, J = 6 Hz), 1.99 (q, 2H, J = 6.2 Hz).
Example 23.
0QMOFo o
3 -(4-F1uor0phcny1)isopr0py1-2,4-diox0-1 ,2,3 rahydr0pyrimidinc-5 -carb0xy1ic acid
[4-(6,7-dimcthoxyquin01iny10xy)phcny1]-amidc. mp = 253-6 0C; LCMS m/z = 571 (M
+ 1); 1H NMR (DMSO) 5: 10.93 (s, 1H), 8.67 (s, 1H), 8.47 (d, 1H, J = 5.3 Hz), 7.78-7.82
(m, 2H), 7.49 (s, 1H), 7.33-7.45 (m, 5H),7.23-7.27 (m, 2H), 6.48 (d, 1H, J = 5.3 Hz), 4.77
(q, 1H, J = 7 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 1.42 (d, 6H, J = 7.4 Hz).
Example 24.
/o N\
\ /
Qo 0 OF NJKELNH | N’ko
3-(4-F1u0r0phcny1)-2,4-di0x0-1,2,3,4-tctrahydropyrimidinccarb0xy1ic acid [4-(6,7-
dimcthoxyquino1iny10xy)phcny1]-amidc. mp = 211-3 0C; LCMS m/z = 529 (M + 1); 1H
NMR (DMSO) 5: 12.36 (s, 1H), 10.90 (s, 1H), 8.46 (d, 1H, J = 5.3Hz), 8.43 (s, 1H), 7.77-
7.80 (m, 2H), 7.49 (s, 1H), 7.39-7.43 (m, 3H), 7.32-7.37 (m, 2H), 7.22-7.25 (m, 2H), 6.47
(d, 1H, J = 5.3 Hz), 3.94 (s, 3H), 3.92 (s, 3H).
Example 25.
/O N\
OmWHOO 0
3 -Cyc10hexyl- 1 —2,4-diox0- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carb0xylic acid [4-(6,7-
dimethoxyquino1iny10xy)—3-fluor0pheny1]—amide. mp 244-6 0C; LCMS m/z = 563 (M
+ 1); 1H NMR (DMSO) 5: 11.22 (s, 1H), 8.73 (s, 1H), 8.48 (d, 1H, J = 5.2 Hz), .03
(dd, 1H, J = 2.6, 12.6 Hz), 7.53-7.57 (m, 2H), 7.41-7.47 (m, 2H), 6.48 (d, 1H, J = 5.2 Hz),
4.7 (m, 1H), 3.92-3.98 (m, 8H), 2.32 (m, 3H), 1.80 (m, 2H), 1.62 (m,3H), 1.29 (m, 2H),
1.25 (m, 3H).
Example 26.
\ /
0 O O
NAKELNH | $0
3 -(4-F1uoropheny1)-2,4-di0x0-1 -(2-pyrr01idin-1 -y1—ethy1)- 1 ,2,3 ,4-tetrahydr0pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xyquinolinyloxy)—3-fluor0 phenyl]—amide. mp = 118-
120 0C; LCMS m/z = 644 (M + 1); 1H NMR (DMSO) 5: 11.00 (s, 1H), 8.79 (s, 1H), 8.47
(d, 1H, J = 5.2 Hz), 8.01, 7.98 (dd, 1H, J = 2.3, 13 Hz), 7.52-7.55 (m, 2H), 7.33-7.45 (m,
6H), 6.46 (dd, 1H, J = 1, 5.3 Hz), 4.08 (t, 2H, J = 6.3 Hz), 3.94 (d, 6H), 2.73 (t, 2H, J =6
Hz), 2.54 (m, 4H), 1.70 (m, 4H).
Example 27.
\ /
0 0 O
3 -(4-F1u0rophcny1)-2,4-di0x0(2-pipcridiny1—cthy1)—1 ,2,3 ,4-tctrahydr0pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp =137-40
0C; LCMS m/z = 658 (M + 1); 1H NMR (DMSO) 5: 11.00 (s,1H), 8.78 (s, 1H), 8.47 (d,
1H, J = 5.5 Hz), 7.97, 8.01 (dd, 1H, J = 2.3, 13 Hz), 7.50-7.56 (m, 2H), 7.34-7.46 (m, 6H),
6.46 (d, 1H, J = 5.5 Hz), 4.06 (t, 2H, J = 5.5 Hz), 3.94 (s, 6H), 2.55 (m, 2H), 2.44 (b, 4H),
1.49 (m, 4H), 1.39 (m, 2H).
Example 28.
/O N\
QWHOH F
0 O
I N/KO
1-Ethy1—3-(4-flu0r0phcny1)-2,4-di0x0-1 ,2,3 ,4-tctrahydr0pyrimidinc-5 xy1ic acid [4-
(6,7-dimcthoxyquino1iny10xy)—phcny1]-amidc. mp = 282-4 0C; LCMS m/z = 557 (M +
1); 1H NMR (DMSO) 5: 10.92 (s, 1H), 8.87 (s, 1H), 8.47 (d, 1H, J = 5.4 Hz), 7.80 (m, 2H,
J = 8Hz), 7.49 (s, 1H), 7.33-7.44 (m, 5H), 7.24-7.26 (m, 2H), 6.48 (d, 1H, J = 5.2 Hz),
4.01 (q, 2H, J = 7.1 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 1.29 (t, 3H, J = 7.1 Hz).
Example 29.
figFO O
1-Cyc10buty1—3-(4-flu0r0phcny1)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrimidinccarb0xy1ic
acid 7-dimcthoxyquino1iny10xy)—3-flu0r0phcny1]—amidc. mp 148-50 0C; LCMS
m/z = 601 (M + 1); 1H NMR (DMSO) 5: 11.02 (s, 1H), 8.91 (s, 0.4H), 8.64 (s, 0.6H), 8.48
(d, 1H, J = 5.4 Hz), 7.99, 8.03 (dd, 1H, J = 2.2, 13Hz), 7.52-7.55 (m, 2H), 7.33-7.46 (m,
6H), 6.47 (d, 1H, J =5.4Hz), 3.94 (d, 6H), 4.8 (m, 0.6H), 3.8 (m, 0.4H), 2.32-2.46 (m, 3H),
.83 (m, 1H), 1.23-1.27, 0.54-0.57 (m, 1H), 0.43-0.46 (m, 1H).
Example 30.
MOF0 o
N O
3 -(4-F1uor0pheny1)-2,4-di0x0(tetrahydr0pyrany1)- 1 ,2,3 ,4-tetrahydr0pyrimidine-5 -
ylic acid [4-(6,7-dimeth0xyquino1iny10xy)—3-fluor0 pheny1]-amide. mp = 164-
167 0C; LCMS m/z = 631 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.65 (s, 1H), 8.48
(d, 1H, J = 5.3 Hz), 7.99, 8.02 (dd, 1H, J = 2.5, 13 Hz), 7.52-7.56 (m, 2H), 7.34-7.46 (m,
6H), 6.48 (d, 1H, J = 5 Hz), 4.64 (m, 1H), 3.98-4.02 (m, 2H), 3.94 (d, 6H), 3.45 (m, 2H),
1.99-2.09 (m, 2H), 1.86-1.89 (m, 2H).
Example 31.
/O039N\
QMOFo o
1-Ethy1(4-flu0r0pheny1)-2,4-di0x0-1 ,2,3 rahydr0pyrimidine-5 -carb0xy1ic acid [5 -
(6,7-dimeth0xyquino1iny10xy)-pyridiny1]-amide was synthesized starting with 5-
(6,7-dimethoxyquino1iny10xy)-pyridiny1amine. mp = 172-4 0C; LCMS m/z = 558 (M
+ 1); 1H NMR (DMSO) 5: 11.39 (s, 1H), 8.93 (s, 1H), 8.48 (d, 1H, J = 5.2 Hz), 8.35-8.38
(m, 2H), 7.84, 7.88 (dd, 1H, J = 2.3, 9.3 Hz), 7.52 (s, 1H), 7.33-7.44 (m, 5H), 6.54 (d, 1H,
J = 5.2 Hz). 4.02 (q, 2H, J = 7.4 Hz), 3.93 (d, 6H), 1.29 (t, 3H, J = 7.2 Hz).
Example 32.
/o N\
I I /]
GE“figFO 0
1-Ethy1(4-fluor0pheny1)methy1—2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine
carboxylic acid [4-(6,7-dimethoxyquino1iny10xy)fluor0pheny1]— amide. mp = 260-4
0C; LCMS m/z = 589 (M + 1); 1H NMR (DMSO) 5: 10.71 (s, 1H), 8.46 (d, 1H), J =
.2Hz), 7.90, 7.94 (dd, 1H, J = 2.3, 12.7 Hz), 7.53 (s, 1H), 7.40-7.47 (m, 3H), 7.32-7.36
(m, 4H), 6.46 (d, 1H, J = 5.2 Hz), 3.97 (q, 2H, J = 7 Hz), 3.94 (s, 6H), 2.47 (s, 3H), 1.25 (t,
3H, J = 7.2 Hz).
Example 33.
06200 .
1-Ethy1(4-flu0r0pheny1)-2,4-di0x0-1 ,2,3 ,4-tetrahydr0pyrimidine-5 -carb0xy1ic acid [4-
(6,7-diethoxyquino1iny10xy)—3-flu0r0pheny1]—amide. mp = 216-8 0C; LCMS m/z = 603
(M +1);1H NMR (DMSO) 5: 11.03 (s, 1H), 8.89 (s, 1H), 8.45 (d, 1H, J = 5.2 Hz),
7.98,8.02 (dd, 1H, J = 2.2, 13 Hz), 7.50-7.54 , 7.31-7.45 (m, 6H), 6.45 (d, 1H, J =
5.2 Hz), 4.21 (m, 4H), 4.01 (q, 2H, J = 6.4 Hz), 1.42 (m, 6H), 1.29 (t, 3H, J = 7.2 Hz).
Example 34.
/O N\
\ /
QfigF0 O
3 -(4-F1uor0pheny1)is0pr0py1-2,4-diox0-1 ,2,3 ,4-tetrahydropyrimidine- 5 xy1ic acid
[5-(6,7-dimethoxyquin01iny10xy)-pyridiny1]-amide was synthesized using the
method for example 31. mp = 220-4 0C; LCMS m/z = 572 (M + 1); 1H NMR DMSO) 5:
11.40 (s, 1H), 8.72 (s, 1H), 8.49 (d, 1H, J = 5.2 Hz), 8.36 (d, 1H, J = 6.5 Hz), 8.35 (s, 1H),
8.86,7.84 (dd, 1H, J = 3.0, 9.3 Hz), 7.52 (s, 1H), 7.41-7.45 (m, 3H), 7.34-7.39 (m, 2H),
6.55 (d, 1H, J = 5.4 Hz), 4.78 (h, 1H, J = 6.8 Hz), 3.94, 3.93 (d, 6H), 1.43 (d, 6H, J = 6.9
Hz).
Example 35.
/o N\
”1%“0
1 -Cyclopr0pylmethyl(4-flu0r0phenyl)—2,4-di0xo- 1 ,2,3 ,4-tetrahydr0pyrimidine
carboxylic acid [5-(6,7-dimethoxyquinolinyloxy)pyridinyl]-amide was synthesized
using the method for example 31. LCMS m/z = 584 (M + 1); 1H NMR (DMSO) 5: 11.43
(s, 1H), 8.97 (s, 1H), 8.74 (m, 1H), 8.44 (m, 2H), 7.96 (m, 1H), 7.70 (s, 1H), 7.50 (s, 1H),
7.42-7.46 (m, 2H), 7.34-7.39 (m, 2H), 6.91 (m, lH),4.0, 4.02 (ss, 6H), 3.88 (m, 2H), 1.21
(m, 1H), 0.55 (m, 2H), 0.45 (m, 2H).
Example 36.
$131”? .
06“10.. .
3 uor0phenyl)—2,4-di0x0pentyl- 1 ,2,3 ,4-tetrahydr0pyrimidine-5 - carboxylic acid
[4-(6,7-dimeth0xyquin0linyloxy)flu0r0phenyl]—amide. mp = 128-30 0C; LCMS m/z
= 617 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.85 (s, 1H), 8.47 (d, 1H, J = 4.7 Hz),
8.0 (d, 1H, J = 12.6 Hz), 7.52-7.55 (m, 2H), 7.33-7.45 (m, 6H), 6.46 (d, 1H, J = 4.5 Hz),
3.95 (bm, 8H), 1.70 (brm, 2H), 1.32 (bm, 4H), 0.89 (bm, 3H).
Example 37.
”wNOFO O N/KO
3 -(4-Fluor0phenyl)is0pr0pyl-2,4-diox0-1 ,2,3 ,4-tetrahydropyrimidinecarb0xylic acid
[4-(6,7-diethoxyquinolinyloxy)fluor0-phenyl]—amide. mp = 128-130 0C; LCMS m/z
= 617 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.68 (s, 1H), 8.45 (d, 1H, J = 5 Hz), 7.99
(d, 1H, J: 13 Hz), 7.50-7.54 (m, 2H), .45 (m, 6H), 6.45 (d, 1H, J = 5 Hz), 4.78 (m,
1H), 4.20 (m, 4H), 1.42 (m, 12H).
Example 38.
OX0 —O H
MeO o /o N D 0M0 PhOPh W
NHZ —> Q“ — >< —»
MeO CH(OMe)3 \o
o /o o
/O N
/O \ /O
N N\
\ Z/NH CIn
POCI3 / 4
/ —> /
——.> —>
N02 0 O
/0 CI Q / O /O 0C
OH N02
Step a. Meldrum acid (470 mg, 3.20 mmol) in triethylorthoformate (4 mL) and heated at
100 0C for 1.5 h. 3,5-Dimethoxyaniline (500 mg, 3.2 mmol) was added and heated and
heated at 100 0C for 4 h. The reaction mixture was cooled to rt and hexanes added and
stirred. The yellow solid was ted and dried to yield a yellow solid. LCMS m/z = 308
(M + 1); 1H NMR(CDC13) 8; 8.61 (d, 1H, J = 14.0 Hz), 6.365 (m, 3H), 3.82 (s, 6H), 1.76
(s, 6H).
Step b. 5-[(3 ,5-Dimethoxyphenylamino)-methylene]-2,2-dimethyl[1 ,3]dioxane-4,6-dione
, 1.30mmol) in yl ether (5 mL) and heated at 200 0C for 30 min. The
reaction mixture was cooled to rt and hexane was added and stirred for 30 min. The brown
solid was filtered and dried to yield 5,7-dimethoxy-1H-quinolinone LCMS m/z = 206
(M + 1).
Step c. 5,7-dimethoxy-1H-quinolinone (300 mg, 1.4 mmol) in POC13 (5 mL) was
heated to reflux for 15 h. The reaction mixture was cooled to rt and poured into ice-water.
The mixture was then basified to pH 7 with NaHC03 and stirred overnight. The solid was
filtered and washed with water and dried to give 4-chloro-5,7-dimethoxyquinoline. LCMS
m/z = 224 (M + 1); 1H NMR(CDC13) 8: 8.56 (d, 1H, J = 4.4 Hz), 7.23 (d, 1H, J = 4.4 Hz),
7.05 (s, 1H), 6.58 (s, 1H), 3.93(s, 6H).
Step d. 4-Chloro-5,7-dimethoxyquinoline (100 mg, 0.40 mmol) and p-nitrophenol (124
mg, 0.89mmol) in chlorobenzene (2mL) was heated at reflux for 14 h. Then the reaction
mixture was cooled to rt, filtered, and the residue washed with toluene. The solid was
suspended in 10% NaOH solution and stirred for 1 h at rt. The yellow solid was collected
and washed with EtOAc to give 5,7-dimethoxy(4-nitrophenoxy)quinoline. LCMS m/z =
327 (M + 1); 1H NMR(CDC13) 5: 8.60 (d, 1H, J = 6.0 Hz), 8.44 (d, 2, J = 8.8 Hz), 7.72 (s,
1H), 7.35 (d, 2H, J = 8.4 Hz) 6.71 (s, 1H), 6.69 (d, 2H, J = 6.4 Hz ), 4.08 (s, 3H) 3.97 (s,
3H).
Step e. A mixture of 5,7-dimethoxy(4-nitrophenoxy)quinoline (50 mg, 0.15 mmol), Zn
dust (100 mg, 1.50 mmol) and ammonium chloride (32 mg, 0.60 mmol) in methanol (3
mL) was heated at reflux for 1 h. The mixture was filtered through celite and washed with
CHC13. The organic layer was washed with 10% NaOH solution and brine, dried over
, and concentrated to afford 4-(5,7-dimethoxyquinolinyloxy)phenylamine as an
offwhite solid. LCMS m/z = 298 (M + 1); 1H NMR(CDC13) 8: 8.44 (d, 1H, J = 4.8 Hz),
7.00 (s ,1H), 6.83 (d, 2H, J = 8.8 Hz), .63 (m, 3H) 6.32 (d, 1H, J = 4.8 Hz) 5.11
, ,
(br s, 2H), 3.89 (s 3.86 (s, 3H).
, 3H),
3 -(4-Fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidinecarboxylic acid
[4-(5,7-dimethoxyquinolinyloxy)phenyl]-amide. mp = 122-4 0C; LCMS m/z = 571 (M
+ 1); 1H NMR (DMSO) 5: 10.87 (s, 1H), 8.65 (s, 1H), 8.53 (d, 1H, J :53 Hz), 7.73 (d,
2H, J = 9Hz), 7.42 (m, 2H), 7.35 (m, 2H), 7.07 (d, 2H, J = 9Hz), 6.99 (d, 1H, J = 2Hz),
6.63 (d, 1H, J = 2Hz), 6.50 (d, 1H, J = 5Hz), 4.78 (q, 1H, J = 7Hz), 3.90 (s, 3H), 3.80 (s,
3H), 1.42 (d, 6H, J = 7Hz).
Example 39.
/O. ; :N\:/
/O OQMwNO
O O
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid [4-
(5,7-dimethoxyquinolinyloxy)-phenyl]-amide was synthesized using 4-(5,7-
oxyquinolinyloxy)phenylamine and 3-(4-fluorophenyl)ethyl-2,4-dioxo-
1,2,3,4-tetrahydropyrimidine- 5-carboxylic acid by the method for example 38. mp = 128-
9 0C; LCMS m/z = 557 (M + 1); 1H NMR (DMSO) 5: 10.87 (s, 1H), 8.85 (s, 1H), 8.52 (m,
1H), 7.72 (m, 2H), 7.33-7.41 (m, 4H), 7.07 (m, 2H), 6.99 (m, 1H), 6.63 (m, 1H), 6.49 (m,
1H), 4.01 (m, 2H), 3.90 (s, 3H), 3.81 (s, 3H), 1.28 (m, 3H).
Example 40.
0752 .
o o
Step a. 4-(7-Benzyloxymethoxyquinolinyloxy)fluorophenylamine. Sodium
hydride (60% disp. in mineral oil, 0.534 g, 13.3 mmol) was added to 4-amino
fluorophenol in dry methylformamide (10.3 mL) at rt and stirred for 30 min under
an atmosphere of nitrogen. Then solid 7-benzyloxychloromethoxyquinoline (2.00 g,
6.67 mmol) was added and the reaction stirred at 100 0C for 30 h. The mixture was
concentrated, dissolved in EtOAc ( about 75 mL), and washed with 1N Na2C03, water and
brine, then dried over MgSO4. The product was chromatographed on silica gel (5%
MeOH/DCM) to give a brown solid 1.9 g (73%). LCMS m/z = 391 (M + 1); 1H NMR
(DMSO) 5: 8.43 (s, 1H), 7.36-7.52 (m, 7H), 7.07 (m, 1H), 6.38-6.56 (m, 3H), 5.50 (m,
2H), 5.3 (s, 2H), 3.95 (s, 3H).
Step b. 1-Ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3 ,4-tetrahydropyrimidinecarboxylic
acid benzyloxymethoxyquinolinyloxy)fluorophenyl]-amide was synthesized
using 4-(7-benzyloxymethoxyquinolinyloxy)fluorophenylamine and 3-(4-
fluorophenyl)ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine- oxylic acid by the
method for example 1. mp = 142-4 0C; LCMS m/z = 651 (M + 1); 1H NMR (DMSO) 5:
11.0 (s, 1H), 8.89 (s, 1H), 8.47 (d, 1H, J = 5.3 Hz), 7.98,8.02 (dd, 1H, J = 2.3, 13 Hz),
7.50-7.54 (m, 5H), 7.41-7.46 (m, 5H), 7.33-7.38 (m, 3H), 6.48 (d, 1H, J = 5 Hz), 5.31 (s,
2H), 4.90 (q, 2H, J = 7 Hz), 3.95 (s, 3H), 1.29 (t, 3H, J = 7 Hz).
Example 41.
3 -(4-Fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 rahydropyrimidinecarboxylic acid
[4-(7-benzyloxymethoxyquinolinyloxy)fluorophenyl]-amide was synthesized
using the method for example 40 and 3-(4-fluorophenyl)isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidine- 5-carboxylic acid. mp = 184-6 0C; LCMS m/z = 665 (M + 1); 1H
NMR (DMSO) 5: 11.0 (s, 1H), 8.6 (s, 1H), 8.46 (d, 1H, J = 5.3 Hz), 8.0, 8.02 (dd, 1H, J =
2.4, 12.6 Hz), 7.48-7.54 (m, 5H), 7.41-7.46 (m, 5H), 7.33-7.38 (m, 3H), 6.47 (d, 1H, J = 5
Hz), 5.31 (s, 2H), 6.78 (m, 1H), 3.95 (s, 3H), 1.43 (d, 6H, J = 5.5 Hz).
Example 42.
015.. .
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid [3 -
fluoro(7-hydroxymethoxyquinolinyloxy)phenyl]-amide. Example 40 (0.50 g, 0.77
mmol) and 20% Pd(OH)2/C, 50% wet :50, palladium hydroxide:carbon
black:Water, 0.1 g, 0.07 mmol) in methylformamide (10 mL) was hydrogenated on
a Parr apparatus under an atmosphere of hydrogen 40 psi for 12 h. The solvent was
removed and the product was triturated with ether to give 42- mg (97%) as a while solid.
mp >200 0C dec; LCMS m/z = 561 (M + 1); 1H NMR (DMSO) 8: 11.75 (bs, 1H), 11.11 (s,
1H), 8.89 (s, 1H), 8.73 (d, 1H, J = 6.5 Hz), 8.07, 8.11 (dd, 1H, J = 2.3, 12.5 Hz), 7.72 (s,
1H), 7.54-7.64 (m, 3H), 7.41-7.45 (m, 2H), 7.34-7.39 (m, 2H), 6.90 (d, 1H, J = 6.5 Hz),
40-405 (s, m, 5H), 1.30 (t, 3H, J = 7.2 Hz).
Example 43.
(Nu/womb
amigo
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid {3-
fluoro[6-methoxy(3-morpholinyl-propoxy)quinolinyloxy] phenyl} -amide.
e 42 (0.100 g, 0.178 mmol), methanesulfonic acid 3-morpholinyl-propyl ester
(0.0438 g, 0.196 mmol) and cesium carbonate (0.116 g, 0.357 mmol) in N,N-
dimethylformamide (2 le) was heated at 65 CC for 8h. The mixture was diluted with
EtOAc and extracted with 1N Na2C03, water and brine solutions then dried over MgSO4.
The solid was ated with ether, then the ether decanted and the product itated
with hexanes to give a white solid. mp = 92-5 0C; LCMS m/z = 688 (M + 1 ); 1H NMR
(DMSO) 5: 11.04 (s, 1H), 8.89 (s, 1H), 8.46 (d, 1H, J = 5.3Hz), 7.98, 8,02 (dd, 1H, J = 2.4,
13Hz), 7.51-7.55 (m, 2H), 7.33-7.46 (m, 6H), 6.46 (d, 1H, J = 5.4 Hz, 4.20 (t, 2H, J = 6.4
Hz), 4.01 (q, 2H, J = 7.4 Hz), 3.94 (s, 3H), 3.58 (t, 4H, J = 4.8 Hz), 2.45 (m, 2H), 2.39 (b,
4H), 1.98 (m, 2H), 1.29 (t, 3H, J = 7.2 Hz).
Example 44
\ o: : ’Y; F
NkalLNH | NKAO
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid {3-
fluoro[6-methoxy(2-methoxyethoxy)quinolinyloxy]-phenyl}-amide. Example 44
was synthesized by the procedure for e 43 using example 42 and 1-bromo
methoxyethane. mp = 178-80 0C; LCMS m/z = 619 (M + 1); 1H NMR (DMSO) 5: 11.00
(s, 1H), 8.89 (s, 1H), 8.46 (d, 1H, J = 5H2), 7.98, 8.00 (dd, 1H, J = 2, 13 Hz), 7.52-7.55
(m, 2H), 7.42-7.46 (m, 4H), 7.33-7.38 (m, 2H), 6.47 (d, 1H, J = 5.4 Hz), 4.28 (m, 2H),
4.01 (q, 2H, J = 7.1 Hz), 3.95 (s, 3H), 3.76-(m, 2H), 3.34 (s, 3H), 1.29 (t, 3H, J = 7.1 Hz).
Example 45
OK/Nwom
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid {3-
fluoro[6-methoxy(2-morpholinyl-ethoxy)-quinolinyloxy]phenyl} .
Example 45 was synthesized by the procedure for example 43 using example 42 and 4-(2-
chloroethyl)morpholine hydrochloride. mp = 222-224 0C; LCMS m/z = 674 (M + 1); 1H
NMR (DMSO) 5: 11.0 (s, 1H), 8.89 (s, 1H), 8.47 (d, 1H, J = 5.4 Hz), 7.98, 8.01 (dd, 1H, J
= 2.4, 12.6 Hz), 7.52-7.55 (m, 2H), 7.41-7.46 (m, 4H), 7.33-7.38 (m, 2H), 6.46 (d, 1H, J =
.4 Hz), 4.27 (t, 2H, J = 6 Hz), 4.02 (q, 2H, J = 7.4 Hz), 3.94 (s, 3H), 3.59 (t, 4H, J = 4.6
Hz), 2.79 (t, 2H, J = 5.8 Hz), 2.53 (m, 4H), 1.29 (t, 3H, J =7.4 Hz).
Example 46.
015..
3 -(4-Fluor0phenyl)is0pr0pyl-2,4-diox0-1 ,2,3 ,4-tetrahydropyrimidinecarb0xylic acid
[3-fluor0(7-hydr0xymeth0xyquin0linyloxy)-phenyl]-amide. Example 46 was
synthesized using example 41 and the procedure for e 42. mp = 205-7 0C; LCMS
m/z = 575 (M NMR(DMSO)5: 11.7 (s, 1H), 11.1 (s, 1H), 8.73 (d, 1H, J =7 Hz),
8.68 (s, 1H), 8.07, 8.11 (dd, 1H, J = 2.4, 12.7 Hz), 7.72 (s, 1H), 7.54-7.64 (m, 3H), 7.34-
7.45 (m, 4H), 6.89 (d, 1H, J = 6.5 Hz), 4.78 (m, 1H), 4.0 (s, 3H), 1.42 (d, 6H, J = 7 Hz).
Example 47.
(\NMongNj
©1010?
3 -(4-Fluor0phenyl)is0pr0pyl-2,4-diox0-1 ,2,3 ,4-tetrahydropyrimidinecarb0xylic acid
{3-fluoro[6-meth0xy(3-m0rpholinyl-pr0p0xy)- quinolinyloxy]phenyl} -amide.
Example 47 was synthesized by the procedure for example 43 using example 46. mp
=160-162 0C; LCMS m/z = 701 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.68 (s, 1H),
8.47 (d, 1H, 5.3 Hz), 7.99, 8.02 (dd, 1H, J = 2.3, 13 Hz), 7.5‘-7.55 (m, 2H), 7.33-7.45 (m,
6H), 6.46 (d, 1, J = 5.3 Hz), 4.78 (m, 1H), 4.2 (t, 2H, J = 6.8 Hz), 3.94 (s, 3H), 3.58 (m,
4H), 2.45 (m, 2H), 2.38 (m, 4H), 1.97 (m, 2H), 1.42 (d, 6H, J = 7 Hz).
Example 48.
2012/065019
OH: .. .
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid [4-
(6,7-dimethoxyquinolinyloxy)fluoro-phenyl]-methyl-amide. Example 1 (0.050 g,
0.087 mmol) in N,N—dimethylformamide (2 mL) at 5 oC (ice bath) was added sodium
hydride, 60% disp. in mineral oil (0.0052 g, 0.13 mmol). The e was stirred 0.5 h,
and then methyl iodide (0.0081 mL, 0.13 mmol) was added. After 2h, EtOAc was added,
washed with 1N N32C03, water and brine. The product was purified by prep LC/MS. The
fractions were combined and concentrated and the solid was crystallized with EtOAc,
ether and hexanes to give a white solid as the TFA salt. mp = 112-5 0C; LCMS m/z = 589
(M +1); 1H NMR (DMSO) 8: 8.66 (d, 1H, J = 5.9 Hz), 8.23 (s, 1H), 7.65 (s, 1H), 7.51-
7.60 (m, 3H), 7.25-7.30 (m, 3H), 7.13-7.16 (m, 2H), 6.6 (d, 1H, J = 5.8Hz), 4.01 (d, 6H),
3.8 (q, 2H, J = 7 Hz), 3.35 (s, 3H), 1.22 (t, 3H, J = 7 Hz).
Example 49.
/O\Om);N\
G”$10Fo o
N O
3 -(4-Fluorophenyl)(2-hydroxyethyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine
carboxylic acid 7-dimethoxyquinolinyloxy)fluorophenyl]-amide. Example 10
(0.06 g, 0.09 mmol) and palladium hydroxide (20%) on carbon (0.016 g, 0.024 mmol) in
ethyl e (7 mL) and MeOH (3 mL) was added 2 drops of 5N HCl. The mixture was
hydrogenated under an atmosphere of hydrogen on a Parr tus at 40 psi for 2 h. The
mixture was diluted with EtOAc and washed with 1N N32C03, and brine, then dried over
MgSO4. The solution was concentrated and the product was triturated with ether-hexanes
and the solid collected and dried at 60 0C under vacuum. mp = 166-8 0C; LCMS m/z = 591
(M +1); 1H NMR (DMSO) 8: 11.00 (s, 1H), 8.75 (s, 1H), 8.47 (d,1H, J = 5.4 Hz), 7.98,
8.01 (dd, 1H, J = 2.2, 13 Hz), 7.52—7.55 (m, 2H),7.34-7.46 (m, 6H), 6.47 (d, 1H, J = 5 Hz),
5.03 (t, 1H, J = 5.4 Hz), 4.05 (m, 2H), 3.94 (d, 6H), 3.67 (m, 2H).
Example 50.
/O\OJCLOQN\
Q”$10Fo o
N O
H\OH
3 -(4-Flu0r0phenyl)(3-hydroxypr0pyl)-2,4-di0xo- 1 ,2,3 ,4-tetrahydropyrimidine
carboxylic acid 7-dimethoxyquinolinyloxy)flu0r0phenyl]—amide. Example 50
was synthesized using example 13 by the procedure for example 49. mp =124-6 0C;
LCMS m/z = 605 (M + 1); 1H NMR (DMSO) 5: 11.00 (s, 1H), 8.82 (s, 1H), 8.47 (d, 1H, J
= 5.4 Hz), 7.98, 8.01 (dd, 1H, J = 2.5, 13 Hz), 7.52-7.55 (m, 2H), 7.33-7.46 (m, 6H), 6.47
(d, 1H, J = 6 Hz), 4.63 (t, 1H, J = 5 Hz), 4.05 (t, 2H, J = 7 Hz), 3.94 (s,s, 6H), 3.50 (q, 2H,
J = 5 Hz), 1.85 (p, 2H, J = 6.2 Hz).
Example 51
/o N\
\ /
3 u0r0phenyl)(3-hydroxypr0pyl)-2,4-di0xo- 1 ,2,3 ,4-tetrahydropyrimidine
carboxylic acid [4-(6,7-dimeth0xy-quinolinyloxy)fluor0-phenyl]- amide. Example
51 was synthesized using example 22 by the procedure for example 49. mp = 220-4 0C;
LCMS m/z = 605 (M + 1);1H NMR (DMSO) 5: 11.16 (s, 1H), 8.83 (s, 1H), 8.45-8.50 (m,
2H), 7.47 (s, 1H), 7.33-7.44 (m, 6H), 7.16 (d, 1H, J = 9H2), 6.58 (d, 1H, J =5Hz), 4.63 (t,
1H, J = 4.9 Hz), 4.04 (t, 2H, J = 7 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.50 (q, 2H, J = 5.4 Hz),
1.84 (q, 2H, J = 7Hz).
Example 52.
WO 74633
Q“610Fo o
N O
KLOH
3 -(4-Flu0r0phenyl)(3-hydroxypr0pyl)-2,4-di0xo- 1 ,2,3 ,4-tetrahydropyrimidine
carboxylic acid 7-dimethoxyquinolinyloxy)phenyl]-amide. Example 52 was
synthesized using example 21 by the procedure for example 49. mp = 123-6 0C; LCMS
m/z = 587 (M + 1); 1H NMR (DMSO) 5: 10.93 (s, 1H), 8.79 (s, 1H), 8.47 (d, 1H, J = 5
Hz), 7.8 )d, 2H, J =9 Hz), 7.50 (s, 1H), 7.33-7.44 (m, 5H), 7.25 (d, 2H, J = 9H2), 6.47 (d,
1H,j= 5.6 Hz), 4.63 (t, 1H, J = 5Hz), 4.04 (t, 2H, J = 7 Hz), 3.94 (s, 3H), 3.92 (s, 3H),
3.50 (q, 2H, J = 5Hz).
Example 53
0Q F
o o
OH
3 -(4-Fluor0phenyl)(2-hydr0xyethyl)-2,4-di0x0-1 ,2,3 ,4-tetrahydr0pyrimidine-5 -
carboxylic acid [4-(6,7-dimethoxyquinolinyloxy)phenyl]-amide. Example 53 was
synthesized using example 19 by the procedure for example 49. mp = 153-4 0C; LCMS
m/z = 573 (M +1); 1H NMR (DMSO) 5: 10.91 (s, 1H), 8.74 (s, 1H), 8.47 (d, 1H, J = 5.8
Hz), 7.80 (d, 2H, J = 9 Hz), 7.49 (s, 1H), 7.34-7.43 (m, 5H), 7.26 (d, 2H, J = 9 Hz), 6.48
(d, 1H, J = 5.4 Hz), 5.02 (t, 1H, J: 5.2 Hz), 4.03 (m, 2H), 3.94 (s, 3H), 3.92 (s, 3H), 3.67
(m, 2H).
Example 54.
/o N\
0 o QF
WO 74633
1-((S)-2,3-Dihydroxypropyl)—3-(4-fluorophenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-
-carboxylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]—amide. -2,2-
Dimethyl-1,3-dioxolanylmethyl)(4-fluorophenyl)—2,4-dioxo-1,2,3 ,4-
tetrahydropyrimidinecarboxylic acid (0.0446 g, 0.122 mmol) and N,N,N',N'-
tetramethyl-O-(7-azabenzotriazolyl)uronium hexafluorophosphate (0.0466 g, 0.122
mmol) in N,N—dimethylformamide (2.00 mL) was added N,N—diisopropylethylamine
(0.0388 mL, 0.223 mmol) and stirred at rt for 15 min. 4-(6,7-Dimethoxyquinolinyloxy)—
3-fluorophenylamine (0.035 g, 0.11 mmol) was added and d overnight. The solution
was d with EtOAc, washed with 1N N32C03, water and brine then dried over
MgSO4 and concentrated. MeOH was added (1 mL) and a solid separated. This material
was dissolved in 4 M of hydrogen chloride in 1,4-dioxane (2 mL, 8 mmol), stirred for 2h
and then concentrated. To this product was added MeOH and the precipitate collected to
give a white solid. mp = 165-6 0C; LCMS m/z = 621 (M + 1); 1H NMR (DMSO) 8: 11.0
(s, 1H), 8.72 (s, 1H), 8.48 9d, 1H, J: 5.4 Hz), 8.01, 7.98 (dd, 1H, J = 2.4, 13.5 Hz), 7.52-
7.55 (j, 1H), 7.34-7.46 (m, 6H), 6.47 (d, 1H, J = 5.4 Hz), 6.17 (d, 1H, J = 5 Hz), 4.78 (t,
1H, J = 5.7 Hz), 4.22 (d, 1H, J = 10 Hz), 3.94 (d, 6H), 3.75-3.78 (m, 2H), 3.3 (m, 2H).
Example 55.
/O N\ \o: : /\(\O/
QHwNONAG F
o o
KNOH
3 -(4-Fluorophenyl)(4-hydroxybutyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine
carboxylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]—amide. LCMS m/z =
619 (M +1);1HNMR(DMSO)5: 11.04 (s, 1H), 8.86 (s, 1H), 8.47 (d, 1H, J = 5 Hz), 8.00
(d, 1H, J = 12 Hz), 7.52-7.55 (m, 2H), 7.33-7.46 (m, 6H), 6.47 (d, 1H, J = 5 Hz), 4.48 (t,
1H, J = 4.5 Hz), 3.99 (m, 2H), 3.94 (d, 6H), 3.42 (m, 2H), 1.73 (m, 2H), 1.48 (m, 2H).
Example 56.
/o N\
N F
4-(2-fluoromethylaminophenoxy)methoxyquinolinecarbonitrile was synthesized
by the method described for 4-(5,7-dimethoxyquinolinyloxy)phenylamine example 38
starting with 4-aminomethoxybenzonitrile; LCMS m/z = 309 (M + 1); 1H NMR
(DMSO-d6) 5: 8.73 (s, 1H), 8.71 (d, 1H, J = 5.2 Hz ), 7.58 (s, 1H), 6.95 (d, 2H, J = 8.8
Hz), 6.67(d, 2H, J = 8.4 Hz ), 6.48 (d, 1H, J = 5.6 Hz), 5.20 (br s, NH, 2H), 4.06 (s, 3H).
3 -(4-Fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid
[4-(6-cyanomethoxy-quinolinyloxy)-phenyl]-amide. N,N,N',N'-Tetramethyl-O-(7-
azabenzotriazol-l-yl)uronium hexafluorophosphate (0.066 g, 0.17 mmol) and 3-(4-
fluorophenyl)isopropyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid
(0.062 g, 0.21 mmol) in N,N-dimethylformamide (2 mL, 20 mmol) was added N,N—
diisopropylethylamine (0.055 mL, 0.32 mmol). After 15 min ng at rt 4-(4-
aminophenoxy)methoxyquinolinecarbonitrile (0.05 g, 0.2 mmol) was added. The
reaction was stirred at rt overnight, d with EtOAc, washed with 1N N32C03, water
and brine solutions then dried over MgSO4. The product was recrystallized from MeOH
then dried overnight at 65 0C under vacuum to give a tan solid. mp = 202-3 0C; LCMS m/z
= 566 (M + l); 1H NMR (DMSO) 5: 10.96 (s, 1H), 8.77 (s, 1H), 8.74 (d, 1H, J = 5 Hz),
8.67 (s, 1H), 7.83 (d, 2H, J = 7.3 Hz), 7.61 (s, 1H), 7.42-7.45 (m, 2H), 7.30-7.38 (m, 5H),
6.56 (d, 1H, J = 5.5 Hz), 4.78 (q, 1H, J = 7 Hz), 4.07 (s, 3H), 1.43 (d, 6H, J = 7 Hz).
Example 57.
MeO ON\ /
MeO F
HO 0
Br
Step a. (4-Bromofluoro-phenyl)-(6,7-dimethoxy-quinolinyl)-methanol. A solution of
o-6,7-dimethoxyquinoline (0.5 g, 1.8 mmol) in tetrahydrofuran (6 mL) was cooled
at -78 0C. n-Butyllithium (0.89 mL, 2.23 mmol, 2.5 M on in hexane) was added
dropwise under an argon atmosphere and further stirred at -78 0C for 1 h. 4-Bromo
fluoro-benzaldehyde (0.45, 2.2 mmol) in 3 mL of tetrahydrofuran was added dropwise.
The reaction mixture was stirred at -78 0C for l h and slowly warmed to 0 0C for 1.5 h.
The reaction was ed with satd. NH4Cl solution and extracted three times with
CHzClz and the combined cs were washed with brine, dried (Na2S04), filtered, and
evaporated to yield a crude product. The crude product was purified by silica gel column
chromatography to e (4-bromofluoro-phenyl)-(6,7-dimethoxy-quinolinyl)-
methanol (0.45 g, 62%) as a yellow solid. MS m/z = 393 (M + l).
MeO N
O \ /
MeO F
Step b. (4-Aminofluoro-phenyl)-(6,7-dimethoxy-quinolinyl)-methanol. A mixture of
4-bromofluoro-phenyl)-(6,7-dimethoxy-quinolinyl)-methanol (0.72 g, 1.8 mmol),
bis(dibenzylideneacetone)palladium(0) (0.19 g, 0.33 mmol), tri-t-butylphosphine (0.54
mL, 10% solution), lithium hexamethyldisilazide (6.24 mL, 3.46 mmol, 1 M on in
THF) and toluene (5 mL) was charged in a pressure reaction vessel with a screw cap. The
mixture was heated at 80 0C for 3 h under an argon atmosphere and quenched with MeOH.
The crude product was purified by Gilson prep. HPLC to produce 4-aminofluoro-
)-(6,7-dimethoxy-quinolinyl)-methanol (0.4 g, 66%). MS m/z = 329 (M + 1).
MeoO N\
MeO /F
HO O o 0 OF
[IV 0
Step c. 3 -(4-fluoro-phenyl)- 1 l-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
carboxylic acid {4-[(6,7-dimethoxy-quinolinyl)-hydroxy-methyl]fluoro-phenyl}-
amide . To a well stirred mixture of 3-(4-fluorophenyl)methyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidinecarboxylic acid (0.058 g, 0.252 mmol) and N, N, N’, N’-
tetramethyl-O-(7-azabenzotriazolyl)-uronium hexafluorophosphate (0.096 g, 0.25
mmol) in N, N-dimethylformamide (2 mL) was added N, N-diisopropylethylamine (0.26
mL, 1.5 mmol). After ng for 10 min, 4-aminofluoro-phenyl)-(6,7-
dimethoxyquinolinyl)-methanol (0.072 g, 0.21 mmol) was added. The reaction mixture
was stirred at rt overnight and purified by Gilson prep. HPLC to produce (0.02 g, 17%) as
a solid. mp 164-166 0; LCMS m/z = 546 (M + 1). 1H NMR (DMSO-d6) 2 (s, 1H),
8.82 (s, 1H), 8.68 (d, 1H, J = 4.6 Hz), 7.73 (dd, 1H. J = 1.9 Hz, J = 12.8 Hz), 7.52 (d, 1H, J
= 4.56 Hz), 7.31-7.39 (m, 6H), 7.25-7.27 (m, 2H), 6.5 (d, 1H, J = 4.5 Hz), 6.28 (d, 1H, J =
4.6 Hz), 3.88 (s, 3H), 3.81 (s, 3H), 3.50 (s, 3H).
Example 58.
MeO ON\ /
MeO F
o 0 GOPNkaN
3 -(4-fiuoro-phenyl)methyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic acid
[4-(6,7-dimethoxy-quinolinylmethyl)fiuoro-phenyl]-amide. A mixture of example 57
(0.08 g, 0.13 mmol) and zinc (1.4 g, 21.5 mmol) in formic acid (5 mL) was heated at 60 0C
for 5 h. The reaction mixture was diluted with CHzClz and filtered over a celite and
washed with CHzClz. The filtrate was evaporated and d by Gilson prep. HPLC to
give a white solid (33 mg, 42%), mp 5 0C; MS m/z = 559 (M + H). 1H NMR
(DMSO-d6) 5:10.92 (s, 1H), 8.84 (s, 1H), 8.55 (d, 1H, J: 4.5 Hz), 7.78 (dd, 1H, J: 1.80
Hz, J: 12.4 Hz), 7.32-7.39 (m, 6H), 7.21-7.29 (m, 2H), 7.01 (d, 1H, J: 4.48 Hz), 4.38 (s,
2H), 3.91 (s, 3H), 3.90 (s, 3H), 3.51 (s, 3H).
Example 59.
Step a. 4-(2-Bromonitro-phenoxy)-6,7-dimethoxy-quinoline. A e of 4-chloro-
6,7-dimethoxyquinoline (0.82 g, 3.67 mmol), 2-bromonitrophenol (0.80 g, 3.67 mmol)
and 4-dimethylaminopyridine (0.067 g, 0.549 mmol) in chlorobenzene (8 mL) was heated
at 140 0C for 2 days under an argon atmosphere. The crude product was purified by silica
gel column chromatography followed by llization from a mixture of CHzClz, MeOH,
ether, and hexane to produce 4-(2-bromonitrophenoxy)-6,7-dimethoxyquinoline (0.74
g, 50%), LCMS m/z = 406 (M + 1).
Step b. 4-(2-Cyclopropylnitro-phenoxy)-6,7-dimethoxy-quinoline. A mixture of 4-(2-
bromonitro-phenoxy)-6,7-dimethoxy-quinoline (0.74 g, 1.8 mmol), ium
cyclopropyltrifiuoroborate (0.49 g, 3.39 mmol), palladium acetate (0.07 g, 0.31 mmol),
butyl-ditricyclo[3.3.1.1(3,7)]decanyl-phosphane (0.12 g, 0.34 mmol), and cesium
carbonate (3.07 g, 9.44 mmol) in a mixture of toluene (24 mL) and water (3.4 mL) was
heated at 85 CC for overnight. The reaction mixture was diluted with CHzClz and filtered
over a pad of celite, washed with . The filtrate was evaporated and purified by
Gilson prep. HPLC to produce 4-(2-cyclopropylnitro-phenoxy)-6,7-dimethoxyquinoline
(0.44 g, 65%). LCMS m/z = 367 (M + 1).
Step c. 3-Cyclopropyl(6,7-dimethoxy-quinolinyloxy)-phenylamine. A e of 4-
(2-cyclopropylnitro-phenoxy)-6,7-dimethoxy-quinoline (0.30 g, 0.82 mmol) and tin(H)
chloride dihydrate (0.92 g, 4.09 mmol) in a mixture of ethanol (10 mL) and ethyl acetate
(3 mL) was refluxed for 2 h. The reaction mixture was evaporated and partitioned
between CHzClz and satd. NaHCOg solution. The heterogeneous mixture was filtered over
celite, washed with CHzClz and the filtrate was separated into two . The aqueous
phase was extracted two times with CHzClz and the combined organics was washed with
brine, dried (Na2S04), filtered, and evaporated to yield a crude product. The crude
product was purified by silica gel column chromatography to produce 3-cyclopropyl
(6,7-dimethoxy-quinolinyloxy)-phenylamine (0.22 g, 80%), MS m/z = 337 (M + 1). 1H
NMR(CDC13) 8: 8.54 (d, 1H, J = 5.2 Hz), 8.1 (dd, 1H, J = 2.73 Hz, J = 8.9 Hz), 7.90 (d,
1H, J = 2.72 Hz), 7.52 (s, 1H), 7.46 (s, 1H), 7.16 (d, 1H, J = 8.85 Hz), 6.43 (d, 1H, J = 5.2
Hz), 4.06 (s, 3H), 4.04 (s, 3H), 2.04-2.14 (m, 1H), 1.59 (brs, 2H), 0.95-1.04 (m, 2H), 0.78-
0.86 (m, 2H).
Step d.
1-Ethyl(4-fiuoro-phenyl)-2,4-dioxo- 1 ,2,3 rahydropyrimidine-5 xylic
acid [3-cyclopropyl(6,7-dimethoxy-quinolinyloxy)-phenyl]-amide was synthesized
from 3-cyclopropyl(6,7-dimethoxyquinolinyloxy)phenylamine (0.06 g, 0.20 mmol)
and 3-(4-fluoro-phenyl)ethyl-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 xylic acid
(0.06 g, 0.21 mmol) in an analogous manner to Example 1. mp 183-185 0C; LCMS m/z =
597 (M + 1). 1H NMR (DMSO-d6) 5: 10.84 (s, 1H), 8.86 (s, 1H), 8.44 (d, 1H, J: 5.2 Hz),
7.71 (d d, 1H, J=2.53 Hz, .1: 8.73 Hz), 7.58 (s 1H), 7.31-7.46 (m, 5H), 7.27 (d, 1H, .1:
2.53 Hz), 7.17 (d, 1H, .1: 8.73 Hz), 6.33 (d, 1H, J: 5.2 Hz), 4.00 (q, 2H, .1: 7.04 Hz),
3.94 (s, 6H), 1.77-1.87 (m, 1H), 1.29 (t, 3H, .1: 7.04 Hz), 0.72-0.82 (m, 2H), 0.62-0.71
(m, 2H).
Example 60.
3:136;
£1310
)N\ O
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidine- 5 xylic
acid [3-cyclopropyl(6,7-dimethoxy-quinolinyloxy)-phenyl]- amide. This compound
was synthesized from 3-cyclopropyl(6,7-dimethoxyquinolinyloxy)phenylamine
(0.06 g, 0.20 mmol) and 3-(4-fluorophenyl)isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidinecarboxylic acid (0.063 g, 0.21 mmol) in an ous manner to
Example 59. mp 172-174 0C; LCMS m/z = 611 (M + 1). 1H NMR (DMSO-d6) 5: 10.86
(s, 1H), 8.67 (s, 1H), 8.44 (d, 1H, J = 5.24 Hz), 7.65 (dd, 1H, J = 2.52 Hz, J = 7.65 Hz),
7.58 (s, 1H), 7.31-7.48 (m, 6H), 7.16 (d, 1H, J = 8.73 Hz), 6.34 (d, 1H, J = 5.20 Hz), 4.70-
4.85 (m, 1H), 3.94 (s, 6H), 1.78-1.88 (m, 1H), 0.73-0.82 (m, 2H), 0.62-0.69 (m, 2H).
The following examples were synthesized using the procedures for Example 1.
Example 61.
/O N\
\O /
3 -(4-Fluoro-phenyl)-2,4-dioxopropynyl-1 ,2,3 rahydro-pyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]—amide. mp 155-157 0C; LCMS
m/z = 585 (M +1);1HNMR(DMSO)5: 10.97 (s, 1H), 8.95 (s, 1H), 8.48 (d, 1H, J = 5.5
Hz), 8.01 (dd, 1H, J = 2.5 Hz, J =13 Hz), 7.56 (bd, 1H, J = 9.0 Hz), 7.53 (s, 1H), 7.47-
7.42 (m, 3H), 7.41 (s, 1H),7.40-7.32 (m, 2H), 6.48 (d, 1H, J = 5.0 Hz), 4.85 (d, 2H, J = 2.5
Hz), 3.95 (s, 3H), 3.94 (s, 3H), 2.69 (s, 1H).
Example 62.
:66;
3 -(4-F1u0r0-pheny1)(2-imidaz01y1-ethy1)-2,4-di0x0-1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xy-quino1iny10xy)flu0r0-pheny1]—amide. mp 218-221
0C; LCMS m/z = 641 (M + 1); 1H NMR (DMSO) 5: 11.05 (s, 1H), 9.20 (s, 1H), 8.77 (s,
1H), 8.75 (m, 1H), 8.06 (dd, 1H, J = 2.5 Hz, J =13 Hz), 7.85 (t, 1H, J = 1.7 Hz), 7.71 (t,
1H, J = 1.7 Hz), 7.68 (s, 1H), 7.62 (dd, 1H, J = 1.7 Hz, J = 9.0 Hz), 7.57 (s, 1H), 7.55 (t,
1H, J = 9.0 Hz), 7.39 (s, 2H), 7.27 (s, 2H), 6.84 (m, 1H), 4.59 (t, 2H, J = 6.5 Hz),4.45 (t,
2H, J = 6.5 Hz), 4.02 (s, 3H), 4.01 (s, 3H).
Example 63.
6.15:1?
3 -(4-F1u0ro-pheny1)-2,4-di0x0(2-pyraz01—1-y1-ethy1)-1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xy-quino1iny10xy)flu0r0-pheny1]—amide. mp 149-
151°C;LCMS m/z = 641 (M + 1); 1H NMR (DMSO) 5: 10.92 (s, 1H), 8.49 (d, 1H, J = 6.6
Hz), 8.36 (s, 1H), 7.97 (dd, 1H, J = 2.5 Hz, J = 12.5 Hz), 7.81 (d, 1H, J = 2.0 Hz), 7.54-
7.50 (m, 3H), 7.46-7.34 (m, 6H), 6.48 (d, 1H, J = 4.8 Hz), 6.27 (t, 1H, J = 2.0 Hz), 4.48 (t,
2H, J = 5.7 Hz), 4.38 (t, 2H, J = 5.4 Hz), 3.95 (s, 3H), 3.94 (s, 3H).
Example 64.
/o N\
F W“;
N O
3 -(4-F1u0r0-pheny1)-2,4-di0x0phenethy1— 1 ,2,3 ,4-tetrahydr0-pyrirnidine-5 -carb0xy1ic
acid [4-(6,7-dirneth0xy-quinoliny10xy)flu0r0-pheny1]—arnide. mp 168-170 0C;
LCMS m/z = 651 (M + 1); 1H NMR (DMSO) 5: 11.00 (s, 1H), 8.79 (s, 1H), 8.48 (d, 1H, J
= 4.8 Hz), 7.99 (dd, 1H, J = 2.5 Hz, J = 12.5Hz), 7.56 (bd, 1H, J = 9.0 Hz), 7.52 (s, 1H),
7.47-7.23 (m, 11H), 6.48 (d, 1H, J = 5.6 Hz), 4.20 (t, 2H, J = 6.8 Hz), 3.95 (s, 3H), 3.94 (s,
3H), 3.02 (t, 2H, J = 6.9 Hz).
e 65.
/O N\
\O /
1-[2-(1 ,3-Di0x01any1-ethy1)](4-flu0r0-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarboxy1ic acid [4-(6,7-dirneth0xy-quin01iny10xy)—3-fluor0-pheny1]—
amide. mp 138-140 0C; LCMS m/z = 647 (M + 1); 1H NMR (DMSO) 8: 11.01 (s, 1H),
8.82 (s, 1H), 8.48 (d, 1H, J :54 Hz), 8.00 (dd, 1H, J = 2.3 Hz, J = 12.5 Hz), 7.55 (bd, 1H,
J = 9.7 Hz), 7.54 (s, 1H), 7.49-7.34 (m, 6H), 6.47 (d, 1H, J = 5.3 Hz), 4.93 (t, 1H, J = 4.2
Hz), 4.10 (t, 2H, J = 6.9 Hz), 3.95 (s, 3H), 3.94 (s, 3H), 3.94-3.90 (m, 2H), .77 (m,
2H), 2.05 (q, 2H, J = 4.5 Hz).
Example 66.
/o N\
on o 0 OF . 1%:
N O
\/N\/
1 -Dicthy1carbamoylmcthy1(4-flu0ro-phcny1)-2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-
-carb0xy1ic acid [4-(6,7-dimcthoxy-quinolinyloxy)flu0r0-phcny1]-amidc. mp 147-
149 0C ; LCMS m/z = 660 (M + 1); 1H NMR (DMSO) 5: 10.98 (s, 1H), 8.86 (s, 1H), 8.48
(d, 1H, J = 4.5 Hz), 8.00 (dd, 1H, J = 3.1 Hz, J = 12.5 Hz), 7.56 (bd, 1H, J = 9.3 Hz), 7.53
(s, 1H), .34 (m, 6H), 6.48 (d, 1H, J = 4.6 Hz), 4.96 (s, 2H), 3.95 (s, 3H), 3.94 (s,
3H), 3.39-3.28 (m,4H), 1.18 (t, 3H, J = 7.0 Hz), 1.05 (t, 3H, J = 7.1 Hz).
Example 67.
/o N\
F 1%:
N O
3 -(4-F1u0ro-phcny1)- 1 rph01iny1—2-oxo-cthy1)-2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-
pyrimidinecarboxy1ic acid [4-(6,7-dimcth0xy-quin01iny10xy)—3-fluor0-phcny1]—
amide. mp 159-161 0C; LCMS m/z = 674 (M + 1); 1H NMR (DMSO) 5: 10.97 (s, 1H),
8.82 (s, 1H), 8.49 (d, 1H, J = 5.3 Hz), 8.00 (dd, 1H, J = 2.6 Hz, J = 12.6 Hz), 7.56 (bd, 1H,
J = 9.5 Hz), 7.53 (s, 1H), 7.48-7.34 (m, 6H), 6.49 (d, 1H, J = 5.0 Hz), 5.00 (s, 2H), 3.95 (s,
3H), 3.94 (s, 3H), 3.65 (t, 2H, J = 4.4 Hz), 3.60 (t, 2H, J = 4.4 Hz), 3.52-3.46 (m, 4H).
Example 68.
/o N\
O91>”ngF
O O
9100
3 -(4-F1u0r0-phcny1)-2,4-di0x0[2-(2-0x0-pyrr01idiny1)-cthy1]—1 ,2,3 ,4-tctrahydr0-
pyrimidinecarboxy1ic acid [4-(6,7-dimcth0xy-quin01iny10xy)—3-fluor0-phcny1]—
amidc. mp 157-159 0C; LCMS m/z = 658 (M + 1); 1H NMR (DMSO) 5: 10.97 (s, 1H),
8.80 (s, 1H), 8.48 (d, 1H, J = 5.3 Hz), 8.00 (dd, 1H, J = 2.6 Hz, J =12.6 Hz), 7.55 (bd, 1H,
J = 9.5 Hz), 7.53 (s, 1H), 7.47-7.36 (m, 6H), 6.48 (d, 1H, J = 5.0 Hz), 4.16 (t, 2H, J = 4.6
Hz), 3.95 (s, 3H), 3.94 (s, 3H), 3.54-3.49 (m, 4H), 2.12 (t, 2H, J = 7.8 Hz), 1.93 (p, 2H, J =
8.2 Hz).
Example 69.
£236;
meifigj
1-(2-F1u0r0-ethy1)(4-flu0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
carboxylic acid 7-dimeth0xy-quino1iny10xy)flu0r0-pheny1]—amide. mp 138-
140 0C; LCMS m/z = 593 (M + 1); 1H NMR (DMSO) 5: 11.00 (s, 1H), 8.82 (s, 1H), 8.48
(d, 1H, J=5.2 Hz), 8.01 (dd, 1H, J = 2.4 Hz, J = 13 Hz), 7.55 (bd, 1H, J = 8.9 Hz), 7.52 (s,
1H), 7.48-7.33 (m, 6H), 6.48 (d, 1H, J = 5.1 Hz), 4.73 (dt, 2H, J = 4.2 Hz, J = 42 Hz), 4.36
(dt, 2H, J = 4.2 Hz, J = 28 Hz), 3.95 (s, 3H), 3.94 (s, 3H).
Example 70.
53::
101,9
[5-[4-(6,7-Dimethoxy-quinoliny10xy)fluor0-pheny1carbamoy1](4-flu0r0-pheny1)-
2,4-di0x0-3,4-dihydr0-2H-pyrimidiny1]-acetic acid tert-butyl ester. mp 138-143 0C;
LCMS m/z = 661 (M + 1); 1H NMR (DMSO) 5: 10.94 (s, 1H), 8.94 (s, 1H), 8.48 (d, 1H, J
= 5.2 Hz), 8.00 (dd, 1H, J = 2.5 Hz, J = 12.8 Hz), 7.56 (bd, 1H, J = 8.9 Hz), 7.52 (s, 1H),
7.48-7.35 (m, 6H), 6.48 (d, 1H, J = 4.9 Hz), 4.76 (s, 2H), 3.95 (s, 3H), 3.94 (s, 3H), 1.44
(s, 9H).
Example 71.
/O N\
\O /
WO 74633
[5-[4-(6,7-Dimeth0xyquinolinyloxy)fluorophenylcarbamoyl]—3-(4-flu0rophenyl)-
2,4-di0x0-3,4-dihydr0-2H-pyrimidinyl]-acetic acid. Example 70 was hydrolyzed using
trifiaoroacetic acid in dichloromethane at room temperature for 18 to give Example 71 mp
225 0C dec.; LCMS m/z = 605 (M + 1); 1H NMR (DMSO) 8: 13.42 (bs, 1H), 11.00 (s,
1H), 8.95 (s, 1H), 8.72 (d, 1H, J = 6.2 Hz), 8.07 (dd, 1H, J :25 Hz, J = 13 Hz), 7.69 (s,
1H),7.62 (bd, 1H, J = 8.6 Hz), 7.54 (t, 1H, J = 9.1 Hz), 7.50 (s, 1H), 7.44-7.34 (m, 4H),
6.84 (bs, 1H), 4.79 (s, 2H), 4.01 (s, 3H), 4.00 (s, 3H).
Example 72.
/o N\
or) 0 0 OF F ”wNNAG
3 -(4-Fluor0-phenyl)0xazolylmethyl-2,4-di0x0-1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid 7-dimeth0xy-quinolinyloxy)flu0r0-phenyl]—amide. mp 148-
150 0C; LCMS m/z = 628 (M + 1); 1H NMR (DMSO) 5: 10.85 (s, 1H), 9.05 (s, 1H), 8.48
(d, 1H, J = 5.2Hz), 8.17 (s, 1H), 8.01 (dd, 1H, J = 2.3 Hz, J =13 Hz), 7.56 (bd, 1H, J = 8.5
Hz), 7.52 (s, 1H), 7.48-7.33 (m, 6H), 7.25 (s, 1H), 6.48 (d, 1H, J = 5.0 Hz), 5.41 (s, 2H),
3.95 (s, 3H), 3.94 (s, 3H).
Example 73.
/o N\
F 1%:
N 0
3 -(4-Flu0r0-phenyl)-2,4-di0x0(tetrahydro-fi.1ranylmethyl)- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xylic acid [4-(6,7-dimeth0xy-quinolinyloxy)fluor0-phenyl]—
amide. mp 127-130 0C; LCMS m/z = 631 (M + 1); 1H NMR (DMSO) 8: 11.01 (s, 1H),
8.77 (s, 1H), 8.48 (d, 1H, J = 5.2 Hz), 8.01 (dd, 1H, J = 2.3 Hz, J =13 Hz), 7.54 (bd, 1H, J
= 9.5 Hz), 7.52 (s, 1H), 7.47-7.33 (m, 6H), 6.48 (d, 1H, J = 5.3 Hz), .09 (m, 2H),
3.99-3.93 (m, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.88-3.81 (m, 1H), 3.74-3.68 (m, 1H), 2.04-
1.77 (m, 3H), 1.65-1.55 (m, 1H).
e 74.
/o N\
. 1%:
N O
3 -(4-F1u0r0-phcny1)-2,4-di0x0(tctrahydro-pyrany1mcthy1)- 1 ,2,3 ,4-tctrahydr0-
pyrimidinecarboxy1ic acid [4-(6,7-dimcth0xy-quin01iny10xy)—3-fluor0-phcny1]—
amide. mp 185-187 0C; LCMS m/z = 645 (M + 1); 1H NMR (DMSO) 8: 11.05 (s, 1H),
8.83 (s, 1H), 8.48 (d, 1H, J = 5.4 Hz), 8.01 (dd, 1H, J = 2.4 Hz, J =13 Hz), 7.54 (bd, 1H, J
= 8.6 Hz), 7.52 (s, 1H), 7.46-7.33 (m, 6H), 6.47 (bd, 1H, J = 5.4 Hz), 3.95 (s, 3H), 3.94 (s,
3H), 3.92-3.85 (m, 4H), 3.26 (bd, 2H, J = 11.1 Hz), 1.60 (bd, 2H, J = 12.2 Hz), 1.32-1.23
(m, 3H).
Example 75.
/ommN\
093%ngN/KO F
O O
3 -(4-F1u0ro-phcny1)(2-mcthy1—thiaz01—4-y1mcthy1)-2,4-dioxo- 1 ,2,3 ,4-tctrahydr0-
dinecarboxy1ic acid [4-(6,7-dimcth0xy-quin01iny10xy)—3-fluor0-phcny1]—
amide. mp 196-198 0C; LCMS m/z = 658 (M + 1); 1H NMR (DMSO) 8: 11.01 (s, 1H),
8.95 (s, 1H), 8.48 (d, 1H, J = 5.3 Hz), 8.01 (dd, 1H, J = 2.3 Hz, J = 12.5 Hz), 7.55 (bd, 1H,
J = 9 Hz), 7.54 (s, 1H), 7.52 (s, 1H), 7.47-7.33 (m, 6H), 6.48 (bd, 1H, J = 5.9 Hz), 5.24 (s,
1H), 3.95 (s, 3H), 3.94 (s, 3H), 2.66 (s, 3H).
Example 76.
9380.0
1-Cyc10pcnty1—3-(4-flu0r0-phcny1)-2,4-di0x0- 1 ,2,3,4-tctrahydr0-pyrimidinccarb0xy1ic
acid [4-(6,7-dimcth0xy-quinolinyloxy)flu0r0-phcny1]—amidc. mp 222-224 0C;
LCMS m/z = 615 (M + 1);1HNMR(DMSO)8: 11.03 (s, 1H), 8.63 (s, 1H), 8.48 (d, 1H, J
= 5.4 Hz), 8.01 (dd, 1H, J = 2.5 Hz, J =13 Hz), 7.54 (bd, 1H, J = 9 Hz), 7.52 (s, 1H), 7.46-
7.33 (m, 6H), 6.48 (bd, 1H, J = 5.4 Hz), 4.90-4.81 (m, 1H), 3.95 (s, 3H), 3.94 (s, 3H),
2.12-2.04 (m, 2H), 1.93-1.78 (m, 4H), 1.69-1.63 (m, 2H).
Example 77.
/o N\
. 1%:
N O
1 -Benzy1—3 -(4-flu0ro-phenyl)-2,4-di0x0- 1 ,2,3 rahydro-pyrirnidine-5 -carb0xylic acid
[4-(6,7-dirneth0xy-quino1iny10xy)—3-flu0r0-phenyl]—arnide. mp 242-244 0C; LCMS m/z
= 637 (M + 1); 1H NMR (DMSO) 5: 11.01 (s, 1H), 8.97 (s, 1H), 8.48 (d, 1H, J = 5.8 Hz),
8.00 (dd, 1H, J = 2.5 HZ, J =13 Hz), 7.54 (bd, 1H, J = 9 Hz), 7.52 (s, 1H), .33 (m,
11H), 6.47 (bd, 1H, J = 5.4 Hz), 5.22 (s, 2H), 3.95 (s, 3H), 3.94 (s, 3H).
Example 78.
/o N\
. 1%:
N 0
3 -(4-F1u0r0-phenyl)[2-(2-fluor0-pheny1)—ethy1]-2,4-diox0-1 ,2,3 ,4-tetrahydr0-
pyrimidinecarboxylic acid [4-(6,7-dirneth0xy-quinoliny10xy)—3-fluor0-pheny1]—
amide. mp 178-180 0C; LCMS m/Z = 669 (M + 1); 1H NMR (DMSO) 5: 10.98 (s, 1H),
8.72 (s, 1H), 8.48 (d, 1H, J = 5.4 Hz), 7.98 (dd, 1H, J = 2.4 Hz, J =13 Hz), 7.53 (bd, 1H, J
= 9 Hz), 7.52 (s, 1H), 7.46-7.28 (m,8H), 7.22-7.16 (m, 2H), 6.47 (bd, 1H, J = 5.3 Hz), 4.23
(t, 2H, J = 7.4 Hz), 3.95 (s, 3H), 3.94 (s, 3H), 3.07 (t, 2H, J = 7.3 Hz).
Example 79.
/o N\
F 1%:
N O
3 -(4-F1u0r0-pheny1)[2-(4-flu0r0-pheny1)—ethy1]-2,4-di0x0-1,2,3 ,4-tetrahydr0-
pyrimidinecarboxy1ic acid 7-dirneth0xy-quin01iny10xy)—3-fluor0-pheny1]—
amide. mp 203-205 0C; LCMS m/z = 669 (M + 1); 1H NMR (DMSO): 11.00 (s, 1H), 8.79
(s, 1H), 8.48 (d, 1H, J = 5.4 Hz), 7.99 (dd, 1H, J = 2.4 Hz, J =13 Hz), 7.53 (bd, 1H, J = 9
Hz), 7.52 (s, 1H), 7.47-7.33 (m,8H), 7.20-7.14 (m, 2H), 6.47 (bd, 1H, J = 5.3 Hz), 4.18 (t,
2H, J = 7.4 Hz), 3.95 (s, 3H), 3.94 (s, 3H), 3.01 (t, 2H, J = 7.3 Hz).
Example 80.
/O N\
F 1%:
N O
1-(2-Cyclohexy1—ethy1)(4-flu0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-pyrirnidine-5 -
carboxylic acid [4-(6,7-dirneth0xy-quino1iny10xy)flu0r0-pheny1]—arnide. mp 186-
190 0C; LCMS m/z = 657 (M + 1); 1H NMR (DMSO) 8: 11.04 (s, 1H), 8.86 (s, 1H), 8.48
(d, 1H, J = 5.2 Hz), 8.01 (dd, 1H, J =2.3 Hz, J =13 Hz), 7.54 (bd, 1H, J = 9.5 Hz), 7.52 (s,
1H), 7.46-7.27 (m, 6H), 6.48 (d, 1H, J = 5.3 Hz), 4.00 (t, 2H, J = 7.2 Hz), 3.95 (s, 3H),
3.94 (s, 3H), 1.75-1.57 (m, 8H), 1.23-1.15 (m, 3H), 0.99-0.90 (m, 2H).
Example 81.
/o N\
\O /
F NkfikNH | NAG
3 -(4-F1uor0-phcny1)-2,4-di0x0(3-phcny1—propy1)- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcth0xy-quino1iny10xy)flu0r0-phcny1]—amidc. mp 128-
131 0C; LCMS m/z = 665 (M + 1); 1H NMR (DMSO) 8: 11.02 (s, 1H), 8.84 (s, 1H), 8.48
(d, 1H, J = 5.4 Hz), 8.01 (dd, 1H, J = 2.5 Hz, J =10 Hz), 7.54 (bd, 1H, J = 11 Hz), 7.52 (s,
1H), 7.46-7.16 (m, 11H), 6.48 (d, 1H, J = 4.9 Hz), 4.03 (t, 2H, J = 7.2 Hz), 3.95 (s, 3H),
3.94 (s, 3H), 2.68 (dd, 2H, J = 7.2 Hz, J = 16 Hz), 2.03 (t, 2H, J = 7.2 Hz).
Example 82.
/O N\
F ”*6:
N 0
3 -(4-F1u0ro-phcny1)-2,4-di0x0(2-0X0pyrr01idiny1—cthy1)-1 ,2,3 ,4-tctrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimcth0xy-quin01iny10xy)—3-fluor0-phcny1]—
amide. mp 2 0C; LCMS m/z = 658 (M + 1); 1H NMR (DMSO) 5: 10.97 (s, 1H),
8.80 (s, 1H), 8.48 (d, 1H, J = 5.3 Hz), 8.00 (dd, 1H, J = 2.4 Hz, J =12 Hz), 7.56 (bd, 1H, J
= 8.5 Hz), 7.53 (s, 1H), 7.47-7.35 (m, 6H), 6.48 (d, 1H, J = 5.2 Hz), 4.88 (s, 2H), 3.95 (s,
3H), 3.94 (s, 3H), 3.48 (t, 2H, J = 6.6 Hz), 3.35 (t, 2H, J = 6.9 Hz), 1.93 (p, 2H, J = 6.7
Hz), 1.80 (p, 2H, J = 6.9 Hz).
Example 83.
O N
/ \
1 -Dimcthy1carbamoylmcthy1(4-flu0r0phcny1)—2,4-di0xo- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-
-carb0xy1ic acid [4-(6,7-dimcth0xy-quino1iny10xy)—3-fluor0phcny1]—amidc. mp 163-
166 0C; LCMS m/z = 632 (M + 1); 1H NMR (DMSO) 5: 10.96 (s, 1H), 8.79 (s, 1H), 8.48
(d, 1H, J = 5.0 Hz), 8.00 (dd, 1H, J = 2.5 Hz, J = 13 Hz), 7.56 (bd, 1H, J = 9.4 Hz), 7.53 (s,
1H), 7.47-7.35 (m, 6H), 6.48 (d, 1H, J = 5.4 Hz), 4.97 (s, 2H), 3.95 (s, 3H), 3.94 (s, 3H),
3.03 (s, 3H), 2.89 (s, 3H).
Example 84.
/o\0mN\
I N O
/N1§J:§/
1-(1-Dimethylcarbamoyloxo-propyl)(4-fluoro-phenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-
dinecarboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]-
amide. mp 137-140 0C; LCMS m/z = 674 (M + 1); 1H NMR (DMSO) 5: 10.93 (s, 1H),
8.56 (s, 1H), 8.48 (d, 1H, J = 5.3 Hz), 8.00 (dd, 1H, J = 2.3 Hz, J =13 Hz), 7.55 (bd, 1H, J
= 9 Hz), 7.52 (s, 1H), 7.47-7.33 (m, 6H), 6.72 (s, 1H), 6.48 (d, 1H, J = 5.7 Hz), 3.95 (s,
3H), 3.94 (s, 3H), 3.17 (s, 3H), 2.97 (s, 3H), 2.31 (s, 3H).
Example 85.
Step a. 4-(6,7-Dimethoxyquinolinyloxy)fluoro-phenylamine. A mixture of 3-fiuoro-
4-nitrophenol (0.644 g, 4.10 mmol) and 60% sodium hydride (0.215 g, 5.60 mmol) in
dimethylformamide (20 mL) was stirred 15 min. 4-Bromo-6,7-dimethoxyquinoline (1.0 g,
3.73 mmol) was added and the mixture stirred at 110 0C for 18 h. After partitioning
between water and ethyl acetate, the organics were washed with water and brine. The
solvent was removed under vacuum, and the residue was purified by column
chromatography (0-5% methanol in romethane).
Step b. The nitro intermediate (0.52 g, 1.51 mmol) from step a in ethanol (20 mL) was
hydrogenated on a Parr apparatus at 50 psi with 10% ium on carbon (0.05 g) for 4 h.
The solution was filtered and the product purified by column chromatography (0-5%
MeOH in dichloromethane) to give 4-(6,7-dimethoxyquinolinyloxy)
fluorophenylamine in 36% yield. 1H NMR (DMSO) 5: 8.80 (d, 1H, J = 6.5 Hz), 7.72 (s,
1H), 7.70 (s, 1H), 7.26 (dd, 1H, J = 2.6 Hz, J = 12 Hz), .96 (m, 2H), 6.90 (d, 1H, J =
6.5 Hz), 4.69 (bs, 2H), 4.04 (s, 3H), 4.03 (s, 3H).
The following examples were synthesized using 4-(6,7-dimethoxy-quinolinyloxy)
fluorophenylamine and the method for Example 1.
/o N\
I10 00
. 1W1
N O
3-(4-F1uor0-phcnyl)-2,4-di0x0- 1 ,2,3 rahydro-pyrimidinccarb0xylic acid [4-(6,7-
dimcthoxy-quino1iny10xy)flu0r0-phcnyl]-amidc. mp 23 8-243 0C; LCMS m/z = 547
(M + 1); 1H NMR (DMSO) 5: 12.44 (bs, 1H), 11.16 (bs, 1H), 8.52-8.46 (m, 3H), 7.47 (s,
1H), 7.44-7.33 (m, 5H) 7.40 (s, 1H), 7.14 (d, 1H, J = 9.0 Hz), 6.59 (d, 1H, J = 5.0 Hz),
3.95 (s, 3H), 3.92 (s, 3H).
Example 86.
/o N\
00 O 0 OF
. 1%:
III 0
3 -(4-F1u0r0-phcny1)mcthy1—2,4-di0x0-1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xylic acid
[4-(6,7-dimcth0xy-quino1iny10xy)—2-fluoro-phcnyl]-amidc. mp 208-210 0C; LCMS m/z
= 561 (M + 1); 1H NMR (DMSO) 5: 11.17 (bs, 1H), 8.90 (s, 1H), 8.51-8.46 (m, 2H), 7.47
(s, 1H), .34 (m, 6H) 7.40 (s, 1H), 7.16 (d, 1H, J = 9.0 Hz), 6.59 (d, 1H, J = 5.0 Hz),
3.95 (s, 3H), 3.92 (s, 3H), 3.54 (s, 3H).
Example 87.
£139”;
9”(EC
1-Ethy1—3-(4-fluor0-phcny1)—2,4-di0xo-1 ,2,3,4-tctrahydr0-pyrimidinccarb0xy1ic acid [4-
(6,7-dimcthoxy-quinolinyloxy)flu0ro-phcnyl]-amidc. mp 142-144 0C; LCMS m/z =
575 (M + 1); 1H NMR (DMSO) 5: 11.18 (bs, 1H), 8.91 (s, 1H), 8.50 (d, 1H, J = 5.2 Hz),
8.48 (t, 1H, J = 9.8 Hz), 7.47 (s, 1H), 7.45-7.33 (m, 6H), 7.16 (bd, 1H, J = 8.3 Hz), 6.59 (d,
1H, J = 5.2 Hz), 4.02 (q, 2H, J = 7.0 Hz), 3.95 (s, 3H), 3.92 (s, 3H), 1.30 (t, 3H, J = 7.0
Hz).
Example 88.
1:131”;
@1181?
1-Allyl-3 -(4-flu0ro-phenyl)-2,4-di0x0- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carb0xylic acid [4-
(6,7-dimethoxy-quinolinyloxy)flu0ro-phenyl]-amide. mp 6 0C; LCMS m/z =
587 (M +1);1HNMR(DMSO)5: 11.16 (s, 1H), 8.82 (s, 1H), 8.50 (d, 1H, J = 5.5 Hz),
8.47 (t, 1H, J = 8.0 Hz), 7.47 (s, 1H), 7.46-7.34 (m, 6H), 7.16 (bd, 1H, J = 8.6 Hz), 6.59 (d,
1H, J = 5.4 Hz), .93 (m, 1H), 5.38 (d, 1H, J =17 Hz), 5.29 (d, 1H, J = 10.6 Hz),
4.63 (d, 2H, J = 5.7 Hz), 3.95 (s, 3H), 3.92 (s, 3H).
Example 89.
/o N\
080 . 0
F ”*61
M O
lu0r0-phenyl)-2,4-di0xo-1,2,3,4-tetrahydr0pyrimidinecarboxylic acid [4-(6,7-
dimethoxy-quinolinyloxy)-3,5-difluor0-phenyl]—amide. Example 89 was synthesized
using the 4-(6,7-dimethoxyquinolinyloxy)-3,5-difluor0phenylamine (synthesized using
the method for example 85 starting with 2,6-difluor0nitrophenol; LCMS m/z = 333 M+
1); LCMS m/z = 565 (M + 1); 1H NMR(CDC13) 5: 8.50 (bd, 1H), 8.47 (s, 1H),7.60 (d,
1H, J = 4.0 Hz), 7.46 (bd, 2H, J = 15 Hz), 7.24-7.12 (m, 6H), 6.36 (d, 1H, J = 8.9 Hz),
.88 (d, 1H, J = 8.1 Hz), 4.07 (s, 3H), 4.05 (s, 3H).
Example 90.
/o\omN\
01> 0 . 0F . NW1
2N O
1-Ethyl(4-flu0r0-phenyl)—2,4-di0x0-1,2,3,4-tetrahydro-pyrimidinecarb0xylic acid [4-
(6,7-dimethoxy-quinolinyloxy)-3,5-difluoro-phenyl]—amide. mp 166-170 0C; LCMS
m/z = 593 (M + 1); 1H NMR (DMSO) 5: 11.13 (s, 1H), 8.91 (s, 1H), 8.50 (d, 1H, J = 6.8
Hz), 7.83 (d, 2H, J = 9.8 Hz), 7.54 (s, 1H), 7.45-7.32 (m, 5H), 6.59 (d, 1H, J = 6.5 Hz),
4.02 (q, 2H, J = 6.5 Hz), 3.96 (s, 6H), 2.69 (t, 3H, J = 6.5 Hz).
Example 91.
/o N\
on o o
. ”W1“
N 0
3 -Ethyl- 1 oro-phenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]-amide. To a solution of 4-
fluoroaniline (1.0 g, 9.01 mmol) in THF (20 mL) at 0 0C, was slowly added ethyl
isocyanate (0.70 g, 10.0 mmol). After stirring 30 min. at 0 0C, the solution was warmed to
rt and the solvent was d under vacuum. To the residue was added ethanol (30 mL),
diethyl ethoxymethylenemalonate (1.95 g, 9.01 mmol) and 21% NaOEt in ethanol (2.92
mL, 9.01 mmol)) and the reaction stirred 48 h at rt. The t was removed under
vacuum and cold conc. HCl was added to pH 6. The aqueous layer was removed under
vacuum and the solids were crystallized from ethyl acetate and hexanes. 3-Ethyl(4-
fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid ethyl ester
isomer was isolated in 25% yield. 1H NMR(CDC13) 5: 8.32 (s, 1H), 7.20-7.14 (m, 4H),
4.35 (q, 2H, J = 7.1 Hz), 3.95 (q, 2H, J = 7.2 Hz), 1.42 (t, 3H, J = 7.2 Hz), 1.36 (t, 3H, J =
7.2 Hz).
3 -Ethyl(4-fluorophenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic acid
ethyl ester was hydrolyzed with 1N LiOH in MeOH and THF at 65 0C. The acid was
coupled with -Dimethoxyquinolinyloxy)fluorophenylamine using the method
for example 1 to give 3-ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-
pyrimidinecarboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]-
amide mp 140-142 0C; LCMS m/z = 575 (M + 1); 1H NMR (DMSO) 5: 11.18 (s, 1H), 8.49
(d, 1H, J = 2.5 Hz), 8.46 (s, 1H), 8.03 (dd, 1H, J = 3 Hz, J =13 Hz), 7.65-7.39 (m, 6H),
7.55 (s, 1H), 7.41 (s, 1H), 6.49 (d, 1H, J = 5.0 Hz), 4.00 (q, 2H, J =7.4 Hz), 3.95 (s, 6H),
1.23 (t, 3H, J =7.3 Hz).
Example 92.
/O N\
000 O F ”w“
methyl-2,4-dioxo-1,2,3 ,4-tetrahydropyrimidinecarboxylic acid [4-(6,7-
dimethoxy-quinolinyloxy)fluorophenyl]-amide.
Step a. A mixture of 2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid ethyl ester
(0.100 g, 0.543 mmol), iodomethane (0.130 mL, 1.63 mmol), and potassium carbonate
(0.225 g, 1.63 mmol) was d in N,N—dimethylformamide (5 mL, 60 mmol) at 80 0C
18 h. The mixture was poured into water and extracted with ethyl acetate. The residue
was hydrolyzed with 1equivalent of 1N LiOH in THF / MeOH (1 :1; 6 mL) at 60 CC 4h.
The cs were removed under vacuum, and the aqueous was washed with ethyl
acetate. The aqueous was then cooled and acidified with conc. HCl. The 1,3-dimethyl-
2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid was filtered off in 60% yield.
1H NMR (DMSO) 8: 12.78 (bs, 1H), 8.72 (s, 1H), 3.45 (s, 3H), 3.22 (s, 3H).
This intermediate acid was d with 4-(6,7-dimethoxyquinolinyloxy)
fluorophenylamine as described in example 1. mp 25 8-260 0C; LCMS m/z = 481 (M + 1);
1H NMR (DMSO) 8: 11.22 (s, 1H), 8.76 (s, 1H), 8.49 (d, 1H, J = 5.3 Hz), 8.02 (dd, 1H, J
= 2.5 Hz,J = 13 Hz), 7.54 (d, 1H, J = 8 Hz), 7.54 (s, 1H), 7.47 (t, 1H, J = 9.0 Hz), 7.41 (s,
1H), 6.49 (d, 1H, J = 9.0 Hz), 3.95 (s, 6H), 3.51 (s, 3H), 3.29 (s, 3H).
Examples 92-98 intermediate acids were synthesized as in Scheme 2 and described in
Example 92 and coupled using methods described for Example 1.
Example 93.
/o N\
on o o
F 1W1“
N O
1,3-Diethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-(6,7-dimethoxyquinolinyloxy
)fluoro-phenyl]-amide. mp 178-180 0C; LCMS m/z = 509 (M + 1); 1H
NMR (DMSO) 5: 11.22 (s, 1H), 8.76 (s, 1H), 8.49 (d, 1H, J = 5.5 Hz), 8.02 (dd, 1H, J =
2.5 Hz, J = 13 Hz), 7.55 (d, 1H, J = 8 Hz), 7.54 (s, 1H), 7.46 (t, 1H, J = 9.0 Hz), 7.41 (s,
1H), 6.49 (d, 1H, J = 9.0 Hz), 4.02-3.96 (m, 4H), 3.95 (s, 6H), 1.27 (t, 3H, J = 7.4 Hz),
1.18 (t, 3H, J = 7.5 Hz).
Example 94.
121)?
.1151ng
)N\ O
1,3-Diisopr0py1—2,4-diox0-1,2,3,4-tctrahydr0-pyrimidinccarb0xy1ic acid [4-(6,7-
dimcthoxy-quino1iny10xy)flu0r0-phcny1]—amidc. mp 6 0C; LCMS m/z = 537
(M +1); 1H NMR (DMSO) 5: 11.22 (s, 1H), 8.54 (s, 1H), 8.49 (d, 1H, J = 5.0 Hz), 8.02
(dd, 1H, J = 2.5 Hz, J =13 Hz), 7.54 (bd, 1H, J = 9 Hz), 7.53 (s, 1H), 7.46 (t, 1H, J = 8.1
Hz), 7.42 (s, 1H), 6.49 (d, 1H, J = 5.6 Hz), 5.18 (h, 1H, J = 6.7 Hz), 4.78 (h, 1H, J = 6.8
Hz), 3.95 (s, 6H), 1.45 (d, 6H, J = 6.7 Hz), 1.38 (d, 6H, J = 6.4 Hz).
Example 95
Dim”
1,3-Bis-cyc10pr0py1mcthy1—2,4-di0x0-1,2,3,4-tctrahydr0-pyrimidinccarb0xy1ic acid [4-
(6,7-dimcthoxy-quinoliny10xy)—3-fluoro-phcny1]—amidc. mp 63-65 0C; LCMS m/z =
561 (M + 1); 1H NMR (DMSO) 5: 11.192 (8, 1H), 8.83 (s, 1H), 8.49 (d, 1H, J = 5.3 Hz),
8.03 (dd, 1H, J = 2.3 Hz, J = 13.5 Hz), 7.55 (bd, 1H, J = 9 Hz), 7.54 (s, 1H), 7.46 (t, 1H, J
= 8.9 41 (s, 1H), 6.49 (d, 1H, J = 5.1 Hz), 3.95 (s, 6H), 3.84 (t, 4H, J = 7.1 Hz),
1.16-1.08 (m, 2H), 0.56-0.38 (m, 8H).
Example 96.
/O N\
on O O
. NW
1,3-Dia11y1-2,4-di0x0-1,2,3,4-tctrahydr0-pyrimidinccarb0xy1ic acid [4-(6,7-dimcthoxy-
quinoliny10xy)flu0r0-phcny1]—amidc. mp 172-174 0C; LCMS m/z = 529 (M + 1); 1H
NMR (DMSO) 8: 11.10 (s, 1H), 8.72 (s, 1H), 8.49 (d, 1H, J = 5.2 Hz), 8.02 (dd, 1H, J =
2.5 Hz, J = 13 Hz), 7.56 (bd, 1H, J = 8.9 Hz), 7.53 (s, 1H), 7.46 (t, 1H, J = 8.8 Hz), 6.49
(d, 1H, J = 5.2 Hz), .03 (m, 2H), 5,31-5.27 (m, 1H), 5.27-5.25 (m, 1H), .17
(m, 1H), 5.16-5.14 (m, 1H), 4.60 (d, 2H, J = 5.5 Hz), 4.53 (d, 2H, J = 5.5 Hz), 3.95 (s,
3H), 3.94 (s, 3H).
Example 97.
/O N\
on O O
. ”$1“
N O
1 ,3-Bis—(3 -methy1—buteny1)-2,4-diox0- 1 ,2,3 ,4-tetrahydr0-pyrimidinecarb0xy1ic acid
[4-(6,7-dimeth0xy-quinoliny10xy)—3-flu0r0-pheny1]—amide. mp 184-186 0C; LCMS m/z
= 589 (M + 1); 1H NMR (DMSO) 5: 11.15 (s, 1H), 8.65 (s, 1H), 8.49 (d, 1H, J = 5.7 Hz),
8.02 (dd, 1H, J = 2. Hz, J =13 Hz), 7.54 (bd, 1H, J = 9 Hz), 7.52 (s, 1H), 7.46 (t, 1H, J =
9.5 Hz), 7.71 (s, 1H), 6.49 (bd, 1H, J = 5 Hz), 5.30 (m, 1H), 5.19 (m, 1H), 4.53 (dd, 4H, J
= 6.7 Hz, J = 15.3 Hz), 3.95 (s, 6H), 1.78 (bs, 3H), 1.77 (bs, 3H), 1.74 (bs, 3H), 1.69 (bs,
3H).
Example 98.
/o N\
\O /
F N N
H I §
N O
2,4-Di0x0-1,3-di-pr0pyny1—1,2,3 ,4-tetrahydro-pyrimidinecarb0xy1ic acid [4-(6,7-
dimethoxy-quino1iny10xy)flu0r0-pheny1]—amide. mp 133-138 0C; LCMS m/z = 529
(M +1); 1H NMR (DMSO) 5: 10.94 (s, 1H), 8.88 (s, 1H), 8.49 (d, 1H, J = 6.5 Hz), 8.03
(dd, 1H, J = 2.5 Hz, J =13 Hz), 7.59 (bd, 1H, J = 8.5 Hz), 7.54 (s, 1H), 7.48(t, 6H, J = 9.1
Hz), 6.50 (d, 1H, J = 5.3 Hz), 4.84 (d, 2H, J = 2.4 Hz), 4.42 (d, 2H, J = 2.2 Hz), 3.96 (s,
6H), 3.61 (t, 1H, J = 2.5 Hz), 3.25 (t, 1H, J = 2.5 Hz).
Example 99.
2012/065019
\0m/o N\
00 o o
F 1%“:
N O
2,4-Dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic acid [4-(6,7-dimethoxy-quinolin
yloxy)fluoro-phenyl]-amide. A solution of 2,4-dioxo-1,2,3,4-tetrahydro-pyrimidine
carboxylic acid (0.156 g, 1.00 mmol) in thionyl chloride (2 mL, 30 mmol) was stirred at
100 oC 3h. After the t was removed under vacuum, [ 4-(6,7-dimethoxy-quinolin
yloxy)fluoro-phenylamine (0.314 g, 1.00 mmol) and pyridine (2 mL, 20 mmol) were
added and stirred at room temperature 18 hr. The solvent was d under vacuum and
the residue was purified on HPLC. 0.15 g of the trifluoracetic acid salt was isolated in
27% yield. mp 251-255 0C; LCMS m/z = 453 (M + 1); 1H NMR (DMSO) 8: 11.99 (bs,
1H), 11.93 (s, .18 (s, 1H), 8.74 (d, 1H, J = 4.5 Hz), 8.31 (d, 1H, J = 7.5 Hz), 8.06
(d, 1H, J = 12 Hz), 7.70 (s, 1H), 7.55 (m, 2H), 7.51 (s, 1H), 6.85 (m, 1H), 4.02 (s, 3H),
4.01 (s, 3H).
Example 100.
1:131“;
£11305)
1-Ethyl-2,4-dioxophenyl-1,2,3 rahydro-pyrimidine-5 -carboxylic acid [4-(6,7-
dimethoxy-quinolinyloxy)fluoro-phenyl]-amide. To a solution of 2-
aminomethylene-malonic acid diethyl ester (0.75 g, 4.0 mmol) and phenyl nate
(0.57 g, 4.4 mmol) in 1,2-dichloroethane (20 mL) was added N,N—diisopropylethylamine
(0.77 mL, 4.4 mmol) and heated at 100 0C 6 h. The mixture was cooled and d. The
solids were purified by column chromatography with 0-5% MeOH in methylene chloride.
This intermediate urea was suspended in ethanol (10 mL) and 21% NaOEt in ethanol (1.29
mL, 4.0 mmol ) was added. After 18 h the solvent was removed under vacuum and the
residue was slurred in ethyl acetate. The organics were washed with 1M citric acid
solution, water and brine. The solvent was removed under vacuum and the residue was
purified by chromatography with 0-5% MeOH in dichloromethane to give 0.50 g (40%).
The ester was alkylated and hydrolyzed using methods for example 92 to give 1-ethyl-2,4-
dioxophenyl-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid. 1H NMR (DMSO) 5:
12.65 (bs, 1H), 8.82 (s, 1H), 7.54-7.43 (m, 3H), 7.32-7.29 (m, 2H), 4.02 (q, 2H, J = 7.1
Hz), 1.26 (t, 3H, J = 7.1 Hz).
This ediate acid was coupled to 4-(6,7-dimethoxyquinolinyloxy)
fluorophenylamine as described in example 1 to give Example 100 . mp 282-285 0C;
LCMS m/z = 557 (M + 1); 1H NMR (DMSO) 5: 11.01 (s, 1H), 8.89 (s, 1H), 8.48 (d, 1H, J
= 4.6 Hz), 8.00 (dd, 1H, J = 2.3 Hz, J = 13 Hz), .34 (m, 9H), 6.47 (d, 1H, J = 4.6
Hz), 4.02 (q, 2H, J = 6.9 Hz), 3.95 (s, 3H), 3.94 (s, 3H), 1.3 (t, 3H, J = 7.4 Hz).
Example 101.
1:131”;
magic
)N\ O
1-Isopropyl-2,4-dioxophenyl-1,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic acid [4-(6,7-
dimethoxy-quinolinyloxy)fluoro-phenyl]—amide. mp 235-237 0C; LCMS m/z = 571
(M +1);1H NMR (DMSO) 5: 11.07 (s, 1H), 8.69 (s, 1H), 8.48 (d, 1H, J = 4.6 Hz), 8.01
(dd, 1H, J = 2.3 Hz, J =13 Hz), 7.55-7.35 (m, 9H), 6.48 (d, 1H, J = 4.6 Hz), 4.79 (h, 1H, J
= 6.9 Hz), 3.95 (s, 3H), 3.94 (s, 3H), 1.43 (d, 6H, J = 6.8 Hz).
e 102.
/OON\\O /
O o 0 00
F ”kw
NH/go
3 -(4-Fluoro-phenyl)-2,4-dioxopropyl-1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic acid
[4-(6,7-dimethoxy-quinolinecarbonyl)fluoro-phenyl]—amide.
O N
/0 O N\ / O \
/ \O /
/O N\ a, b \O C, d
+ F
\o / O O O O
F HO O
Br CHO 0
F N N
Step a. A solution of 4-bromo-6,7-dimethoxyquinoline (1.0 g, 3.73 mmol) in dry THF (20
mL) was cooled to -78 0C. A solution of 2,5M n-butyllithium in hexanes (1.50 mL, 3.73
mmol) was added and stirred 15 min. A solution of 4-bromofluoro-benzaldehyde
WO 74633
(0.757 g, 3.73 mmol) in THF (10 mL) was added dropwise over 5 min. After stirring 30
min. at -78 0C, saturated ammonium de solution (1 mL) was added. The solvent was
d under reduced pressure. The residue was dissolved in ethyl acetate and washed
with water. After the solvent was removed under vacuum, the residue was purified by
chromatography with 0-5% MeOH in dichloromethane to give (4-bromofluoro-phenyl)-
(6,7-dimethoxy-quinolinyl)-methanol in 52% yield. 1H NMR(CDC13) 5: 8.63 (d, 1H, J
= 4.1 Hz), 7.57 (d, 1H, J = 4.7 Hz), 7.34 (s, 1H), 7.25-7.17 (m, 2H), 7.08 (s, 1H), 6.67 (s,
1H), 4.02-3.96 (m, 1H), 3.94 (s, 3H), 3.88 (s, 3H).
Step b. The intermediate from step a (0.196 g, 0.50 mmol) was dissolved in THF (5 mL)
and 1M lithium hexamethyldisilazane in THF (0.55 mL, 0.55 mmol),
bis(dibenzylideneacetone)palladium (0.014 g, 5 mol%) and tri-tert-butylphosphine (0.061
mL, 5 mol%) were added. The sealed tube was heated at 65 0C 18 hr. After cooling,
concentrated HCl was added to pH 1 and stirred 1 hr. The solvent was removed under
vacuum, ethyl acetate and saturated sodium bicarbonate solution was added until slightly
basic. The organics were separated, the t d under vacuum and the residue
purified by chromatography with 0-5% MeOH in romethane to give (4-amino
fluoro-phenyl)-(6,7-dimethoxy-quinolinyl)methanone in 60% yield. 1H NMR(CDC13)
8: 8.78 (d, 1H, J = 4.7 Hz), 7.69 (d, 1H, J = 4.7 Hz), 7.42 (s, 1H), 7.10 (s, 1H), 6.90 (t, 1H,
J = 8.3 Hz), 6.65 (s, 1H), 6.41 (dd, 1H, J = 2.2 Hz, J = 12.1 Hz), 6.33 (dd, 1H, J = 2.2 Hz, J
= 8.4 Hz), 4.00 (s, 3H), 3.90 (s, 3H), 3.80 (bs, 2H), 2.33 (bs, 1H).
Steps c and d. 3-(4-Fluoro-phenyl)-2,4-dioxopropyl-1,2,3,4-tetrahydro-pyrimidine
carboxylic acid [4-(6,7-dimethoxy-quinolinecarbonyl)fluoro-phenyl]-amide. The
intermediate from step b was coupled with 3-(4-fluorophenyl)-2,4-dioxopropyl-1,2,3,4-
tetrahydro-pyrimidinecarboxylic acid using the methods for Example 1.. The alcohol
(0.075 g, 0.12 mmol) product was dissolved in dichloromethane (5 mL) and cooled to 0
0C. Dess-Martin periodinane (0.076 g, 0.18 mmol) was added slowly and the solution
warmed to room temperature for 4 h. The organics were washed with saturated sodium
bicarbonate and the t removed under vacuum. The residue was purified by column
chromatography with 5% MeOH in dichloromethane to give 0.063g (84%) mp 125-127
0C; LCMS m/z = 601 (M + 1); 1H NMR (DMSO) 8: 11.30 (s, 1H), 8.88 (s, 1H), 8.79 (d,
1H, J = 4.0 Hz), 7.87 (dd, 1H, J = 1.9 Hz, J =13 Hz), 7.72 (t, 1H, J = 8.5 Hz), 7.56 (dd,
1H, J = 1.8 Hz, J = 8.7 Hz), 7.49 (s, 1H), .32 (m, 5H), 7.29 (s, 1H), 3.96 (s, 3H),
3.94 (t, 2H, J = 7.4 Hz), 3.77 (s, 3H), 1.71 (q, 2H, J = 7.8 Hz), 0.92 (t, 3H, J = 8.3 Hz).
Synthesis of 3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid
Method A.
Step a. uorophenyl)oxothioxo-2,3 ,4,5-tetrahydro-[1,2,4]triazinecarboxylic
acid ethyl ester. A mixture of 2-oxo-malonic acid diethyl ester (2.5 mL, 16 mmol) and 4-
fluorophenyl thiosemicarbazide (3.0 g, 16 mmol) in ethanol (60 mL, 1000 mmol) was
heated at reflux for 3 days. The mixture was cooled to rt and the separated solid was
filtered, washed with cold l and dried to give 3.44 g (71%). LCMS m/z = 296 (M +
1); 1H NMR (DMSO) 8: 7.35 (m, 4H), 4.30 (q, 2H, J = 7.1 Hz), 1.27 (t, 3H, J = 7.1 Hz).
Step b. 4-(4-Fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid
ethyl ester. To a solution of 4-(4-fluorophenyl)oxothioxo-2,3,4,5-tetrahydro-1,2,4-
triazinecarboxylic acid ethyl ester (11 g, 37 mmol) in N,N—dimethylformamide (100
mL) and acetic acid (40 mL, 700 mmol) was added 50% aq. hydrogen peroxide (11 mL,
190 mmol). The mixture was stirred at rt 2 days, the solvent was removed and the product
was taken up in ethylacetate and washed successively with water and brine. After drying,
the solvent was ated. The solid obtained was triturated with ether, filtered and
washed with cold ether to yield 9.85 g (95%). LCMS m/z = 280 (M + 1); 1H NMR
(DMSO) 8: 13.1 (s, 1H), 7.42-7.28 (2m, 4H), 4.29 (q, 2H, J = 7.1 Hz), 1.27 (t, 3H, J = 7.1
Hz).
Step c. 4-(4-Fluorophenyl)isopropyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine
carboxylic acid ethyl ester. 4-(4-Fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-
necarboxylic acid ethyl ester (1000 mg, 4 mmol), isopropyl iodide (0.72 mL, 7.16
mmol) and potassium carbonate (544 mg, 3.94 mmol) in N,N—dimethylformamide (20 mL)
was heated at 65 CC for 60 min. The reaction mixture was cooled to rt and was
trated, diluted with EtOAc and was filtered through a pad of celite. The filtrate was
concentrated and the product purified by flash chromatography (hexane: EtOAc 3:1) to
give a white solid (1.1 g, 96%). LCMS m/z = 322 (M + 1); 1H NMR (DMSO) 5: 7.41-7.31
(m, 4H), 4.86 (m, 1H), 4.31 (q, 2H, J = 7.0 Hz), 1.31-1.26 (overlapping t and d, 9H).
Step d. 4-(4-Fluorophenyl)isopropyl-3 ,5-dioxo-2,3 ,4,5-tetrahydro[1,2,4]triazine
carboxylic acid. Sulfuric acid (10 mL, 200 mmol) was carefully added to a mixture of 4-
(4-fluorophenyl)isopropyl-3 ,5-dioxo-2,3 ,4,5 -tetrahydro-1 ,2,4-triazinecarboxylic acid
ethyl ester (1100 mg, 3.4 mmol) and water (2 mL). The mixture became homogenous after
a few minutes. The reaction mixture was d at 40 OC overnight, was cooled to rt and
was carefully added to ice. The mixture was saturated with solid NaCl and was extracted
repeatedly from EtOAc (3 x). The combined EtOAc layer was washed with brine, dried
over ium e, and concentrated to give the product as foam (100%). LCMS m/z
= 294 (M + 1); 1H NMR (Methanol d4) 5: 7.35-7.31 (2m, 4H), 4.95 (m, 1H), 4.31 (q, 2H, J
= 7.0 Hz), 1.41 (d, 6H, J = 6.6 Hz).
The following 3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazinecarboxylic acids were
synthesized using the previous procedure.
2-Ethyl(4-fluorophenyl)-3 ,5-dioxo-2,3 ,4,5 -tetrahydro-[1,2,4]triazinecarboxylic acid.
LCMS m/z = 280 (M + 1); 1H NMR (Methanol-d4) 8: 7.34-7.18 (m, 4H), 4.10 (q, 2H, J =
7.2 Hz), 1.38 (t, 3H, J = 7.2 Hz).
4-(4-Fluorophenyl)(2-hydroxyethyl)-3 xo-2,3 ,4,5 -tetrahydro- [1 ,2,4]triazine
carboxylic acid. Synthesized from 2-[2-(t-butyldimethylsilanyloxy)ethyl](4-
fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid. LCMS m/z =
296 (M + 1); 1H NMR (DMSO) 5: 7.41-7.36 (m, 4H), 4.09-4.01 (2m, 3H), 3.72 (m, 2H).
Tert(4-Fluorophenyl)-3 ,5 -dioxo(2-oxo-propyl)-2,3 ,4,5 -tetrahydro-[1,2,4]triazine
carboxylic acid. (from the ester precursor, 4-(4-fluorophenyl)-3,5-dioxopropynyl-
2,3,4,5-tetrahydro-[1,2,4] triazinecarboxylic acid ethyl ester). LCMS m/z = 308 (M +
1); 1H NMR (DMSO) 8: 7.46-7.32 (m, 4H), 4.95 (s, 2H2.21 (s, 3H).
2-Cyclopropylmethyl(4-fluoro-phenyl)-3 ,5-dioxo-2,3 ,4,5 -tetrahydro- [1 riazine
carboxylic acid. LCMS m/z = 306 (M + 1).
4-(4-Fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid. 4-(4-
Fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazinecarboxylic acid ethyl ester
(300 mg, 1 mmol) in THF (3 mL) and MeOH (7 mL) was added 5M NaOH (2 mL, 2
mmol). The mixture was stirred at rt for 1h and was trated. Water was added and
the mixture was extracted with ether. The aq. layer was made acidic with HCl at 0°C and
was extracted with EtOAc and trated. LCMS m/z = 274 (M + Na); 1H NMR
(DMSO) 5: 13.03 (s, 1H), 7.35-7.30 (m, 4H).
4-(4-F|uoro-pheny|)—2-methyI-3,5-di
3,4,5-tetrahydro-[1,2,4]triazine
carboxylic acid
Method B
Step a. 4-(4-Fluoro-phenyl)methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine
carboxylic acid. To a mixture of 2-methyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine
WO 74633
carboxylic acid ethyl ester (220 mg, 1.1 mmol) (Yuen, K. J Org. Chem. 1962, 27, 976) 4-
Fluorophenyl boronic acid (230 mg, 1.6 mmol) and triethylamine (0.46 mL, 3.3 mmol) in
ene chloride (5 mL, 80 mmol) was added copper acetate (150 mg, 1.2 mmol). The
mixture was stirred under argon at rt 18h. The solvent was removed and the product was
purified by flash chromatography (hexane: EtOAc 60:40) to yield 34 mg (10%). LCMS =
294 (M + 1).
Step b. 4-(4-Fluorophenyl)methyl-3 ,5-dioxo-2,3 ,4,5 -tetrahydro- [1 ,2,4]triazine
ylic acid. 4-(4-fiuorophenyl)methyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-
6-carboxylic acid ethyl ester (30 mg, 0.1 mmol) was dissolved in THF-MeOH (1 :1, 2 mL)
and 1M of lithium ide (0.102 mL, 0.102 mmol) was added. After stirring at rt
overnight, the solution was concentrated, dissolved in 1N N32C03 and washed with
EtOAc. The aqueous layer was filtered and made acidic with 5N HCl and extracted with
EtOAc. The combined organics were washed with water and brine, dried (MgSO4) and
ated to give a white solid (30 mg, 100%). LCMS m/z = 266 (M + 1); 1H NMR
(Methanol d4): 7.55-7.52 (m, 2H), 7.07-7.03 (m, 2H), 3.52 (s, 3H).
Example 103.
9G?\ /
NJYlLNH |
N\ARI/£0
4-(4-Fluoro-phenyl)isopropyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)fiuoro-phenyl]-amide. A mixture of 4-(4-
fiuorophenyl)isopropyl-3 ,5-dioxo-2,3 ,4,5 -tetrahydro- 1 ,2,4-triazinecarboxylic acid
(500 mg, 2 mmol), 4-(6,7-dimethoxyquinolinyloxy)fluorophenylamine (535 mg,
1.70 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazolyl)uronium
hexafiuorophosphate (639 mg, 1.68 mmol) and N,N—diisopropylethylamine (279 uL, 1.60
mmol) in N,N—dimethylformamide (8 mL) was stirred at rt for 3h. The solvent was
removed and the e dissolved in EtOAc and washed with saturated NaHC03 on
water and brine. After drying over magnesium sulfate, solvent was evaporated and the
product was purified by ISCO silica gel chromatography (hexane: EtOAc 1:4) to give 835
mg (83%), which triturated with ether and dried. mp =225-226 C’C; LCMS m/z = 590 (M
+ 1); 1H NMR DMSO) 5: 10.87 (s, 1H), 8.49 (d, 1H, J = 5.2 Hz), 7.97 (dd, 1H, J = 12.6,
2.2 Hz), 7.59-7.36 (m, 8H), 6.50 (d, 1H, J = 4.9 Hz), 4.90 (m, 1H), 3.95 (s, 6H), 3.32 (s,
3H), 1.38 (d, 6H, J = 6.6 Hz).
The following examples were synthesized using the procedure for Example 103.
Example 104.
/o N\
\OI I /]
OQ”M10FO 0
N"? O
4-(4-Fluorophenyl)methyl-3 ,5-dioxo-2,3 ,4,5 hydro-[1,2,4]triazinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]—amide TFA salt. The product
was purified by reverse phase HPLC (Gilson) and the fractions showing product were
concentrated as the TFA salt to give an off-white solid. LCMS m/z = 562 (M + 1); 1H
NMR (DMSO) 5: 10.98 (s, 1H), 8.74 (d, 1H, J = 6.1 Hz), 8.02 (dd, 1H, J = 12.7, 2.3 Hz),
7.70 (s, 1H), 7.67-7.56 (2m, 2H), 7.52 (s, 1H), .37 (m, 4H), 6.88 (d, 1H, J = 5.5 Hz),
4.02 (s, 3H), 4.01 (s, 3H), 3.69 (s, 3H).
Example 105.
/o N\
I I /]
OQ”JJYILNOFO O
N‘N/ko
2-Ethyl(4-fluoro-phenyl)-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro-[1,2,4]triazinecarboxylic acid
[4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]-amide TFA salt. ite solid,
LCMS m/z = 576 (M + 1); 1H NMR (DMSO) 5: 10.99 (s, 1H), 8.78(d, 1H, J = 6.2 Hz),
8.03 (dd, 1H, J = 12.7, 2.3 Hz), 7.72 (s, 1H), 7.67-7.58 (m, 2H), 7.54 (s, 1H), 7.45-7.32 (2
m, 4H), 6.93 (d, 1H, J = 6.1 Hz), 4.08 (q, 2H, J = 7.1 Hz), 4.03 (s, 3H), 4.02 (s, 3H), 1.35
(t, 3H, J = 7.1 Hz).
Example 106.
(21>? .
QMEJF
‘AN 0
4-(4-Fluorophenyl)isopropyl-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro-[1,2,4]triazinecarboxylic
acid [4-(2,3-dihydro-[1,4]dioxino[2,3-g]quinolinyloxy)fluorophenyl]-amide TFA
salt. This compound was sized from 4-(2,3-dihydro[1,4]dioxino[2,3-g]quinolin
yloxy)fluorophenylamine; hydrochloride (synthesized using the ure for example
111 step a; LCMS m/z = 313 (M + 1); 1H NMR (DMSO) 5: 8.85 (d, 1H, J = 6.5 Hz), 7.87
(s, 1H), 7.76 (s, 1H), 7.26 (t, 1H, J = 8.9 Hz), 6.88 (dd, 1H, J = 6.6, 0.8 Hz), 6.78 (dd, 1H,
J = 8.6, 1.9 Hz), 6.67 (br d, 1H, J = 8.6 Hz), 4.52 (m, 4H)) and 4-(4-fluorophenyl)
isopropyl-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro- 1 ,2,4-triazinecarboxylic acid using the
procedure for example 103 to give an off-white solid, LCMS m/z = 588 (M + 1); 1H NMR
(DMSO) 5: 10.94 (s, 1H), 8.74 (d, 1H, J = 6.0 Hz), 8.02 (dd, 1H, J = 12.6, 2.3 Hz), 7.80 (s,
1H), 7.63-7.53 (2m & s, 3H), 7.54 (s, 1H), 7.45-7.36 (m, 4H), 6.81 (d, 1H, J = 5.9 Hz),
4.90 (q, 1H, J = 6.6 Hz), 4.48 (m, 4H), 1.38 (d, 6H, J = 6.6 Hz).
Example 107.
/m\ /
NJJYlLNH |
N\N’ko
H
4-(4-Fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid [4-(6,7-
dimethoxy-quinolinyloxy)fluoro-phenyl]-amide TFA salt. Off-White solid, LCMS
m/z = 548 (M + 1); 1H NMR DMSO) 5: 13.30 (s, 1H), 10.97 (s, 1H), 8.71(d, 1H, J = 6.0
Hz), 8.02 (dd, 1H, J = 12.7, 2.3 Hz), 7.68 (s, 1H), 7.65 (m, 1H), 7.65 , 7.56 (m,
1H), 7.5 (s, 1H), 7.46-7.31 (2 m, 4H), 6.83 (d, 1H, J = 6.3 Hz),4.01 (s, 6H).
Example 108.
a” o oN/Q/F
N.NA
4-(4-Fluorophcnyl)(2-hydroxycthyl)-3 ,5-dioxo-2,3 ,4,5 -tctrahydro- [1 ,2,4]triazinc
carboxylic acid 7-dimcthoxyquinolinyloxy)—3-fluorophcnyl]—arnidc. TFA salt
Off-white solid; LCMS m/z = 592 (M + 1); 1H NMR DMSO) 5: 10.96 (s, 1H), 8.75 (d,
1H, J = 6.2 Hz), 8.02 (dd 1H, J = 12.6, 2.4 Hz), 7.70 (s, 1H), 7.66-7.57 (m, 2H), 7.51 (s,
1H), .39 (m and s, 4H), 6.89 (d, 1H, J = 5.4 Hz), 4.11 (m, 2H), 4.02 (2s, 6H), 3.77
(m, 2H).
Example 109.
V0 N\
0 O 0
“MNH |
2-Ethyl(4-fluorophcnyl)-3 ,5-dioxo-2,3 ,4,5 -tctrahydro [1 ,2,4]triazinccarboxylic acid
[4-(6,7-dicthoxy-quinolinyloxy)—3-fluoro-phcnyl]—arnidc. TFA salt Off-White solid;
LCMS m/z = 604 (M + 1); 1H NMR (DMSO) 5: 10.98 (s, 1H), 8.74 (d, 1H, J = 6.2 Hz),
8.03 (dd 1H, J = 12.6, 2.2 Hz), 7.69 (s, 1H), 7.66-7.54 (m, 2H), 7.51 (s, 1H), 7.46-7.34 (m,
4H), 6.89 (d, 1H, J = 5.0 Hz), 4.29 (m, 4H), 4.09 (q, 2H, J = 7.1 Hz) 1.45 (overlapping
triplets, 6H), 1.35 (t, 3H, J = 7.1 Hz).
Example 110.
/o N\
NHJKNIHLN
4-(4-Fluoro-phcnyl)isopropyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinccarboxylic
acid [5-(6,7-dimcthoxy-quinolinyloxy)-pyridinyl]-arnidc di-TFA salt. Off-White
solid, LCMS m/z = 573 (M + 1); 1H NMR DMSO) 5: 11.29 (s, 1H), 8.75 (d, 1 H, J = 6.2
Hz), 8.50 (d, 1H, J = 2.8 Hz), 8.42 (m, 1H), 7.99 (dd, 1H, J = 9, 2.9 Hz), 7.70 (s, 1H), 7.51
-104—
(s, 1H), .37 (m, 4H), 6.93 (d, 1H, J = 6.1 Hz), 4.91 (m, 1H), 4.02 (s, 3H), 4.01 (s,
3H), 1.38 (d, J = 6.6 Hz).
Example 111.
Qfififlg
3-Fluoro(7-methoxy-quinolinyloxy)-phenylamine; hydrochloride.
Step a. A e of 4-chloromethoxyquinoline (1.0 g mg, 5 mmol), ro
hydroxyphenyl)-carbamic acid t-butyl ester (1.88 mg, 8.26 mmol) and 4-
dimethylaminopyridine (1010 mg, 8.26 mmol) in N,N—dimethylformamide (25 mL) was
stirred at 145 0C for 5h. The mixture was cooled to rt, the solvent was removed and the
residue was taken in DCM and washed with water and brine. After drying, the solvent was
evaporated. The crude product was purified by flash chromatography (hexanes:EtOAc 1:1)
to give a white solid; LCMS = 385 (M + 1).
Step b. The intermediate from step-a was treated with 4M HCl in dioxane (4 mL, 50
mmol) and the mixture was stirred at rt overnight. The solvent was removed and the
mixture was triturated with ether and dried to 368 mg (20%, two steps) of o(7-
methoxy-quinolinyloxy)-phenylamine; hydrochloride. LCMS m/z = 285 (M + 1); 1H
NMR (DMSO) 5: 8.98 (d, 1H, J = 6.6 Hz), 8.50 (d, 1H, J = 9.3 Hz), 7.78 (d, 1H, J = 2.4
Hz), 7.42 (t, 1H), 7.61 (m, 1H), 7.04-6.84 (m, 4H), 4.03 (s, 3H), 3.72 (s, 3H).
Step c. 4-(4-Fluorophenyl)isopropyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazine
carboxylic acid [3-fluoro(7-methoxyquinolinyloxy)-phenyl]-amide TFA salt. This
compound was synthesized from 3-fluoro(7-methoxy-quinolinyloxy)-phenylamine
hydrochloride and 4-(4-fluorophenyl)isopropyl-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-
necarboxylic acid using the procedure for example 103 to give a white solid,
LCMS m/z = 560 (M + 1); 1H NMR (DMSO) 5: 10.98 (s, 1H), 8.88 (d, 1H, J = 6.1 Hz),
8.43 (d, 1H, J = 9.8 Hz), 8.04 (dd, 1H, J = 12.6, 2.2 Hz), 7.63-7.34 (m, 8H), 6.88 (d, 1H, J
= 6.0 Hz), 4.90 (m, 1H), 1.38 (d, 6H, J = 6.6 Hz).
Example 112.
2012/065019
Ca F
O O
H I A
N\N O
4-(4-Fluorophenyl)-3 ,5 -dioxo(2-oxo-propyl)-2,3 ,4,5 -tetrahydro-[1,2,4]triazine
carboxylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]—amide. TFA salt off-
white solid, LCMS m/z = 604 (M + 1); 1H NMR (DMSO) 5: 11.04 (s, 1H), 8.78 (d, 1H, J
= 6.3 Hz), 8.02 (dd 1H, J = 11.5, 2.1 Hz), 7.73 (s, 1H), 7.62 (m, 2H), 7.55 (s, 1H), 7.39-
7.34 (m, 4H), 6.94 (d, 1H, J = 6.2 Hz), 4.02 (2s, 6H), 2.25 (s, 3H).
e 113.
/ohmN\
Cafilm/[LNGFO O
N\N O
4-(4-Fluoro-phenyl)-3 ,5-dioxopropynyl-2,3 ,4,5 -tetrahydro-[1,2,4] triazine
carboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]—amide TFA salt. A
mixture of example 107 (25 mg, 0.046 mmol), propargyl bromide (10 uL, 0.1 mmol), and
ium carbonate (10 mg, 0.07 mmol) in N,N—dimethylformamide (1 mL) was stirred at
rt 18h. The mixture was filtered, solvent was removed and the product was purified by
reverse phase HPLC to give an off-white solid (7 mg, 30%). LCMS m/z = 586 (M + 1); 1H
NMR (DMSO) 5: 10.99 (s, 1H), 8.71 (d, 1H, J = 6.1 Hz), 8.0 (dd, 1H, J = 2.3, 12.7 Hz),
7.68 (s, 1H), 7.65-7.58 (m, 2H), 7.4 (s, 1H), 7.37-7.35 (m, 4H), 6.84 (d, 1H, J = 5.8 Hz),
4.88 (d, 2H, J = 2.3 Hz), 4.01 (2s, 6H), 3.53 (s, 3H).
Example 114.
\ /
2-Methyl-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro-[1,2,4]triazinecarboxylic acid 7-
dimethoxy-quinolinyloxy)fluoro-phenyl]—amide. TFA salt. A mixture of 2-methyl-
3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazinecarboxylic acid (500 mg, 3 mmol) (Yuen, K.
J Org. Chem. 1962, 27, 976), 4-(6,7-dimethoxyquinolinyloxy)fluorophenylamine
(0.80 g, 2.54 mmol) and N,N,N',N'-tetramethyl-O-(7-azabenzotriazolyl)uronium
hexafluorophosphate (1.06 g, 2.80 mmol) and N,N—diisopropylethylamine (1.33 mL, 7.64
mmol) in N,N—dimethylformamide (8 mL) was stirred at rt 18h. The solvent was removed
and the residue was triturated with DCM collected and dried. Yield-quantitative, LCMS
m/z = 468 (M + 1); 1H NMR (DMSO) 5: 12.69 (br s, 1H), 11.01 (s, 1H), 8.77 (d, 1H, J =
6.2Hz), 8.01 (dd, 1H, J = 2.2, 11.4 Hz), 7.72 (s, 1H), 7.64-7.57 (m, 2H), 7.56 (s, 1H), 6.92
(d, 1H, J = 5.6Hz), 4.03 (2s, 6H), 3.58 (s, 3H).
Example 115.
0319\ /
o o f
NJIYtkNH
N‘nll’go|
2-Methyl-3,5-dioxopropynyl-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid [4-
(6,7-dimethoxy-uinolinyloxy)fluoro-phenyl]—amide. TFA salt A e of
example 114 (100 mg, 0.2 mmol), propargyl bromide (60 uL, 0.7 mmol), and ium
ate (44.4 mg, 0.321 mmol) in N,N—dimethylformamide (3 mL) was stirred at rt 18h.
The mixture was filtered and the solvent was removed. The product was purified by
reverse phase HPLC to give an off-white solid (36 mg, 30%). LCMS m/z = 506 (M + 1);
1H NMR (DMSO) 8: 10.98 (s, 1H), 8.79 (d, 1H, J = 6.2 Hz), 8.00 (dd, 1H, J = 2.3, 12.5
Hz), 7.72 (s, 1H), 7.66-7.58 (m, 2H), 7.53 (s, 1H), 6.92 (d, 1H, J = 6.1 Hz), 4.61 (d, 2H, J
= 2.4 Hz), 4.03 (2s, 6H), 3.65 (s, 3H), 3.29 (t, 1H, J = 2.4 Hz).
The following examples were synthesized from Example 114 using the procedure for
Example 115.
Example 116.
”m\ /
o /9
o o
yl(5-rncthyl-isoxazolylrncthyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinc-
6-carboxylic acid [4-(6,7-dimcthoxy-quinolinyloxy) fluoro-phcnyl]—arnidc. TFA salt.
Off-white solid; LCMS m/z = 563 (M + 1); 1H NMR (DMSO) 5: 10.99 (s, 1H), 8.76(d, J =
6.2 Hz, 1H), 8.0 (dd, 1H, J = 2.2, 12.6 Hz), 7.71 (s, 1H), 7.66-7.53 (m, 2H), 7.71 (s, 1H),
6.80 (d, 1H, J = 6.0 Hz), 6.27 (s, 1H), 5.05 (s, 2H), 4.02 (2xs, 6H), 3.66 (s, 3H), 2.38 (s,
3H).
e 117.
2-Mcthyl-3,5-dioxopcntynyl-2, 3,4,5-tctrahydro-[1,2,4]triazinccarboxylic acid [4-
(6,7-dirncthoxy-uinolinyloxy)fluoro-phcnyl]—arnidc. TFA salt. yellowish solid.
LCMS m/z = 534 (M + 1); 1H NMR (DMSO) 5: 10.98 (s, 1H), 8.75 (d, 1H, J = 6.2 Hz),
8.00 (dd, 1H, J = 2.3, 12.5 Hz), 7.71 (s, 1H), 7.66-7.57 (m, 2H), 7.53 (s, 1H), 6.89 (d, 1H,
J = 6.0 Hz), 4.56 (s, 2H), 4.02 (2s, 6H), 3.65 (s, 3H), 2.18 (m, 2H), 1.04 (t, 3H, J = 7.5
Hz).
Example 118.
\ /
O O
III 0
4-(4-Hydroxy-but—2-ynyl)—2-rncthyl-3 ,5 -dioxo-2,3 ,4,5 -tctrahydro-[1 ,2,4] triazinc
carboxylic acid [4-(6,7-dimcthoxy-quinolinyloxy)—3-fluoro-phcnyl]—arnidc. TFA salt
Off-white solid; LCMS m/z = 536 (M + 1); 1H NMR (DMSO) 5: 10.98 (s, 1H), 8.74 (d, J
= 6.1Hz, 1H), 7.99 (dd, 1H, J = 2.1, 12.7Hz), 7.70 (s, 1H), 7.65-7.54 (m, 2H), 7.51 (s, 1H),
6.87 (d, 1H, J = 5.9Hz), 4.65 (s, 2H), 4.07 (s, 2H), 4.02 (2xs, 6H), 3.65 (s, 2H).
Example 119.
WO 74633
4-(1 ,5 -Dimcthyl-1H-pyrazol-3 -ylmcthyl)—2-mcthyl-3 ,5 -dioxo-2,3 ,4,5 hydro-
[1,2,4]triazinccarboxylic acid [4-(6,7-dimcthoxyquinolinyloxy)—3-fluorophcnyl]—
amide. TFA salt Off-White solid; LCMS m/z = 576 (M + 1); 1H NMR (DMSO) 5: 11.00
(s, 1H), 8.81 (d, 1H, J = 6.3 Hz), 8.01 (d, 1H, 11.2 Hz), 7.74 (s, 1H), 7.65-7.59 (s, m, 3H),
6.96 (d, 1H, J = 5.9 Hz), 6.02 (s,1H), 5.01 (s, 2H), 4.04 (s, 6H), 3.84 (s, 3H), 3.65 (s, 3H),
2.07 (s, 3H).13.30 (s, 1H), 10.97 (s, 1H), 8.71(d, 1H, J = 6.0 Hz), 8.02 (dd, 1H, J = 12.7,
2.3 Hz), 7.68 (s, 1H), 7.65 (m, 1H), 7.65 (m,1H), 7.56 (m, 1H), 7.5 (s, 1H), 7.46-7.31 (2
m, 4H), 6.83 (d, 1H, J = 6.3 Hz),4.01 (s, 6H)
Example 120.
/I:Q\ /
o 0 IN/“3
NJJYtkNH
lel/koI
2-Mcthyl-3 ,5 -dioxo(2-pyrazolyl-cthyl)-2,3 ,4,5 -tctrahydro- [1 ,2,4] triazinc
carboxylic acid [4-(6,7-dimcthoxyquinolinyloxy)fluorophcnyl]—amidc. TFA salt Off-
Whitc solid. LCMS m/z = 562 (M + 1); 1H NMR (DMSO) 5: 10.98 (s, 1H), 8.77 (d, 1H, J
= 6.0 Hz), 8.01 (dd, 1H, J = 2.2, 12.6 Hz), 7.77 (d, 1H, J = 2.0 Hz), 7.72 (s, 2H), .57
(m, 2H), 7.55 (s, 1H), 7.42 (d, 1H, J = 1.4 Hz), 6.90 (d,1H, J = 6.0 Hz)), 6.22 (d, 1H, J
:19 Hz), 4.39 (m, 2H), 4.22 (m, 2H),4.03 (2s, 6H), 3.61 (s, 3H).
Example 121.
UCQ\ /
F /
//\N
N I
o o
NMNH )7“
N\ (ll/k0
2-Mcthyl(1-mcthyl-1H-[1,2,4]triazolylmcthyl)-3 ,5-dioxo-2,3 ,4,5-tetrahydro-
[1,2,4]triazinccarboxylic acid [4-(6,7-dimcthoxy-quinolinyloxy)fluoro-phcnyl]—
amidc TFA salt Off-White solid; LCMS m/z = 563 (M + 1); 1H NMR( DMSO) 5: 11.06
(s,1H), 8.78 (d, 1H, J = 6.3 Hz), 8.39 (s, 1H), 7.99 (dd, 1H, J = 2.3, 12.5 Hz), 7.93 (s, 1H),
7.68-7.58 (m, 2H), 7.73 (s, 1H), 6.93 (d, 1H, J = 6.2 Hz), 5.06 (s, 2H), 4.03 (s, 3H), 4.02
(s, 3H), 3.81 (s, 3H), 3.66 (s, 3H).
Example 122.
/I:Q\ /
o 0
NMNH j“
N‘lil’goI
orncthylrncthyl-3 ,5 -diox0-2, 3 ,4,5 -tctrahydro-[1 ,2,4]triazinccarb0xylic acid
[4-(6,7-dirncth0xy-quinolinyloxy)flu0r0-phcnyl]—arnidc. TFA salt; LCMS m/z = 507
(M + 1); 1H NMR (DMSO) 5: 10.95 (s, 1H), 8.76 (d, 1H, J = 6.2 Hz), 7.81 (dd, 1H, J =
2.2, 12.6 Hz), 7.72 (s, 1H), 7.68-7.58 (m, 2H), 7.56 (s, 1H), 4.92 (s, 2H), 4.03 (s, 3H), 4.02
(s, 3H), 3.66 (s, 3H).
Example 123.
UCQ\ /
O O J
NJKHLNH I
N\”1&0
4-Ethylrncthyl-3,5-di0X0-2,3,4,5-tetrahydr0-[1,2,4]triazinccarboxylic acid [4-(6,7-
dirncthoxyquinolinyloxy)fluor0-phcnyl]-arnidc TFA salt. LCMS m/z = 496 (M + 1);
1H NMR (DMSO) 5: 11.03 ((s, 1H), 8.78 (d, 1H, J = 6.2 Hz), 8.04 (dd, 1H, J = 2.2, 12.6
Hz), 7.72 (s, 1H), .58 (m, 2H), 7.55 (s, 1H), 6.92 (d, 1H, J = 6.2 Hz), 4.03 (s, 6H),
3.89 (q, 2H, J = 7.1 Hz), 3.64 (s, 3H), 1.18 (t, 3H, J = 7.1Hz).
Example 124.
0319\ /
o o f/
NJIYtkNH
WACI
4-Allylmcthyl-3,5-di0X0-2,3,4,5-tetrahydro-[1,2,4]triazinccarb0xylic acid [4-(6,7-
dimcthoxy-quinolinyloxy)flu0r0-phcnyl]—arnidc TFA salt. LCMS m/z = 508 (M +
1); 1H NMR DMSO) 5: 11.00 (s, 1H), 8.76 (d, 1H, J = 6.2 Hz), 8.02 (dd, 1H, J = 2.0, 12.6
-1 10-
Hz), 7.72 (s, 1H), 7.67-7.57 (m, 2H), 7.53 (s, 1H), 6.90 (d, 1H, J = 6.0 Hz), 5.84 (m, 1H),
.23 (ddd, 2H, J = 25.8, 7.2 and 1.4 Hz), 4.46 (d, 1H, J = 4.3 Hz), 4.03 (25, 6H), 3.65 (s,
3H).
Example 125.
03K}\ /
4-Cyclopropylmethylrnethyl-3 ,5-di0X0-2,3 ,4,5 -tetrahydro-[1 riazinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-phenyl]—arnide TFA salt. LCMS m/z =
522 (M + 1); 1H NMR (DMSO) 5: 11.01 (s, 1H), 8.74 (d, 1H, J = 6.1 Hz), 8.01 (m, 1H),
7.70(s, 1H), 7.65-7.59 (m, 2H), 7.53 (s, 1H), 6.87 (d, 1H, J = 6.0 Hz), 4.02 (25, 6H), 3.92
(m, 1H), 3.75 (d, 1H, J = 7.0 Hz), 3.64 (s, 3H), 2.36 (m, 2H), 1.18 (m, 1H), 0.49 (m, 1H),
0.38 (m, 1H).
Example 126.
/o N\
\ /
F O
o 0
“MNH |
N\N’kO
2-Methyl-3 ,5 -di0x0(tetrahydr0-pyranylrnethyl)-2,3 ,4,5 -tetrahydro-[1 ,2,4]triazine
carboxylic acid [4-(6,7-dirneth0xy-quinolinyloxy)- 0-phenyl]—amide TFA salt .
LCMS m/z = 566 (M + 1); 1H NMR (DMSO) 5: 10.99 (s, 1H), 8.75 (d, 1H, J = 6.1 Hz),
8.01 (dd, 1H, J = 12.6, 2.3 Hz), 7.71 (s, 1H), 7.65-7.57 (m, 2H), 7.52 (s, 1H), 6.88 (d, 1H,
J = 6.1 Hz), 4.02 (25, 6H), 3.84 (m, 2H), 3.76 (d, 2H, J = 7.0 Hz), 3.64 (s, 3H), 3.24 (m,
3H), 2.02 (m, 1H), 1.57 (m, 2H), 1.27 (m, 2H).
Example 127.
/o N\
\ /
O O f
NijNH |
N\TAO
4-Isobutylmcthyl-3,5-di0X0-2,3,4,5-tetrahydr0-[1,2,4]triazinccarboxylic acid [4-(6,7-
dimcthoxy-quinolinyloxy)flu0r0-phcnyl]—arnidc TFA salt. LCMS m/z = 524 (M +
1); 1H NMR (DMSO) 8: 11.02 (s, 1H), 8.76 (d, 1H, J = 6.2 Hz), 8.01 (dd, 1H, J = 2.3, 12.6
Hz), 7.71 (s, 1H), 7.66-7.57 (m, 2H), 7.53 (s, 1H), 6.90 (d, 1H, J = 5.9 Hz), 4.03 (25, 6H),
3.70 (d, 2H, J = 7.3 Hz), 3.64 (s, 3H), 2.07 (m, 1H), 0.90 (d, 6H, J = 6.7 Hz).
Example 128.
/o N\
\ /
4-Cyclobutylrncthylrncthyl-3 ,5 -di0X0-2,3 ,4,5 -tctrahydr0- [1 ,2,4]triazinccarb0xylic
acid 7-dirncth0xy-quinolinyloxy)flu0r0-phcnyl]—arnidc. TFA salt. LCMS m/z =
536 (M + 1); 1H NMR (DMSO) 5: 11.02 (s, 1H), 8.79 (d, 1H, J = 6.3 Hz), 8.01 (dd, 1H, J
= 2.2, 12.4 Hz), 7.74 (s, 1H), 7.69-7.58 (m, 2H), 7.55 (s, 1H), 6.95 (d, 1H, J = 6.2 Hz),
4.03 (s, 6H), 3.92 (d, 2H, J = 7.0 Hz), 3.63 (s, 3H), 2.66 (m, 1H), 1.99 (m, 2H), 1.81 (m,
4H).
Example 129.
0319\ /
o o f
NMNH |
4-(2,2-Dirncthylpropyl)rncthyl-3 , 5 -di0X0-2,3 ,4,5 -tctrahydro-[1 ,2,4]triazinc
ylic acid [4-(6,7-dimcthoxyquinolinyloxy)—3-flu0r0phcnyl]—arnidc TFA salt.
LCMS m/z = 538 (M + 1); 1H NMR (DMSO) 5: 11.0 (s, 1H), 8.72 (d, 1H, J = 6.0 Hz),
7.99 (dd, 1H, J = 2.2, 12.5 Hz), 7.69 (s, 1H), 7.63-7.55 (m, 2H), 7.50 (s, 1H), 6.83 (d, 1H,
J = 5.8 Hz), 4.01 (25, 6H), 3.63 (s, 3H), 0.94 (s, 9H).
Example 130.
”Di:\ /
0 O 3)
“MNH I
N\ "1&0
::2-Methyl(2-methyl-butyl)-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro-[1,2,4]triazinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]-amide TFA salt. LCMS m/z =
538 (M + 1); 1H NMR (DMSO) 5: 11.01 (s, 1H), 8.76 (d, 1H, J = 6.2 Hz), 8.01 (dd, 1H, J
= 2.2, 12.6 Hz), 7.71 (s, 1H), 7.66-7.57 (m, 2H), 7.53 (s, 1H), 6.89 (d, 1H, J = 6.1 Hz),
4.03 (2s, 6H), 3.76 (m, 2H), 3.64 (s, 3H), 1.87 (m, 1H), 1.40 (m, 1H), 1.17 (m, 1H), 0.87
(m, 6H).
Example 131.
o N\
Ca:”MNOFO O
N‘N’go
3 -(4-Fluoro-phenyl)methyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidine-5 xylic acid
[4-([1,3]dioxolo[4,5-g]quinolinyloxy)fluoro-phenyl]-amide, TFA salt. This
compound was synthesized from uorophenyl)methyl-2,4-dioxo-1,2,3,4-
tetrahydro-pyrimidinecarboxylic acid and -dioxolo[4,5-g]quinolinyloxy)
fluoro-phenylamine hydrochloride (LCMS m/z = 299 (M + 1); 1H NMR (DMSO) 5: 8.80
(d, 1H, J = 6.6 Hz), 7.85 (s, 1H), 7.74 (s, 1H), 7.31 (t, 1H, J = 8.9 Hz), 6.94 (dd, 1H, J =
6.6, 0.8 Hz), 6.87 (dd, 1H, J = 12.6, 2.2 Hz), 6.76 (d, 1H, J = 12.6, 2.1 Hz), 6.43 (s, 2H);
synthesized using the procedure for example 111 steps a-b)) using the procedure for
examples 103. LCMS m/z = 545 (M + 1); 1H NMR (DMSO) 5: 11.08 (s, 1H), 8.89 (s, 1H),
8.69 (d, 1H, J = 6.0 Hz), 8.43 (d, 1H, J = 9.8 Hz), 8.05 (dd, 1H, J = 12.8, 2.4 Hz), 7.76 (s,
1H), 7.68-7.52 (2 m and a s, 3H), 7.48-7.31 (m, 4H), 6.84 (d, 1H, J = 5.9 Hz), 6.36 (s, 2H),
3.54 (s, 3H).
Example 132.
cm“; .
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(2,3-dihydro-[1, 4]dioxino[2,3-g]quinolinyloxy)fluoro-phenyl]-amide TFA salt. This
compound was synthesized from 1-ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-
tetrahydropyrimidinecarboxylic acid and 4-(2,3-dihydro-[1,4]dioxino[2,3-g]quinolin
fluorophenylamine using the procedure for examples 103. LCMS m/z = 545 (M
+ 1); 1H NMR (DMSO) 5: 11.09 (s, 1H), 8.89 (s, 1H), 8.78 (d, 1H, J = 6.2 Hz), 8.43 (d,
1H, J = 9.8 Hz), 8.07 (dd, 1H, J = 12.8, 2.2 Hz), 7.83 (s, 1H), 7.62-7.50 (2 m and a s, 3H),
7.44-7.32 (2m, 4H), 6.85 (d, 1H, J = 6.1 Hz), 4.49 (m, 4H), 4.02 (q, 2H, J = 7.0 Hz), 1.30
(t, 3H, J = 7.0 Hz).
Example 133.
/I>Q\ /
0 00
NHJJYlLN
2-Cyclopropylmethyl(4-fluorophenyl)-3 xo-2,3 ,4,5 -tetrahydro-[1 ,2,4]triazine
carboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)fluoro-phenyl]-amide TFA salt.
This compound was synthesized from 1-cyclopropylmethyl(4-fluorophenyl)-2,4-dioxo-
1,2,3,4-tetrahydropyrimidinecarboxylic acid and 4-(6,7-dimethoxyquinolinyloxy)
fluorophenylamine using the procedure for example 103. LCMS m/z = 602 (M + 1); 1H
NMR (DMSO) 5: 10.98 (s, 1H), 8.72 (d, 1H, J = 5.9 Hz), 8.02 (dd 1H, J = 12.6, 2.2 Hz),
7.69 (s, 1H), 7.66-7.56 (m, 2H), 7.50 (s, 1H), .36 (m and s, 4H), 7.27 (m, 1H), 6.85
(d, 1H, J = 5.1 Hz), 5.12 (m, 1H), 4.02 (m and 2s, 7H), 2.49 (m, 1 H), 2.32 (m, 2H), 1.80
(m, 2H).
Example 134.
HNCZ F
O O
Step a. 4-Chloro-6,7-dimethoxyquinoline (0.40 g, 1.79 mmol, p-nitroaniline (0.414 g, 2.68
mmol) and p-toluenesulfonic acid (0.154 g, 0.894 mmol) in 1-methoxypropanol (5 mL)
were heated to 120 0C for 8h. The mixture was cooled to rt, triturated with ether and
filtered to yield (6,7-dimethoxyquinolinyl)-(4-nitrophenyl)amine (0.43 g, 73%). LCMS
m/z = 326 (M + 1); 1H NMR (DMSO) 5: 14.37 (s, 1H), 10.72 (s,1H), 8.54 (d, 1H, J = 6.80
Hz), 8.39 (d, 2H, J = 9.08 Hz), 8.05 (s, 1H), 7.74 (d, 2H, J =9.09 Hz), 7.47 (d, 1H, 8.13
-114—
2012/065019
Hz), 7.43 (s, 1H), 7.19 (d, 1H, J = 6.85), 7.10 (d, 1H, J = 7.84),4.02 (d, 7H, J = 5.48), 2.28,
(s, 1H).
Step b. N-(6,7-Dimethoxyquinolinyl)-benzene-1,4-diamine. imethoxyquinolin
yl)-(4-nitrophenyl)amine (0.425 g, 1.31 mmol), palladium hydroxide 4 g, 0.601
mmol) and potassium carbonate (0.542 g, 3.92 mmol) in ol (106 mL) were
hydrogenation on a Parr apparatus at 40 psi overnight. The mixture was filtered through
Celite and concentrated to yield a crude product which was purified by prep. HPLC to
yield N—(6,7-dimethoxyquinolinyl)-benzene-1,4-diamine (0.13 g, 33%). LCMS m/z =
296 (M + 1).
Step c. 1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinylamino)-phenyl]-amide 1 -Ethyl(4-fluorophenyl)-
2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid (0.104 g, 0.372 mmol), and
N,N,N',N'-tetramethyl-O-(7-azabenzotriazolyl)uranium hexafluorophosphate (0.154 g,
0.406 mmol) in N,N—dimethylformamide (5 mL) was added N,N—diisopropylethylamine
(0.425 mL, 2.44 mmol). After 15 min N—(6,7-dimethoxyquinolinyl)-benzene-1,4-
diamine (0.10 g, 0.34 mmol) was added and stirred at rt for18 h. The reaction mixture was
evaporated under vacuum, quenched with saturated NaHC03 solution and extracted with
CHzClz. The combined organics were washed with brine, dried (Na2S04), filtered and
concentrated to obtain a crude product which was purified by prep. HPLC to give a brown
solid (0.58 g, 31%). mp = 178-181 0C (CHCl2, MeOH, ether and hexane); LCMS m/z =
556 (M + H); 1H NMR (DMSO-d6) 5: 10.85 (s, 1H), 8.85 (s, 1H), 8.65 (s, 1H), 8.25 (d,
1H, J = 6.3Hz), 7.70 (d, 2H, J = , 7.65 (s, 2H), 7.45-7.29 (m, 7H),7.23 (s, 1H), 6.74
(d, 1H, J = 5.3Hz), 4.01 (d, 2H, J = 7.1Hz), 3.91 (d, 7H, J = 10.6), 1.30 (t, 3H, J = 7.1).
Example 135.
HNOMOF0 O
3 -(4-Fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 xylic acid
[4-(6,7-dimethoxyquinolinylamino)-phenyl]-amide. This compound was synthesized
using N—(6,7-dimethoxyquinolinyl)-benzene-1,4-diamine and 3-(4-fluorophenyl)
isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine- 5-carboxylic acid the method for
WO 74633
example 134. mp = 190-193 0C; LCMS m/z = 570 (M + 1); 1H NMR (DMSO- d6) 5: 10.85
(s, 1H), 8.65 (brs, 2H), 8.26 (d, 1H, J = 5.3 Hz), 7.71 (d, 2H, J = 8.8 Hz), 7.65 (s, 1H),
7.27-7.47 (m, 7H), 7.23 (s, 1H), 6.75 (d, 1H, J = 5.3 Hz), 4.72-4.84 (m, 1H), 3.92 (s, 3H),
3.90 ( s, 3H), 1.42 (d, 7H, J = 6.8 Hz).
Example 136.
Q F
0 O
4-(4-Fluoro-phenyl)isopropyl-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic
acid [4-(6,7-dimethoxy-quinolinylamino)-phenyl]-amide. This compound was
synthesized using N—(6,7-dimethoxyquinolinyl)-benzene-1,4-diamine and 4-(4-
fluorophenyl)isopropyl-3 ,5-dioxo-2,3 ,4,5-tetrahydro[1,2,4]triazinecarboxylic acid by
the method for example 134. mp = 152-155 0C; LCMS m/z = 571 (M + 1); 1H NMR
(DMSO- d6) 5: 8.67 (s, 1H), 7.68 (d, 2H, J = 8.87 Hz), 7.54 (d, 2H, J = 8.68 Hz), 7.20-7.34
(m, 12H), 7.10 (brs, 1H), 6.99 (s,1H), 6.60 (d, 2H, J = 8.6 Hz), 4.04 (d, 7H, J = 2.2 Hz),
3.79 (brs, 2H), 1.21 (t, 1H, J = 7.0 Hz), .91 (m, 1H).
Example 137.
Step a. 4-[(6,7-dimethoxyquinolyl)sulfanyl]aniline. 4-Chloro-6,7-dimethoxyquinoline
(0.40 g, 1.79 mmol) and othiophenol (0.379 g,2.68 mmol) in N,N—
dimethylformamide (5 mL) was d at rt for 8 h. The product was extracted with
calcium carbonate, washed with brine, dried with sodium sulfate, filtered and
concentrated. The crude product was dissolved in CHzClz and was recrystallized with
ether and hexanes, and was filtered to yield 4-[(6,7-dimethoxyquinolyl)sulfanyl]aniline
(0.49 g, 88%) as a yellow solid. mp = 235-238 0C LCMS m/z = 313 (M + 1); 1H NMR
(CDC13)52 8 8.58 (d, 1H, J = 6.41Hz), 7.51 (s, 1H), 7.46 (s, 1H), 7.31 (d, 2H, J = 8.7 Hz),
6.81(d, 1H, J = 6.1Hz), 6.77 (d, 2H, J = 8.6Hz), 4.03 (d, 7H, J = 5.6 Hz).
/0 N\
\ /
2012/065019
Step b. 1-Ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinylsulfanyl)-phenyl]-amide. l(4-
fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid and 4-(6,7-
dimethoxyquinolinylsulfanyl)phenylamine were coupled using the procedure for
example 134 to produce 1-ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-
pyrimidinecarboxylic acid [4-(6,7-dimethoxy-quinolinylsulfanyl)-phenyl]-amide as a
white solid, mp = 241-244 0C; LCMS m/z = 573 (M + 1); 1H NMR (DMSO-dg) 5:11.04 (s,
1H), 8.88 (s, 1H), 8.43 (d, 1H, J = 4.8 Hz), 7.84 (d, 2H, J = 8.72 Hz), 7.58 (d, 2H, J = 8.7
Hz),7.30-7.44 (m, 6H), 6.64 (d, 1H, J = 4.9 Hz), 4.01 (q, 2H, J = 7.05 Hz), 3.96 (q, 7H, J =
6.4 Hz), 1.29 (t, 3H, J = 7.1 Hz).
Example 138.
SQ F
o o
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxy-quinolinylsulfanyl)-phenyl]-amide. This compound was
sized using the procedure for example 134 to give a light tan solid. mp = 236-239
0C; LCMS m/z = 587 (M + 1); 1H NMR (DMSO- d6) 5: 11.04 (s, 1H), 8.67 (s, 1H), 8.44
(d, 1H, J = 4.8 Hz), 7.84 (d, 2H, J = 8.78 Hz), 7.58 (d, 2H, J = 8.7 Hz), 7.30-7.47 (m, 7H),
6.71 (d, 2H, J = 4.9 Hz), .81 (m, 1H), 3.92 (d, 7H, J = 7.1 Hz), 1.42 (d, 7H, J = 6.8).
Example 139.
”QMOFo o
Step a. 4-Chloro-6,7-dimethoxyquinoline (0.50 g, 2.24 mmol), N-methyl(4-
nitrophenyl)amine; (0.564 g, 3.35 mmol) and p-toluenesulfonic acid (0.192 g, 1.12 mmol)
in 1-methoxypropanol (6.56 mL, 67.1 mmol) were heated tol20 0C for 8h. The
reaction was cooled to rt, triturated with ether and filtered to yield (6,7-
dimethoxyquinolinyl)methyl(4-nitrophenyl)amine (0.40 g, 40%). LCMS m/z = 340 (M
WO 74633
+ 1); 1H NMR (CDCl3) 5: 8.80 (d, 1H, J = 4.8 Hz), 8.10 (d, 2H, J = 9.4 Hz),7.5 (brs, 1H),
7.16 (d, 1H, J = 4.8), 6.84 (s, 1H), 6.64 (d, 2H, J = 9.4 Hz), 4.05 (s, 3H), 3.81 (s, 3H), 3.52
(s, 3H).
Step b. (6,7-Dimethoxyquinolinyl)-methyl-(4-nitrophenyl)amine (0.30 g, 0.88 mmol),
potassium carbonate (1.3 g, 9.4 mmol) and ium hydroxide (1.00 g, 7.12 mmol) was
hydrogenated in a e of l (32 mL, 540 mmol), N,N-dimethylformamide (5 mL,
60 mmol) and methylene chloride (19 mL, 290 mmol) at 40 psi overnight. The mixture
was filtered through Celite, and washed with calcium carbonate solution and brine then
dried over sodium sulfate and concentrated to yield a crude product. This material was
purified by prep. HPLC to yield [N-(6,7-Dimethoxy-quinolinyl)-N-methyl-benzene-
1,4-diamine (0.180 g, 66%). LCMS m/z = 310 (M + 1).
Step c. 3 -(4-Fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 rahydropyrimidine-5 -
carboxylic acid {4-[(6,7-dimethoxy-quinolinyl)-methyl-amino]-phenyl}-amide. This
compound was synthesized using 3-(4-fluorophenyl)isopropyl-2,4-dioxo-1,2,3,4-
tetrahydro-pyrimidinecarboxylic acid and N—(6,7-dimethoxyquinolinyl)-N-methyl-
benzene-1,4-diamine by the method described for example 134. mp = 224-227 0C; LCMS
m/z = 584 (M + 1); 1HNMR(CDC13) 5: 10.66 (s, 1H), 8.65 (s, 1H), 8.64 (d, 1H, J = 5.0
Hz), 7.51 (d, 2H, J = 9.0 Hz), 7.38 (s, 1H), 7.00 (d, 1H, J = 5.8 Hz), 6.90 (s, 1H), 6.86 (d,
2H, J = 9.0 Hz), 4.90-5.00 (m, 1H), 4.00 (t, 3H), 3.63 (t, 3H), 3.44 (t, 3H).
Example 140.
/o N\
\ /
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid {4-
[(6,7-dimethoxy-quinolinyl)-methylamino]-phenyl}-amide. This compound was
synthesized using 1-ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3 ,4-tetrahydropyrimidine
carboxylic acid and N—(6,7-dimethoxyquinolinyl)-N-methyl-benzene-1,4-diamine by
the method described for example 134. mp = 199-202 0C; LCMS m/z = 570 (M + 1); 1H
NMR(CDC13)5: 10.62 (s, 1H), 8.64 (d, 1H, J = 5.0 Hz), 8.60 (s, 1H), 7.50 (d, 2H, J = 9.0
Hz), 7.38 (s, 1H), 7.31 (s, 1H), 7.00 (d, 1H, J = 5.3 Hz), 6.90 (s, 1H), 6.86 (d, 2H J = 8.9
Hz), 4.01 (s, 1H), 4.00 (s, 3H), 3.63 (s, 3H), 3.44 (s, 3H).
Example 141.
0QV10Fo o
Step a. 4-(6,7-Dimethoxy-quinazolinyloxy)-phenylamine. 4-Chloro-6,7-dimethoxy-
quinazoline (0.500 g, 2.22 mmol), 4-aminophenol (0.291 g, 2.67 mmol), 2-butanone (4.01
mL, 44.5 mmol), 2N sodium hydroxide solution (1.00 mL, 0.213 mmol), and tetra-N-
butylammonium bromide (0.308 g, 0.957 mmol) were combined and heated to reflux (80
0C) for 15 min. The reaction was cooled to rt. DCM was added and washed with calcium
carbonate solution and brine, then dried over sodium sulfate and concentrated to yield a
crude product. The solid was ated with diethyl ether and hexanes to yield 4-(6,7-
dimethoxyquinazolinyloxy)-phenylamine (0.52 g, 78%). LCMS m/z = 298 (M + 1).
Step b. 3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
carboxylic acid [4-(6,7-dimethoxy-quinazolinyloxy)-phenyl]-amide. This compound
was synthesized using -dimethoxyquinazolinyloxy)-phenylamine and 3-(4-
fluorophenyl)isopropyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid by
the procedure for e 134. mp = 1 0C; LCMS m/z = 572 (M + 1); 1H NMR
(CDC13)83 10.86 (s, 1H), 8.70 (s, 1H), 8.62 (s, 1H), 7.76 (d, 2H, J = 9.0 Hz), 7.54 (s, 1H),
7.32 (s, 1H), 4.90-5.03 (m, 1H), 4.06 (t, 7H, J = 20 Hz).
Example 142.
0Q F
o o
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidine-5 xylic acid [4-
(6,7-dimethoxy-quinazolinyloxy)-phenyl]-amide. This compound was synthesized
using 1-ethyl(4-fluorophenyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic
acid and 4-(6,7-dimethoxy-quinazolinyloxy)-phenylamine by the procedure for
example 134. mp = 1 0C; LCMS m/z = 558 (M+H); 1H NMR (CDCl3): 5 10.82 (s,
1H), 8.63 (d, 2H J = 6.5 Hz), 7.76 (d, 2H, J = 9.0 Hz), 7.55 (s, 1H), 7.32 (s, 1H), 7.23 (d,
2H, J = 8.9 Hz), 4.07 (s, 7H), 4.03 (q, 3H, J = 7.2 Hz), 1.59 (s, 1H), 1.49 (s, 1H), 1.46 (t,
3H, 7.2 Hz), 1.20 (t, 1H, J = 7.0 Hz), 1.03 (t, 1H, J = 7.3 Hz).
Example 143.
/o N\
\ /
Q 0 00N
MeO Hkfii
NK 0
Step a. A solution of 4-chloro-6,7-dimethoxyquinoline (0.4 g, 2 mmol) , 3-methoxy
henol (0.30 g, 1.8 mmol) and 4-dimethylaminopyridine (0.011 g, 0.089 mmol) in
chlorobenzene (5 mL) was stirred at 140 OC overnight. After cooling to rt the solid that
formed was filtered and dried to yield pure product 0.48 g (75%), MS: 357 (M+H).
Step b. 6,7-Dimethoxy(3-methoxynitrophenoxy)quinoline was hydrogenated in
EtOH/DMF using 10% Pd/C at 40 psi to yield 4-(6,7-dimethoxyquinolinyloxy)
methoxy-phenylamine. LCMS m/z = 327 (M + 1); 1H NMR (DMSO) 5: 8.43 (d, 1H, J = 6
Hz), 7.5 (s, 1H), 7.37 (s, 1H), 6.76 (d, 1H, J = 2.6 Hz), 6.72 (d, 1H, J = 9 Hz), 6.60 (dd,
1H, J = 2.5, 8.5 Hz), 6.41 (d, 1H, J = 5.6 Hz), 3.75 (s, 3H), 3.31 (s, 6H).
1-Ethyl(4-fluorophenyl)-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)methoxyphenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxyquinolinyloxy)methoxy-phenylamine and 1-
ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using
the procedure for e 1. LCMS m/z = 587 (M + 1); 1H NMR(CDC13) 5: 11 (s, 1H),
8.63 (s, 1H), 8.54 (d, 1H, J = 9 Hz), 8.49 (d, 1H, J = 5 Hz), 7.55 (s, 1H), 7.42 (s, 1H),
7.26-7.23 (m, 3H), 6.82 (dd, 1H, J = 3, 9 Hz), 6.74 (d, 1H, J = 3 Hz), 6.52 (d, 1H, J = 6
Hz), 4.05 (d, 6H), 4.01 (q, 2H, J = 8 Hz), 3.85 (s, 3H), 1.45 (t, 3H, J = 8 Hz).
Example 144.
/o N\
\ /
Q 0 00N
MeO Hwi
)1 o
WO 74633
1-Methyl(4-fluoro-phenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic acid
[4-(6,7-dimethoxy-quinolinyloxy)methoxy-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxyquinolinyloxy)methoxy-phenylamine and 3-(4-
fluorophenyl)methyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid using
the procedure for example 1. LCMS m/z = 573 (M + 1); 1H NMR(CDC13) 5: 11 (s, 1H),
8.61 (s, 1H), 8.54 (d, 1H, J = 9 Hz), 8.49 (d, 1H, J = 5 Hz), 7.55 (s, 1H), 7.42 (s, 1H),
7.26-7.23 (m, 4H), 6.81 (dd, 1H, J = 3, 9 Hz), 6.74 (d, 1H, J = 3 Hz), 6.5 (d, 1H, J = 5 Hz),
4.05 (s, 6H), 3.84 (s, 3H), 3.61 (s, 3H).
Example 145.
/O N\
\ /
Q 0 00F
1-Isopropyl(4-fluoro-phenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)methoxy-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxyquinolinyloxy)methoxy-phenylamine and 3-(4-
fluorophenyl)isopropyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid using
the procedure for example 1. LCMS m/z = 601 (M + 1); 1H NMR(CDC13) 5: 11.0 (s, 1H),
8.68 (s, 1H), 8.54 (d, 1H J = 9 Hz), 8.5 (d, 1H, J = 6 Hz), 7.55 (s, 1H), 7.42 (s, 1H), 7.25-
7.23 (m, 3H), 6.81 (dd, 1H, J = 3.9 Hz), 6.74 (d, 1H, J = 3 Hz), 6.52 (d, 1H, J = 6 Hz),
4.96 (p, 1H, J = 7 Hz), 4.05 (d, 6H), 3.83 (s, 3H), 1.47 (d, 6H, J = 6 Hz).
Example 146.
/O N\
1 W50FO O F
F H l A
Ii] 0
Step a. Potassium utoxide (0.13 g, 1.12 mmol) was added to 4-aminofluorophenol
in dry N—methylpyrrolidinone (5 mL, 50 mmol) at rt and stirred for 30 min under an
atmosphere of nitrogen . Then solid 4-bromo-6,7-dimethoxyquinoline (0.30 g, 1.1 mmol)
was added and the reaction d at 100 0C for 30 h. The mixture was concentrated,
ved in EtOAc (~75 mL), and washed 1x with 1N Na2C03, water and NaCl solution,
then dried over MgSO4. The t was chromatographed on silica gel (5%
MeOH/DCM) to give -dimethoxyquinolinyloxy)-2,3-difluoro-phenylamine 0.066
g (18%). LCMS m/z = 333 (M + 1). 1H NMR(CDC13) 5: 8.5 (d, 1H, J = 8 Hz), 7.58 (s,
1H), 7.44 (s, 1H), 6.89-6.83 (m, 1H), 6.64-6.58 (m, 1H), 6.42 (d, 1H, J = 5 Hz), 4.05 (d,
6H, J = 5 Hz).
Step b. yl(4-fluorophenyl)-2,4-dioxo-1,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)-2,3-difluoro-phenyl]-amide. This compound
was synthesized using 4-(6,7-dimethoxyquinolinyloxy)-2,3-difluoro-phenylamine and
3 -(4-fluorophenyl)methyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid
using the procedure for example 1. mp = 226-267 0C; LCMS m/z = 579 (M + 1); 1H NMR
)52 11.07 (s, 1H), 8.62 (s, 1H), 8.51 (d, 1H, J = 6 Hz), 8.25 (m, 1H), 7.55 (s, 1H),
7.43 (s, 1H), 7.25-7.23 (m, 4H), 7.05 (m, 1H), 6.46 (d, 1H, J = 5 Hz), 4.05 (d, 6H), 3.65 (s,
3H).
Example 147.
/o N\
F/Q F
o o O
F #1
)N o
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)-2,3-difluoro-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxyquinolinyloxy)-2,3-difluoro-phenylamine and 1-
ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using
the procedure for example 1. mp = 270-272 0C; LCMS m/z = 593 (M + 1); 1H NMR
(CDC13)52 11.08 (s, 1H), 8.63 (s, 1H), 5.51 (d, 1H, J = 6 Hz), 8.28-8.22 (m, 1H), 7.55 (s,
1H), 7.43 (s, 1H), 7.25-7.23 (m, 4H), 7.09-7.03 (m, 1H), 6.46 (d, 1H, J = 5 Hz), 4.05 (d,
6H), 4.04-3.99 (m, 2H), 1.47 (t, 3H, J = 8 Hz).
Example 148.
:QMOF0 O
Step a. 4-(6,7-Dimethoxy-quinolinyloxy)methylphenylamine was synthesized using
the procedure for example 143 steps a/b. LCMS m/z = 311 (M + 1).
Step b. 1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)methyl-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxy-quinolinyloxy)methylphenylamine and 1-ethyl-
3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using the
procedure for example 1. mp = 265-267 0C; LCMS m/z = 571 (M + 1); 1H NMR (DMSO-
d6) 5: 10.93 (s, 1H), 8.85 (s, 1H), 8.44 (d, 1H, J = 5 Hz), 7.73 (dd, 1H, J = 2, 8 Hz), 7.66
(d, 1H, J = 3 Hz), 7.55 (s, 1H), 7.46-7.33 (m, 5H), 7.18 (d, 1H, J = 8 Hz), 6.31 (d, 1H, J =
5 Hz), 4.02 (q, 2H, J = 8 Hz), 3.32 (s, 6H), 2.09 (s, 3H), 1.30 (t, 3H, J = 8 Hz).
Example 149.
3-(4-Fluoro-phenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic acid [4-(6,7-
oxy-quinolinyloxy)methyl-phenyl]-amide. This compound was synthesized
using 4-(6,7-dimethoxy-quinolinyloxy)methylphenylamine and 3-(4-fluorophenyl)-
2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using the procedure for example
1. mp = 2 0C; LCMS m/z = 543 (M + 1); 1H C13) 5: 10.74 (s, 1H), 8.61
(s, 1H), 8.45 (d, 1H, J = 5 Hz), 7.63-7.61 (m, 1H), 7.60 (s, 1H), 7.58-7.53 (m, 1H), 7.44 (s,
1H), 7.29-7.26 (m, 3H), 7.08 (d, 1H, J = 10 Hz), 6.30 (d, 1H, J = 5 Hz), 5.30 (s, 1H), 4.05
(d, 6H, J = 5 Hz), 2.05 (s, 3H).
Example 150.
MeO/Z: F
O O 0/
NJKELNH | VITO
3-(4-Fluoro-phenyl)-2,4-dioxo- 1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic acid 7-
dimethoxy-quinolinyloxy)methoxy-phenyl]-amide. This compound was synthesized
using 4-(6,7-dimethoxy-quinolinyloxy)methoxy-phenylamine (LCMS m/z = 327 (M
+ 1)) and 3-(4-fluorophenyl)-2,4-dioxo-l,2,3,4-tetrahydropyrimidinecarboxylic acid
using the procedure for example 1. LCMS m/z = 559 (M + l); 1H NMR (CDClg) 8: 10.94
(s, 1H), 8.69 (s, 1H), 8.45 (d, 1H, J = 6 Hz), 8.2 (d, 1H, J = 5 Hz), 7.61 (s, 1H), 7.42 (s,
1H), .26 (m, 3H), 7.2 (s, 1H), 6.57 (d, 1H, J = 7 Hz), 6.33 (d, 1H, J = 7 Hz), 5.30 (s,
1H), 4.05 (s, 6H), 3.76 (s, 3H).
Example 151.
MeOO/Q F
O O
l(4-fluoro-phenyl)-2,4-dioxo- l ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)methoxy-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxy-quinolinyloxy)methoxy-phenylamine and lethyl
(4-fluorophenyl)-2,4-dioxo-l ,2,3,4-tetrahydropyrimidinecarboxylic acid using
the ure for example 1. mp = 245-247 0C; LCMS m/z = 587 (M + l); 1H NMR
(DMSO-d6) 5: 10.98 (s, 1H), 8.89 (s, 1H), 8.46 (d, 1H, J: 6 Hz), 7.56 (d,lH, J = 2 Hz),
7.53 (s, 1H), 7.49 (dd, 1H, J = 3, 9 Hz), 7.45-7.41 (m, 2H), 7.39-7.34 (m, 3H), 7.25 (d, 1H,
J = 9 Hz), 6.36 (d, 1H, J = 6 Hz), 4.01 (q, 2H, J =8 Hz), 3.95 (d, 6H), 3.71 (s, 3H), 1.3 (t,
3H, J =8 Hz).
Example 152.
0|:CZ F
O O
3-Chloro(6,7-dimethoxy-quinolinyloxy)-phenylamine was synthesized using the
procedure for example 146 step a, LCMS = 331 (M + l).
l-Ethyl(4-fluoro-phenyl)-2,4-dioxo- l ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic
acid [3-chloro(6,7-dimethoxy-quinolinyloxy)methoxy-phenyl]-amide. This
compound was synthesized using 3-chloro(6,7-dimethoxy-quinolin
yloxy)phenylamine and l-ethyl(4-fluorophenyl)-2,4-dioxo- 1 ,2,3,4-
tetrahydropyrimidinecarboxylic acid using the procedure for example 1. mp = 257-259
—124—
0C; LCMS m/z = 591 (M + 1); 1H NMR (DMSO-d6) 8: 11.0 (s, 1H), 8.88 (s, 1H), 8.47 (d,
1H, J = 6 Hz), 8.18 (d, 1H, J = 3 Hz), 7.71 (dd, 1H, J = 3, 9 Hz), 7.52 (s, 1H), 7.45-7.33
(m, 6H), 6.37 (d, 1H, J = 6 Hz), 4.0 (q, 2H, J = 7 Hz), 3.95 (d, 6H), 1.30 (t, 3H, J = 7 Hz).
Example 153.
[5-(6,7-Dimethoxy-quinolinyloxy)methyl-phenyl]-dimethyl-amine was synthesized
using the procedure for example 143 step a. LCMS m/z = 340 (M + 1). 1H NMR(CDC13)
: 8.48 (d, 1H, J = 9 Hz), 7.89 (s, 1H), 7.63(s, 1H), 6.83 (d, 1H, J = 3 Hz), 6.80 (d, 1H, J =
8 Hz), 6.74 (dd, 1H, J = 3, 8.6 Hz), 6.66 (d, 1H, J = 5 Hz), 4.10 (d, 6H), 2.69 (s, 6H).
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)dimethylamino-phenyl]-amide. This compound was
synthesized using [5-(6,7-dimethoxyquinolinyloxy)methylphenyl]dimethylamine
and 1-ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid
using the procedure for example 1. mp = 144-145 0C; LCMS m/z = 600 (M + 1); 1H NMR
(DMSO-d6) 5: 11.18 (s, 1H), 8.87 (s, 1H), 8.51 (d, 1H, J = 9 Hz), 8.47 (d, 1H, J = 5 Hz),
7.51 (s, 1H), 7.45-7.33 (m, 5H), 7.10 (d, 1H, J = 3 Hz), 6.98 (dd, 1H, J = 3, 9 Hz), 6.49 (d,
1H, J = 5 Hz), 4.01 (q, 2H, J = 7 Hz), 3.94 (d, 6H), 2.58 (s, 6H), 1.29 (t, 3H, J = 7 Hz).
Example 154.
gm“;
8919
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)dimethylamino- ]-amide. This
nd was synthesized using [5-(6,7-dimethoxyquinolinyloxy)
methylphenyl]dimethylamine and 3-(4-fluorophenyl)isopropyl-2,4-dioxo-1,2,3,4-
tetrahydropyrimidinecarboxylic acid using the procedure for example 1. mp = 231-233
0C; LCMS m/z = 614 (M + 1); 1H NMR (DMSO-d6) 5: 11.19 (s, 1H), 8.67 (s, 1H), 8.52-
8.46 (m, 2H), 7.50 (s, 1H), 7.45-7.33 (m, 5H), 7.11 (d, 1H, J = 3 Hz), 6.97 (dd, 1H, J =3, 9
Hz), 6.50 (d, 1H, J = 5 Hz), 4.78 (p, 1H, J = 6 Hz), 3.94 (d, 6H), 2.58 (s, 6H), 1.42 (d, 6H,
J: 6 Hz).
Example 155.
/o N\
\ /
Q o 00F
NAKELNH | N/KO
4-(6,7-Dimethoxy-quinolinyloxy)isopropyl-phenylamine was synthesized using the
ure for example 143 step a. LCMS m/z = 338 (M + 1); 1H NMR (CDC13) 8: 8.45
(d, 1H, J = 7 Hz), 7.63 (s, 1H), 7.27 (s, 1H), 6.88 (d, 1H, J = 8.5 Hz), 6.73-6.71 (m, 1H),
6.63-6.58 (m, 1H), 6.44 (d, 1H, J = 6 Hz), 4.07 (s, 6H), 2.98-2.90 (m, 1H0, 1.16 (d, 6H, J
= 6 Hz).
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)isopropyl-phenyl]-amide. This nd was
synthesized using 4-(6,7-dimethoxy-quinolinyloxy)isopropyl-phenylamine and 1-
ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using
the procedure for example 1. mp = 173-175 S m/z = 599 (M + 1); 1H NMR
(DMSO-d6) 5: 10.93 (s, 1H), 8.80 (s, 1H), 8.45 (d, 1H, J = 6 Hz), 7.76 (dd, 1H, J = 2, 8
Hz), 7.68 (d, 1H, J = 2 Hz), 7.55 (s, 1H), 7.46-7.33 (m, 5H), 7.16 (d, 1H, J = 8 Hz), 6.36
(d,1H, J =5 Hz), 4.01 (q, 2H, J = 8 Hz), 3.94 (d, 6H), 2.99 (m, 1H), 1.3 (t, 3H, J = 7 Hz),
1.14 (d, 6H, J = 7 Hz).
Example 156.
/o N\
\ /
NJKELNH | NAG
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)isopropyl-phenyl]- amide. This compound
was synthesized using 4-(6,7-dimethoxy-quinolinyloxy)isopropyl-phenylamine and
3 -(4-fluorophenyl)isopropyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid
using the procedure for example 1. mp = 165-167 S m/z = 613 (M + 1); 1H NMR
)52 10.86 (s, 1H), 8.72 (s, 1H), 8.46 (d, 1H, J = 5.5 Hz), 7.66 (dd, 1H, J = 2.5, 8
Hz), 7.63 (d, 1H, J = 2 Hz), 7.60 (s, 1H), 7.44 (s, 1H), 7.27-7.25 (m, 3H), 7.05 (d, 1H, J =
9 Hz), 6.37 (d, 1H, J = 5.5 Hz), 4.98 (p, 1H, J = 8 Hz), 4.06 (s, 6H), 3.09 (p, 1H, J = 8 Hz),
1.5 (d, 6H, J = 7 Hz), 1.18 (d, 6H, J = 7 Hz).
Example 157.
@HiSE/[Ej/
4-(6,7-Dimethoxy-quinolinyloxy)-2,3-dimethyl-phenylamine was synthesized using the
procedure for example 143 step a. LCMS m/z = 325 (M + 1).; 1H NMR(CDC13) 5: 8.42
(d, 1H, J = 7 Hz), 7.64 (s, 1H), 7.42 (s, 1H), 6.83 (d, 1H, J = 8 Hz), 6.65 (d, 1H, J = 8 Hz),
6.26 (d, 1H, J = 8 Hz), 4.06 (d, 6H, J = 4.5 Hz), 2.15 (s, 3H), 2.06 (s, 3H).
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)-2,3-dimethyl-phenyl]-amide. This compound was
synthesized using 4-(6,7-Dimethoxy-quinolinyloxy)-2,3-dimethyl-phenylamine and 1-
ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using
the procedure for example 1. mp = 283-285 0C; LCMS m/z = 585 (M + 1); 1H NMR
(DMSO-d6) 5: 10.81 (s, 1H), 8.88 (s, 1H), 8.43 (d, 1H, J = 5.5 Hz), 8.07 (d, 1H, J = 8.5
Hz), 7.56 (s, 1H), .42 (m, 2H), 7.40 (s, 1H), 7.39-7.33 (m, 2H), 7.10 (d, 1H, J = 9
Hz), 6.26 (d, 1H, J = 6 Hz), 4.02 (q, 2H, J = 7 Hz), 3.95 (s, 6H), 2.21 (s, 3H), 2.07 (s, 3H),
1.3 (t, 3H, J = 7 Hz).
Example 158.
@110?
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)-2,3-dimethyl-phenyl]-amide. This compound
was synthesized using 4-(6,7-Dimethoxy-quinolinyloxy)-2,3-dimethyl-phenylamine
and 3-(4-fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic
acid using the procedure for example 1. mp = 238-240 0C; LCMS m/z = 599 (M + 1); 1H
NMR (DMSO-d6) 8: 10.82 (s, 1H), 8.68 (s, 1H), 8.43 (d, 1H, J = 5.5 Hz), 8.06 (d, 1H, J =
9 Hz),7.56 (s, 1H), 7.47-7.42 (m, 2H), 7.39-7.34 (m, 2H), 7.09 (d, 1H, J = 9 Hz), 6.27 (d,
1H, J = 5.5 Hz), 4.78 (p, 1H, J = 8 Hz), 3.95 (s, 6H), 2.21 (s, 3H), 2.07 (s, 3H), 1.43 (d,
6H, J = 6 Hz).
Example 159.
3-(1,1-Difluoro-ethyl)(6,7-dimethoxy-quinolinyloxy)-phenylamine was sized
using the procedure for example 143 step a. LCMS m/z = 365 (M + 1). 1H NMR(CDC13)
: 8.48 (d, 1H, J = 6 Hz), 7.56 (s, 1H), 7.42 (s, 1H), 7.06-7.01(m, 2H) 6.90-6.86 (m, 1H),
6.41 (d, 1H, J = 6 Hz), 4.05 (s, 6H).
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)trifluoromethyl-phenyl]-amide. This nd was
synthesized using 3-(1,1-difluoroethyl)(6,7-dimethoxy-quinolinyloxy)-phenylamine
and 1-ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid
using the procedure for example 1. mp = 260-262 0C; LCMS m/z = 625 (M + 1); 1H NMR
(DMSO-d6) 5: 11.08 (s, 1H), 8.89 (s, 1H), 8.51 (d, 1H, J = 5 Hz), 8.37 (d, 1H, J = 2.5 Hz),
7.45-7.41 (m, 5H), 7.36 (t, 2H, J = 8.5 Hz), 6.58 (d, 1H, J = 6 Hz), 4.02 (q, 2H, J = 7.5
Hz), 3.90 (d, 6H), 1.30 (t, 3H, J = 8 Hz).
Example 160.
”318100F F
O O
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)trifluoromethyl- phenyl]-amide. This
nd was sized using 3-(1,1-difluoroethyl)(6,7-dimethoxy-quinolin
yloxy)-phenylamine and 3-(4-fluorophenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-
tetrahydropyrimidinecarboxylic acid using the procedure for example 1. mp = 228-230
0C; LCMS m/z = 639 (M + 1); 1H NMR (DMSO-d6) 5: 11.08 (s, 1H), 8.89 (s, 1H), 8.51
(d, 1H, J = 5 Hz), 8.37 (d, 1H, J = 2.5 Hz), 7.45-7.41 (m, 5H), 7.36 (t, 2H, J = 8.5 Hz),
6.58 (d, 1H, J = 6 Hz), 4.02 (q, 2H, J = 7.5 Hz), 3.90 (d, 6H), 1.30 (t, 6H, J = 8 Hz).
Example 161.
/o N\
\ /
N N
4-(6,7-Dimethoxy-quinolinyloxy)-3,5-dimethyl-phenylamine was synthesized using the
procedure for example 143 step a. LCMS m/z = 325 (M + 1). 1H NMR(CDC13) 8: 8.43 (d,
1H, J = 8 Hz), 7.65 (s, 1H), 7.48 (s, 1H), 6.48 (s, 2H), 6.26 (d, 1H, J = 6 Hz), 4.07 (s, 6H),
2.03 (s, 6H).
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(6,7-dimethoxy-quinolinyloxy)-3,5-dimethyl-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxy-quinolinyloxy)-3,5-dimethyl-phenylamine and 1-
ethyl(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using
the ure for e 1. mp = 240-242 0C; LCMS m/z = 585 (M + 1); 1H NMR
(DMSO-d6) 5: 10.90 (s, 1H), 8.84 (s, 1H), 8.41 (d, 1H, J = 5 Hz), 7.61 (s, 1H), 7.55 (s,
1H), 7.45-7.33 (m, 6H), 6.19 (d, 1H, J = 6 Hz), 4.01 (q, 2H, J = 8 Hz), 3.95 (d, 6H, J = 5
Hz), 2.07 (s, 6H), 1.30 (t, 3H, J = 7 Hz).
Example 162.
@110?
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid 7-dimethoxy-quinolinyloxy)-3,5-dimethyl-phenyl]-amide. This compound
was synthesized using 4-(6,7-dimethoxy-quinolinyloxy)-3,5-dimethyl-phenylamine and
3 -(4-fluorophenyl)- 1 opyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid
WO 74633
using the ure for example 1. mp = 180-182 0C; LCMS m/z = 599 (M + 1); 1H NMR
(DMSO-d6) 8: 10.89 (s, 1H), 8.65 (s,1H), 8.41 (d, 1H, J = 5 Hz), 7.60 (s, 1H), 7.58 (s,
2H), 7.45-7.33 (m, 5H), 6.19 (d, 1H, J = 7 Hz), 4.18 (p, 1H, J = 7 Hz), 3.95 (d, 6H, J = 6
Hz), 2.05 (s, 6H), 1.45 (d, 6H, J = 7 Hz).
Example 163.
filiflofij
4-(6,7-Dimethoxy-quinolinyloxy)methyl-phenylamine was synthesized using the
procedure for example 143 step a. LCMS m/z = 311(M + 1).
3 -(4-Fluoro-phenyl)isopropyl-2,4-dioxo-1 ,2,3 ,4-tetrahydro-pyrimidinecarboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)methyl-phenyl]-amide. This compound was
synthesized using 4-(6,7-Dimethoxy-quinolinyloxy)methyl-phenylamine and 3-(4-
fluorophenyl)isopropyl-2,4-dioxo- 1 ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic acid using
the procedure for example 1. mp = 238-240 0C;LCMS m/z = 585 (M + 1); 1H NMR
d6) 5: 10.92 (s, 1H), 8.65 (s, 1H), 8.44 (d, 1H, J = 6 Hz), .67 (m, 2H), 7.55
(s, 1H), 7.45-7.41 (m, 2H), 7.39-7.34 (m, 3H), 7.17 (d, 1H, J = 8 Hz), 6.31 (d, 1H, J = 4.5
Hz), 4.78 (p, 1H, J = 6 Hz), 3.95 (s, 6H), 2.09 (s, 3H), 1.43 (d, 6H, J = 7 Hz).
Example 164.
Q F
0 O
2-Ethyl(4-fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine- 6-carboxylic acid
[5-(6,7-dimethoxy-quinolinyloxy)-pyridinyl]-amide This compound was synthesized
using 5-(6,7-dimethoxyquinolinyloxy)-pyridinylamine and 2-ethyl(4-
fluorophenyl)-3,5-dioxo-2,3,4,5-tetrahydro-[1,2,4]triazinecarboxylic acid using the
procedure for example 1. mp = 200-202 0C; LCMS m/z = 585 (M + 1); 1H NMR(CDC13)
: 11.13 (s, 1H), 8.52 (d, 1H, J = 5 Hz), 8.48 (d, 1H, J = 8.5 Hz), 8.27 (d, 1H, J = 2.6 Hz),
7.60 (dd, 1H, J = 2, 9 Hz), 7.52 (s, 1H), 7.43 (s, 1H), 7.28-7.26 (m, 3H), 6.47 (d, 1H, J =
4.3 Hz), 4.33 (q, 2H, J = 8.5 Hz), 4.05 (d, 6H), 1.51 (t, 3H, J = 8 Hz).
Example 165.
/o N\
\ /
NJJYlLNH |
N\JAG
2-Ethyl(4-fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine- 6-carboxylic acid
[4-(6,7-dimethoxy-quinolinyloxy)isopropyl-phenyl]-amide. This nd was
sized using 4-(6,7-dimethoxy-quinolinyloxy)isopropyl-phenylamine and 2-
ethyl(4-fluorophenyl)-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro-[1 ,2,4]triazinecarboxylic acid
using the procedure for example 1. mp = 155-156 0C; LCMS m/z = 600 (M + 1); 1H NMR
(CDC13)52 10.78 (s, 1H), 8.47 (d, 1H, J = 5.5 Hz). 7.72 (s, 1H), 7.66 (d, 1H, J = 8 Hz),
7.59 (s, 1H), 7.43 (s, 1H), 7.31-7.24 (m, 3H), 7.07 (d, 1H, J = 9 Hz), 6.35 (d, 1H, J = 6
Hz), 4.34 (q, 2H, J = 7.3 Hz), 4.05 (s, 6H), 3.11 (m, 1H), 1.58 (t, 3H, J = 6 Hz), 1.19 (d,
6H, J = 7 Hz).
Example 166.
/o N\
\ /
Q F
0 0 O
MeO HM“
4-(4-Fluoro-phenyl)isopropyl-3 ,5 -2,3 ,4,5 -tetrahydro-1,2,4-triazine- 6-carboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)methoxy-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxyquinolinyloxy)methoxy-phenylamine and 4-(4-
Fluorophenyl)isopropyl-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro[1,2,4]triazinecarboxylic acid
using the procedure for examplel. mp = 216-218 0C; LCMS m/z = 602 (M + 1); 1H NMR
(CDC13)82 11.02 (s, 1H), 8.66 (d, 1H, J = 8.5 Hz), 8.50 (d, 1H, J = 5 Hz), 7.54 (s, 1H),
7.43 (s, 1H), 7.30-7.27 (m, 3H), 6.83 (dd, 1H, J = 3.5, 10 Hz), 6.75 (d, 1H, J = 2.5 Hz),
6.53 (d, 1H, J = 5 Hz), 5.09 (m, 1H), 4.05 (s, 6H), 3.86 (s, 3H), 1.53 (d, 6H, J = 6.5 Hz)
Example 167.
\or»
O O
W0F0 O
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(5,6-dimethoxy-quinolinyloxy)-phenyl]-amide. This compound was synthesized using
4-(5,6-dimethoxy-quinolinyloxy)-phenylamine and 1-ethyl(4-fluorophenyl)-2,4-
1,2,3,4-tetrahydropyrimidinecarboxylic acid using the procedure for example 1.
mp > 250 0C; LCMS m/z = 557 (M +1); 1H NMR (DMSO) 5: 10.92 (s, 1H), 8.86 (s, 1H),
8.48 (m, 1H), 7.79 (m, 2H), 7.49 (s, 1H), 7.35-7.42 (m, 5H), 7.24-7.27 (m, 2H), 6.49 (m,
1H), 4.00 (m, 2H), 3.94 (s, 3H), 3.92 (s, 3H), 1.29 (m, 3H).
Example 168.
0Q F
o o
1-Ethyl(4-fluoro-phenyl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidinecarboxylic acid [4-
(6,8-dimethoxy-quinolinyloxy)-phenyl]-amide. This compound was synthesized using
4-(6,8-dimethoxy-quinolinyloxy)-phenylamine and 1-ethyl(4-fluorophenyl)-2,4-
dioxo-1,2,3,4-tetrahydropyrimidinecarboxylic acid using the procedure for example 1.
mp = 127-9 0C; LCMS m/z = 557 (M + 1); 1H NMR (DMSO) 5: 10.93 (s, 1H), 8.87 (s,
1H), 8.45 (d, 1H, J = 5Hz), 7.79 (d, 2H, J = 8.8 Hz), 7.41-7.45 (m, 2H), .37 (m, 2H),
7.24- (d, 2H, J = 8.8 Hz), 7.10 (d, 1H, J = 2.3 Hz), 6.86 (d, 1H, J = 2.3 Hz), 6.61 (d, 1H, J
=5 Hz), 4.01 (q, 2H, J = 7 Hz), 3.94 (s, 3H), 3.89 (s, 3H), 1.29 (t, 3H, J = 7 Hz).
Example 169.
WO 74633
2-Ethyl(4-fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine- oxylic acid
[4-(6,7-dimethoxy-quinolinyloxy)trifluoromethyl-phenyl]-amide. This compound
was synthesized using 4-(6,7-dimethoxy-quinolin- y)trifluoromethyl-
phenylamine and 2-ethyl(4-fluoro-phenyl)- 3,5-dioxo-2,3,4,5-tetrahydro- 1,2,4-triazine-
6-carboxylic acid using the procedure for example 1. mp = 148-50 0C; LCMS m/z = 626
(M + 1); 1H NMR (DMSO): 10.95 (s, 1H), 8.52 (d, 1H), 8.32 (s, 1H), 8.04 (m, 1H), 7.35-
7.49 (m, 8H), 6.60 (m, 1H), 4.08 (q, 2H, J = 7Hz), 3.97 (s, 3H), 3.89 (s, 3H), 1.35 (t, 3H, J
= 7Hz).
Example 170.
/O N\
\ /
P888“
2-Ethyl(4-fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine- 6-carboxylic acid
7-dimethoxy-quinolinyloxy)methoxy-phenyl]-amide. This compound was
synthesized using 4-(6,7-dimethoxy-quinolin- 4-yloxy)methoxy-phenylamineand 2-
ethyl(4-fluoro-phenyl)- 3,5-dioxo-2,3,4,5-tetrahydro- 1,2,4-triazinecarboxylic acid
using the procedure for example 1. mp = 264-6 0C; LCMS m/z = 588 (M + 1); ); 1H NMR
(DMSO): 11.00 (s, 1H), 8.47-8.52 (m, 2H), 7.51 (s, 1H), 7.38-7.46 (m, 5H), 7.10 (m, 1H),
6.88 (m, 1H), 6.53 (d, 1H, J = 5Hz), 4.10 (q, 2H, J = 7Hz), 3.94 (s, 3H), 3.93 (s, 3H), 3.84
(s, 3H), 1.35 (t, 3H, J = 7Hz).
Example 171.
QVLOF
2-Ethyl(4-fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine- 6-carboxylic acid
[3-fluoro(7-methoxy-quinolinyloxy)-phenyl]-amide. This compound was
synthesized using 3-fluoro(7-methoxy-quinolinyloxy)-phenylamine and 2-ethyl
(4-fluoro-phenyl)-3,5-dioxo-2,3,4,5-tetrahydro- 1,2,4-triazinecarboxylic acid. LCMS
m/z = 546 (M + 1); ); 1H NMR (DMSO): 11.00 (s, 1H), 8.88 (m, 1H), 8.01-8.05 (m, 1H),
-133—
2012/065019
7.58-7.67 (m, 2H), 7.52—7.55 (m, 2H), 7.36-7.45 (m, 4H), 6.88 (m, 1H), 4.08 (q, 2H, J =
7Hz), 4.01 (s, 3H), 1.35 (t, 3H, J = 7Hz).
VI. Biology
AXL Kinase Assay
The ability of compounds to inhibit the kinase activity of recombinant human
baculovirus-expressed AXL was measured by homogeneous TRF (HTRF) using Cisbio’s
KinEASETM assay system in white 384-well Optiplates. Assay buffer contained 1 mM
DTT, 2 mM MnClz, 2% DMSO, 50 nM ment enzymatic , and 1x enzymatic
buffer. A 2x concentration of tyrosine kinase (TK) substrate-biotin/ATP mixture made in
assay buffer was added to plates at 10 uL/well using the Multidrop Combi (Thermo Fisher
ific, Waltham, MA). The final concentrations were 0.3 uM TK substrate-biotin, and
1.3 uM ATP. Compounds (100 nL), diluted in 100% DMSO on the Biomek FX,
(Beckman Coulter, lnc., Brea, CA), were transferred to the assay plates using the Biomek
FX pintool (2.5% final DMSO in assay). A 2x concentration (final = 12 ng/mL) of GST-
AXL (diluted in assay buffer) was added to plates at 10 uL/well using the Multidrop
Combi. Plates were sealed, briefly shaken and incubated at 25°C for 30 minutes. A 4x
stock of Streptavidin-XL665 (final = 18.8 nM) and a 1:100 d stock of TK antibody-
cryptate were made in HTRF detection buffer and mixed together just prior to adding 20
uL/well 0n the Multidrop Combi. Plates were sealed, briefly shaken and incubated at
°C for 1 hour. The fluorescence of the resulting solution was measured using the
PerkinElmer EnVisionTM 2102 multi-label plate reader (PerkinElmer, Waltham, MA) with
an excitation wavelength of 337 nm (laser) and emission wavelengths of 590 and 665 nm.
Raw data was expressed as the ratio of 665/590 x 10,000.
C-MET Kinase Assay
The cMET kinase assay was med in 384-well FluotracTM 200 HiBase microplates
using the HTRF KinEASETM assay described above for AXL except that the assay volume
was d to half. Enzyme concentration was 8 ng/mL of recombinant human
virus-expressed cMET while the substrate concentrations were 0.1 uM and 0.02 uM
for the biotinylated peptide and ATP, tively. Instead of the Multidrop Combi, the
—134—
BioRAPTR® FRD microfiuidic workstation (Beckman Coulter, Brea, CA) was ed
for reagent additions.
Data Analysis
Inhibition curves for compounds were generated by plotting percent control
ty versus log10 of the concentration of compound. IC50 values were calculated by
nonlinear regression using the sigmoidal dose-response (variable slope) on in
GraphPad Prism as follows:
y = bottom + (top - bottom)/(l + 10 (log IC50-x)*Hill Slope)
where y is the % kinase activity at a given concentration of compound, x is the logarithm
of the concentration of compound, bottom is the % of control kinase activity at the highest
compound concentration tested, and top is the % of control kinase activity at the lowest
compound concentration examined. The values for bottom and top were fixed at 0 and
100, tively.
Results
Biological data for Example compounds is presented in the following Table 1.
Unless otherwise specified in Table l, IC50 nanomolar value ranges ated as A, B, or
C indicate the following ranges:
IC50 < 10 nM A;
IC50 10 nM to 100 nM B; and
IC50 101 nM to 1,000 nM C;.
“NT” s not .
Unless otherwise specified, all values are an average of two or more
determinations.
Table 1. AXL and c-MET Inhibition
c-MET IC50
Example AXL IC50 nM
l A A
2 A A
3 A B
4 A B
-l35-
2012/065019
C-MET IC50
Example AXL IC50 nM
©00\]O\
37 ODS0303{73>ijUJ>UJUJO>>UJUJUJUJUJ>>UJ>UJUJUJUJ>UJUJ>UJ
38 Z.4
39 Z.4
48 owwwwwwow>wwoow>>>>>>>>>w>>>>>w>>>w>ww>00>>>>> OUJD>UJUJUJUJOUJ
C-MET IC50
e AXL IC50 11M
50 AAAA
52 AAAA
54 AAAA
56 Anhb
58 AnAA
60 puhb
62 AAAA
64 AAAA
66 AAAA
68 AAAA
70 Anhb
72 AAAA
74 AAAA
76 AAAA
78 AAAA
80 Anhb
82 puAA
84 Anhb
86 AAAA
88 AAAA
90 RUAA
91 A
92 by MAAABABBBCBBCAAABBABAABABBBMMBBBCBBBBABBBCBBM
2012/065019
C-MET IC50
Example AXL IC50 nM
98 03003030303
118 nowww>wwww>>ww>w>ww§
121 5005
122 Z.4
136 wcoww>>>>>>>>wwooonoww>w>>>>w>>>>>>>>>o>w>www OOOUJUJUJUJUJUJUJOUJUJO
C-MET IC50
Example AXL IC50 nM
140 550W
152 www>w>>ww>ww
153 Za
166 OUJUJUJUJUJOUJOOUJUJO
167 Za
168 >>ww>03w>wwww>wwwwwo>>>>w>>>>>>wooww Za
171 >UJD>
In one embodiment, the invention es a compound of Formula I or a salt
thereof having an AXL IC50 of less than 1 uM. In one embodiment, the invention
provides a compound of Formula I or a salt thereof having an AXL IC50 of less than 100
nM. In one embodiment, the invention provides a nd of a I or a salt thereof
having an AXL IC50 of less than 10 nM. In one embodiment, the invention provides the
exemplified compounds of Formula I or salts thereof having AXL IC50s of less than 1 uM.
2012/065019
In one embodiment, the invention provides the exemplified compounds of Formula I or
salts thereof having AXL IC50s of less than 100 nM. In one ment, the invention
provides the exemplified compounds of Formula I or salts thereof having AXL IC50s of
less than 10 nM.
In one embodiment, the invention provides a compound of Formula I or a salt
thereof having a c-Met IC50 of less than 1 uM. In one embodiment, the invention provides
a compound of a I or a salt f having a c-Met IC50 of less than 100 nM. In one
embodiment, the invention provides a compound of Formula I or a salt thereof having a c-
Met IC50 of less than 10 nM. In one embodiment, the invention es the exemplified
compounds of Formula I or salts thereof having c-Met IC50s of less than 1 uM. In one
embodiment, the invention provides the exemplified compounds of Formula I or salts
thereof having c-Met IC50s of less than 100 nM. In one embodiment, the invention
provides the exemplified compounds of Formula I or salts f having c-Met IC50s of
less than 10 nM.
In one embodiment, the invention provides a compound of Formula I or a salt
thereof having AXL and c-Met IC50s of less than 1 uM. In one embodiment, the invention
provides a compound of Formula I or a salt thereof having AXL and c-Met IC50s of less
than 100 nM. In one ment, the invention provides a compound of Formula I or a
salt f having AXL and c-Met IC50s of less than 10 nM. In one embodiment, the
invention provides the exemplified nds of Formula I or salts thereof having AXL
and c-Met IC50s of less than 1 uM. In one embodiment, the invention provides the
exemplified compounds of Formula I or salts thereof having AXL and c-Met IC50s of less
than 100 nM. In one embodiment, the invention provides the exemplified compounds of
Formula I or salts thereof having AXL and c-Met IC50s of less than 10 nM.
—140—
WO 74633
Additional preferred Embodiments of the present invention include:
1. A compound of the a
T3 NY0
R2 XI/
I ”WE
Rd \ Y O O
Ra 1
Rb N/J
wherein:
Ra is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, dialkylamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, N—alkylcarbamoyl,
N,N—diall<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
different, trihalomethyl, or Ra is OA;
Rb is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, dialkylamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, lcarbamoyl,
N,N—diall<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
different, trihalomethyl, or Rb is OB;
Rc is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, lamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, N—alkylcarbamoyl,
all<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
different, trihalomethyl, or RC is OJ;
Rd is H, alkyl, halo, cyano, hydroxyl, amino, alkylamino, dialkylamino Where the
alkyl groups of dialkylamino may be the same or different, carbamoyl, N—alkylcarbamoyl,
N,N—diall<ylcarbamoyl, Where the alkyl groups of dialkylcarbamoyl may be the same or
different, trihalomethyl, or Rd is OL;
Where A, B, J and L, are, independently, H, alkyl, alkoxyalkyl, cycloalkyl,
cycloalkoxyalkyl, heterocyclylalkyl, heterocyclylalkoxyalkyl, arylalkyl or arylalkoxyalkyl,
- l 4 l -
or A and B together with the oxygen atoms to which they are attached form or
D is O, S, SO, SOZ, C=O, C(H)OH, CH2, NH or N-alkyl;
E is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted
alkynyl, cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclyl
or heteroarylalkyl, where the heteroaryl group of heteroarylalkyl may be substituted or
unsubstituted;
G is H, aryl, tuted aryl, aryl, substituted heteroaryl, heterocyclyl, alkyl
or lkyl, lkylalkyl, alkenyl or alkynyl, where alkyl, alkenyl or cycloalkyl may
be substituted by one, two or three groups selected from the group ting of alkanoyl,
cycloalkyl, alkenyl, alkynyl, halo, hydroxyl, alkoxy, alkoxycarbonyl, heterocyclyl, aryl,
substituted aryl, aryloxy, arylalkoxy, amino, mino, dialkylamino, where the alkyl
groups of dialkylamino may be the same or different, heteroaryl, carboxyl, oxo,
carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, where the alkyl groups of lcarbamoyl
may be the same or different, and heterocycyclylcarbonyl;
W is CH or N;
X is C-R4 or N, where R4 is H, OH or alkyl, where the alkyl group may be
substituted by hydroxyl, alkoxy, alkylamino, or dialkyl amino, where the alkyl groups of
dialkylamino may be the same or different;
Y is N, CH or C where C may be substituted with one of the groups R1 or R2; and
R1 and R2 are, independently, H, alkyl, cycloalkyl, halo, alkoxy, trihaloalkyl,
amino, mino, dialkylamino, where the alkyl groups on dialkylamino may be the
same or different, or heterocyclyl; and
R3 is H, or alkyl; or
a ceutically acceptable salt thereof.
2. A compound according to preferred Embodiment 1 wherein W is CH.
3. A compound according to preferred Embodiment 1 wherein W is N.
—142—
A compound according to red Embodiment l of the formula
A_O R1
8—0 N
wherein:
A and B are, independently, H, alkyl, alkoxyalkyl, cycloalkyl,
cycloalkoxyalkyl, heterocyclylalkyl, heterocyclylalkoxyalkyl, arylalkyl or
arylalkoxyalkyl, or A and B together with the oxygen atoms to which they are
C: [0
ed form or ;
D is O, S, NH, or C=O;
E is H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted l, cycloalkyl, aryl, substituted aryl, heteroaryl, heterocyclyl,
tuted aryl, or heteroarylalkyl, where the heteroaryl group of
heteroarylalkyl may be substituted or unsubstituted;
G is H, aryl, substituted aryl, heteroaryl, substituted heteroaryl,
heterocyclyl, alkyl or cycloalkyl, lkylalkyl, alkenyl or alkynyl, where alkyl,
alkenyl or cycloalkyl may be substituted by one, two or three groups selected from
the group consisting of alkanoyl, cycloalkyl, alkenyl, alkynyl, halo, hydroxyl,
alkoxy, alkoxycarbonyl, heterocyclyl, aryl, substituted aryl, aryloxy, arylalkoxy,
amino, alkylamino, dialkylamino, where the alkyl groups of dialkylamino may be
the same or different, heteroaryl, carboxyl, oxo, oyl, alkylcarbamoyl,
dialkylcarbamoyl, where the alkyl groups of dialkylcarbamoyl may be the same or
different, and heterocycyclylcarbonyl;
X is C-R4 or N, where R4 is H or alkyl;
—143—
Y is N, CH or C where C may be substituted with one of the groups R1 or
R2; and
R1 and R2 are, independently, H, alkyl, halo, alkoxy, trihaloalkyl, amino,
alkylamino, dialkylamino, where the alkyl groups on dialkylamino may be the
same or different; or
a pharmaceutically acceptable salt thereof.
. A compound according to preferred Embodiment 4 wherein A and B are,
independently, alkyl, heterocyclylalkyl or heterocyclylalkoxyalkyl.
6. A compound according to preferred Embodiment 4 wherein A and B are,
independently, alkyl.
7. A compound according to preferred Embodiment 4 wherein D is O, S or NH.
8. A compound according to red Embodiment 4 wherein D is O.
9. A compound according to preferred Embodiment 4 wherein R1 and R2 are,
ndently, halo, alkoxy, alkyl or H.
. A compound according to red Embodiment 4 wherein R1 and R2 are,
independently, halo or alkoxy.
11. A compound ing to preferred Embodiment 4 wherein R1 and R2 are,
independently, methoxy or fluoro.
12. A compound according to preferred Embodiment 4 wherein X is N or CH.
13. A compound according to preferred Embodiment 4 wherein X is CH.
14. A compound according to red Embodiment 4 wherein G is alkyl where alkyl
may be substituted by one, two or three groups selected from the group consisting of
alkanoyl, cycloalkyl, l, alkynyl, halo, hydroxyl, alkoxy, carbonyl,
heterocyclyl, aryl, substituted aryl, aryloxy, arylalkoxy, amino, mino, dialkylamino,
-l44-
where the alkyl groups of dialkylamino may be the same or different, heteroaryl, carboxyl,
oxo, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, where the alkyl groups of
dialkylcarbamoyl may be the same or different, and heterocycyclylcarbonyl.
. A compound according to preferred Embodiment 4 wherein E is aryl, substituted
aryl or cycloalkyl.
16. A nd according to preferred Embodiment 4 wherein E is substituted aryl.
17. A compound according to preferred Embodiment 4 wherein A and B are,
independently, alkyl; D is O, S or NH; R1 and R2 are, independently, halo, alkoxy, alkyl or
H; X is N or CH; G is alkyl where alkyl may be tuted by one, two or three groups
selected from the group consisting of alkanoyl, cycloalkyl, alkenyl, alkynyl, halo,
hydroxyl, alkoxy, alkoxycarbonyl, heterocyclyl, aryl, substituted aryl, aryloxy, arylalkoxy,
amino, alkylamino, dialkylamino, where the alkyl groups of dialkylamino may be the
same or different, heteroaryl, carboxyl, oxo, carbamoyl, alkylcarbamoyl,
lcarbamoyl, where the alkyl groups of dialkylcarbamoyl may be the same or
different, and heterocycyclylcarbonyl; and E is aryl, substituted aryl or cycloalkyl.
l 8. A compound which is
l-Ethyl(4-fluorophenyl)-2,4-dioxo- l ,2,3 ,4-tetrahydropyrimidine-5 -
carboxylicacid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]amide;
3 uorophenyl)- l l-2,4-dioxo- l ,2,3 ,4-tetrahydropyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxyquinolinyloxy)fluoro-phenyl]-amide;
3 -(4-Fluorophenyl)- l -(2-methoxyethyl)-2,4-dioxo- l ,2,3 rahydropyrimidine-5 -
carboxylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]-amide;
l-(2-Ethoxyethyl)(4-fluorophenyl)-2,4-dioxo- l ,2,3 ,4-tetrahydropyrimidine
carboxylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]-amide;
3 -(4-Fluorophenyl)- l -isopropyl-2,4-dioxo- l ,2,3 ,4-tetrahydropyrimidine
ylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]-amide;
l -Cyclopropylmethyl(4-fluorophenyl)-2,4-dioxo- l ,2,3 ,4-tetrahydropyrimidinecarboxylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]-amide;
3 -(4-Fluorophenyl)- l -(3 -methoxypropyl)-2,4-dioxo-l ,2,3 ,4-tetrahydropyrimidine-
oxylic acid [4-(6,7-dimethoxyquinolinyloxy)fluorophenyl]-amide;
-l45-
2012/065019
3 -(4-F1u0r0phcnyl)—1-isobuty1—2,4-di0xo-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -
carboxylic acid 7-dimcthoxyquino1iny10xy)fluor0phcny1]—arnidc;
1-A11y1—3-(4-fluor0phcnyl)-2,4-di0xo-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid [4-(6,7-dirncthoxyquino1iny10xy)fluor0phcny1]—arnidc;
1 -(2-Bcnzyloxycthyl)(4-flu0r0phcnyl)-2,4-di0xo-1 ,2,3 ,4-tctrahydropyrirnidinccarb0xy1ic acid [4-(6,7-dirncthoxyquinolinyloxy)fluor0phcny1]—arnidc;
3 -(4-F1uorophcny1)-2,4-di0x0-1 -pr0py1—1 ,2,3 ,4-tctrahydr0pyrimidinc-5 - carboxylic
acid [4-(6,7-dirncthoxyquino1iny10xy)fluor0phcny1]—arnidc;
3 uorophcnyl)(2-isopr0p0xycthyl)—2,4-dioxo-1 ,2,3 ,4-tctrahydr0pyrimidinc-
5 -carb0xy1ic acid [4-(6,7-dirncthoxyquinolinyloxy)fluor0phcny1]—arnidc;
1-(3 -Bcnzy10xypr0pyl)(4-fluor0phcnyl)-2,4-dioxo-1,2,3 ,4-
ydropyrimidinc-S-carb0xylic acid [4-(6,7-dirncth0xyquinoliny10xy)—3-fluor0
phenyl] -arnidc;
1-(3 ,3 -Difluor0-allyl)-3 -(4-fluor0phcny1)—2,4-di0xo-1 ,2,3 ,4-tctrahydropyrimidinccarb0xy1ic acid [4-(6,7-dirncthoxyquinolinyloxy)fluor0phcny1]—arnidc;
3 -(4-F1u0r0phcnyl)—1-(3 -rncthy1—butcnyl)-2,4-diox0- 1 ,2,3 ,4-
tctrahydropyrimidinc-S-carb0xy1ic acid [4-(6,7-dimcthoxyquino1iny10xy)
fluorophcnyl]—arnidc;
3 -(4-F1u0r0phcnyl)—1-(2-rn0rph01iny1—cthy1)—2,4-dioxo-1 ,2,3 ,4-
tctrahydropyrimidinc-S-carb0xylic acid [4-(6,7-dirncth0xyquinoliny10xy)—3-fluor0
phenyl] -arnidc;
3 -(4-F1uorophcny1)-2,4-di0x0-1 ,2,3 rahydr0pyrirnidinc-5 -carb0xy1ic acid [4-
(6,7-dimcthoxyquinolinyloxy)flu0r0phcny1]—arnidc;
3 -(4-F1uorophcnyl)rncthy1—2,4-di0x0-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 - carboxylic
acid [4-(6,7-dimcthoxyquino1iny10xy)—phcnyl]-arnidc;
1 -(2-Bcnzyloxycthyl)(4-flu0ro-phcnyl)-2,4-di0x0- 1 ,2,3 rahydropyrimidinc-
-carboxy1ic acid [4-(6,7-dimcthoxyquinolinyloxy)-phcnyl]-arnidc;
1-(2-Dirncthy1arninocthyl)(4-flu0r0phcny1)-2,4-diox0-1 ,2,3 ,4-
tctrahydropyrimidinc-S-carb0xy1ic acid [4-(6,7-dimcthoxyquino1iny10xy)
fluorophcnyl]—arnidc;
1-(3 -Bcnzy10xypr0pyl)(4-fluor0phcnyl)-2,4-dioxo-1,2,3 ,4-
tctrahydropyrimidinc-S-carb0xylic acid [4-(6,7-dimcthoxyquino1iny10xy)phcnyl]-
amide;
1-(3 -Bcnzy10xypr0pyl)(4-fluor0phcnyl)-2,4-dioxo-1,2,3 ,4-
tctrahydropyrirnidinc-S xy1ic acid [4-(6,7-dimcthoxyquino1iny10xy)
fluorophcnyl]—arnidc;
3 -(4-F1uor0phcnyl)—1-is0pr0py1—2,4-diox0-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquinoliny10xy)phcnyl]-arnidc;
3 -(4-F1uorophcny1)-2,4-di0x0-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic acid [4-
(6,7-dirncth0xyquino1iny10xy)phcnyl]-arnidc;
3 -Cyclohcxylcthy1—2,4-dioxo-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xylic acid
[4-(6,7-dirncthoxyquin01iny10xy)—3-fluor0phcny1]—arnidc;
3 -(4-F1uor0phcny1)-2,4-di0x0(2-pyrr01idiny1—cthy1)-1,2,3 ,4-
tctrahydropyrirnidinc-S-carb0xylic acid [4-(6,7-dirncth0xyquinoliny10xy)—3-fluor0
phenyl] -arnidc;
3 -(4-F1u0rophcny1)-2,4-di0x0(2-pipcridiny1-cthy1)—1,2,3 ,4-
ydropyrirnidinc-S-carb0xy1ic acid [4-(6,7-dimcthoxyquino1iny10xy)
fluorophcnyl]—arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid [4-(6,7-dimcthoxyquino1iny10xy)—phcnyl]-arnidc;
1 -Cyc10buty1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrimidinc
carboxylic acid [4-(6,7-dirncthoxyquinoliny10xy)fluor0phcny1]—arnidc;
3 -(4-F1u0r0phcnyl)-2,4-dioxo(tctrahydr0pyranyl)-1 ,2,3 ,4-
tctrahydropyrirnidinc-S-carb0xylic acid [4-(6,7-dirncth0xyquinoliny10xy)—3-fluor0
phenyl] -arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid [5 -(6,7-dimcthoxyquinoliny10xy)-pyridin-2—yl] -arnidc was synthesized ng
With 5-(6,7-dirncth0xyquino1iny10xy)—pyridiny1arninc;
1-Ethy1—3-(4-fluor0phcnyl)rncthyl-2,4-dioxo-1 ,2,3 ,4-tctrahydropyrirnidinc
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)fluor0phcny1]—arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 rahydr0pyrirnidinc-5 -carb0xy1ic
acid [4-(6,7-dicthoxyquino1iny10xy)—3-flu0r0phcny1]—arnidc;
3 -(4-F1uorophcny1)is0pr0py1—2,4-dioxo- 1 ,2,3 ,4-tctrahydropyrirnidinc
carboxylic acid [5 -(6,7-dirncth0xyquino1inyloxy)-pyridinyl]-arnidc;
1 -Cyclopr0pylmcthyl(4-flu0r0phcny1)—2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrimidinccarboxylic acid [5 -(6,7-dimcthoxyquinolinyloxy)pyridiny1] -arnidc;
—147—
3 -(4-F1uor0phcny1)-2,4-di0x0pcnty1— 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 - carboxylic
acid [4-(6,7-dirncthoxyquino1iny10xy)fluor0phcny1]—arnidc;
3 -(4-F1uorophcny1)isopr0py1—2,4-dioxo- 1 ,2,3 ,4-tctrahydropyrirnidinc
carboxylic acid [4-(6,7-dicthoxyquino1iny10xy)flu0r0-phcny1] -arnidc;
3 -(4-F1uorophcny1)isopr0py1—2,4-dioxo- 1 ,2,3 rahydropyrirnidinc
carboxylic acid [4-(5,7-dimcthoxyquinoliny10xy)phcnyl]-arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid [4-(5,7-dimcthoxyquino1iny10xy)—phcnyl]-arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid [4-(7-bcnzyloxyrncth0xyquino1iny10xy)—3-fluor0phcny1]—arnidc;
3 -(4-F1uorophcny1)- 1 0py1—2,4-dioxo- 1 ,2,3 ,4-tctrahydropyrirnidinc
carboxylic acid [4-(7-bcnzyloxymcthoxyquino1inyloxy)flu0r0phcny1]—arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 rahydr0pyrirnidinc-5 -carb0xy1ic
acid [3-fluoro(7-hydr0xyrncthoxyquino1iny10xy)phcny1]-arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid {3-flu0ro[6-rncthoxy(3-rnorpho1iny1—pr0poxy)quino1iny10xy] phcny1}-
amide;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid {3-fluor0[6-rncthoxy(2-rncthoxycthoxy)quinolinyloxy]-phcny1} -arnidc;
1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid {3-flu0r0[6-mcthoxy(2-rnorpho1iny1—cthoxy)-quin01inyloxy]phcnyl} -
amide;
3 -(4-F1uorophcny1)isopr0py1—2,4-dioxo- 1 ,2,3 ,4-tctrahydropyrirnidinc
carboxylic acid [3-fluoro(7-hydr0xyrncthoxyquino1iny10xy)-phcnyl]-arnidc;
3 -(4-F1uorophcny1)isopr0py1—2,4-dioxo- 1 ,2,3 ,4-tctrahydropyrirnidinc
ylic acid {3-flu0r0[6-mcth0xy(3-rn0rpholiny1—propoxy)- quinolin
yloxy]phcny1}-arnidc;
3 -(4-F1uor0phcnyl)(2-hydr0xycthyl)-2,4-di0x0-1 ,2,3 ,4-tctrahydropyrirnidinc
carboxylic acid [4-(6,7-dimcthoxyquino1iny10xy)fluor0phcny1]—arnidc;
3 -(4-F1uorophcnyl)(3 -hydroxypr0pyl)-2,4-di0xo- 1 ,2,3 rahydropyrirnidinccarb0xy1ic acid [4-(6,7-dirncthoxyquinolinyloxy)fluor0phcny1]—arnidc;
3 -(4-F1uorophcnyl)(3 -hydroxypr0pyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydropyrimidinc-
-carb0xy1ic acid [4-(6,7-dirncthoxy-quinoliny10xy)—2-fluor0-phcnyl]-arnidc;
3 -(4-F1uorophenyl)(3 -hydroxypr0pyl)-2,4-di0xo- 1 ,2,3 ,4-tetrahydropyrimidine-
-carboxy1ic acid [4-(6,7-dimethoxyquinoliny10xy)phenyl]-amide;
3 -(4-F1uor0phenyl)—1-(2-hydr0xyethy1)-2,4-di0x0-1 ,2,3 rahydr0pyrimidine-5 -
carboxylic acid [4-(6,7-dimethoxyquinoliny10xy)phenyl]-amide;
1-((S)-2,3-Dihydr0xypropyl)(4-fluor0phenyl)-2,4-dioxo-1,2,3 ,4-
tetrahydropyrimidine-S-carb0xy1ic acid [4-(6,7-dimethoxyquino1iny10xy)
fluorophenyl]—amide;
3 -(4-F1uorophenyl)(4-hydr0xybuty1)-2,4-di0x0-1 ,2,3 rahydropyrimidine
carboxylic acid [4-(6,7-dimethoxyquino1iny10xy)fluor0pheny1]—amide;
3 -(4-F1uor0phenyl)—1-isopr0py1—2,4-diox0-1 ,2,3 ,4-tetrahydr0pyrimidine-5 -
ylic acid [4-(6-cyanometh0xy-quino1inyloxy)-phenyl]-amide;
3 -(4-flu0ro-pheny1)-1 -methy1-2,4-di0X0-1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid {4-[(6,7-dimeth0xy-quinoliny1)-hydroxy-methyl] flu0r0-pheny1} -
amide;
3 -(4-flu0ro-pheny1)-1 -methy1-2,4-di0X0-1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xy-quinolinylmethy1)flu0r0-phenyl]-amide;
1-Ethy1—3-(4-flu0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0pyrimidine-5 -carb0xy1ic
acid [3-cyc10propy1—4-(6,7-dimethoxy-quinolinyloxy)-phenyl]-amide;
3 u0r0-pheny1)isopr0py1—2,4-di0xo-1 ,2,3 ,4-tetrahydr0-pyrimidine
ylic acid [3-cyclopr0pyl(6,7-dimethoxy-quino1iny10xy)-phenyl]-amide;
3 -(4-F1u0r0-phenyl)-2,4-di0xopr0pyny1—1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xy-quinolinyloxy)fluoro-phenyl]-amide;
3 -(4-F1uor0-phenyl)(2-imidaz01—1-y1—ethy1)-2,4-dioxo-1,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
3 -(4-F1u0ro-phenyl)-2,4-di0x0(2-pyraz01—1-y1-ethy1)-1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
3 -(4-F1u0r0-phenyl)-2,4-di0xophenethyl-1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xy-quinolinyloxy)fluoro-phenyl]-amide;
1-[2-(1,3 -Dioxolany1—ethyl)]—3 0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
—149—
1-Diethy1carbamoylmethy1(4-flu0r0-phenyl)-2,4-di0x0-1,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
3 -(4-F1u0ro-pheny1)(2-m0rph01iny1—2-0X0-ethy1)-2,4-di0x0-1,2,3 ,4-
tetrahydro-pyrimidine-S-carb0xy1ic acid [4-(6,7-dimeth0xy-quinoliny10xy)flu0ro-
pheny1]-amide;
3 -(4-F1u0r0-phenyl)-2,4-di0x0[2-(2-0x0-pyrr01idiny1)-ethy1]—1 ,2,3 ,4-
tetrahydro-pyrimidine-S-carb0xy1ic acid [4-(6,7-dimeth0xy-quinoliny10xy)flu0ropheny1
]-amide;
1 -(2-F1u0r0-ethy1)-3 -(4-flu0r0-pheny1)-2,4-diox0-1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xy-quinolinyloxy)fluoro-phenyl]-amide;
[5 -[4-(6,7-Dimeth0xy-quinolinyloxy)fluor0-pheny1carbamoyl](4-flu0r0-
phenyl)-2,4-di0X0-3 ydr0-2H-pyrimidiny1]-acetic acid tert-butyl ester;
[5 -[4-(6,7-Dimethoxyquinoliny10xy)flu0r0phenylcarbamoy1]—3 -(4-
henyl)-2,4-dioxo-3 ,4-dihydr0-2H-pyrimidiny1]-acetic acid;
3 -(4-F1uor0-phenyl)oxaz01ylmethy1-2,4-di0x0-1 ,2,3 ,4-tetrahydr0-pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-phenyl]-amide;
3 -(4-F1u0r0-phenyl)-2,4-di0x0(tetrahydro-fi1rany1methyl)- 1 ,2,3 rahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
3 -(4-F1u0r0-phenyl)-2,4-di0x0(tetrahydro-pyrany1methy1)- 1 ,2,3 ,4-tetrahydr0-
dinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
3 -(4-F1u0r0-pheny1)(2-methy1—thiaz01—4-y1methy1)-2,4-di0xo-1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
1-Cyc10penty1—3-(4-flu0ro-phenyl)-2,4-di0x0- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
carboxylic acid [4-(6,7-dimeth0xy-quinolinyloxy)fluoro-phenyl]-amide;
1-Benzy1—3-(4-flu0ro-phenyl)-2,4-di0x0- 1 ,2,3 ,4-tetrahydro-pyrimidine-5 -
ylic acid [4-(6,7-dimeth0xy-quinolinyloxy)fluoro-phenyl]-amide;
3 -(4-F1u0r0-phenyl)[2-(2-fluor0-pheny1)—ethy1]-2,4-diox0-1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
3 -(4-F1u0r0-phenyl)[2-(4-fluor0-pheny1)—ethy1]-2,4-diox0-1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
1-(2-Cyc10hexy1—ethyl)(4-flu0r0-pheny1)—2,4-di0x0-1,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)flu0r0-pheny1]—
amide;
3 -(4-F1uor0-phenyl)-2,4-di0x0(3-pheny1—propy1)-1 ,2,3 ,4-tetrahydr0-pyrimidinecarb0xy1ic acid [4-(6,7-dimeth0xy-quinolinyloxy)flu0r0-phenyl]-amide;
3 -(4-F1u0r0-phenyl)-2,4-di0xo(2-oxopyrrolidiny1—ethy1)-1,2,3 ,4-
tetrahydro-pyrimidine-S-carb0xy1ic acid [4-(6,7-dimeth0xy-quinoliny10xy)flu0rophenyl
]-amide;
1 -Dimethy1carbamoylmethy1-3 0rophenyl)-2,4-di0xo- 1 ,2,3 ,4-tetrahydr0-
pyrimidinecarb0xy1ic acid [4-(6,7-dimethoxy-quinolinyloxy)fluor0pheny1]—
amide;
1-(1-Dimethy1carbamoy1—2-0X0-pr0py1)(4-flu0ro-phenyl)-2,4-di0x0-1,2,3 ,4-
tetrahydro-pyrimidine-S-carb0xy1ic acid [4-(6,7-dimeth0xy-quinoliny10xy)flu0rophenyl
]-amide;
3 -(4-F1uor0-phenyl)-2,4-di0x0-1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carb0xy1ic acid [4-
(6,7-dimethoxy-quinolinyloxy)fluoro-pheny1]-amide;
3 -(4-F1uor0-phenyl)methy1-2,4-di0x0-1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -
carboxylic acid 7-dimethoxy-quino1iny10xy)fluoro-phenyl]-amide;
1—3-(4-flu0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -carb0xy1ic
acid [4-(6,7-dimethoxy-quinoliny10xy)fluor0-phenyl]-amide;
1-A11y1—3 -(4-flu0r0-phenyl)-2,4-diox0-1 ,2,3 ,4-tetrahydro-pyrimidine-5 -carb0xylic
acid [4-(6,7-dimethoxy-quinoliny10xy)fluor0-phenyl]-amide;
3 uor0-phenyl)-2,4-di0x0-1 ,2,3 rahydr0pyrimidine-5 -carb0xylic acid [4-
imethoxy-quinolinyloxy)-3 ,5-difluor0-pheny1]—amide;
1-Ethy1—3-(4-flu0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -carb0xy1ic
acid [4-(6,7-dimeth0xy-quino1inyloxy)-3,5-diflu0ro-pheny1]—amide;
3 -Ethy1— 1 -(4-flu0ro-pheny1)—2,4-di0x0- 1 ,2,3 ,4-tetrahydr0-pyrimidine-5 -carb0xy1ic
acid [4-(6,7-dimethoxy-quinoliny10xy)fluor0-pheny1]-amide;
1,3 -Dimethy1—2,4-dioxo-1,2,3 ,4-tetrahydr0pyrimidine-5 -carb0xy1ic acid [4-(6,7-
dimethoxy-quino1iny10xy)fluoropheny1]—amide;
1,3-Dicthyl-2,4-di0X0-1,2,3,4-tctrahydro-pyrirnidinccarb0xylic acid [4-(6,7-
dimcthoxy-quino1iny10xy)fluor0-phcny1]—arnidc;
1,3-Diisopr0pyl-2,4-dioxo-1,2,3,4-tctrahydr0-pyrirnidinccarb0xylic acid [4-
(6,7-dimcthoxy-quinolinyloxy)fluoro-phcny1]—arnidc;
1 ,3 -Bis-cyc10propy1rncthy1—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -carb0xylic
acid [4-(6,7-dimcthoxy-quinoliny10xy)fluor0-phcnyl]-arnidc;
1,3-Dia11y1—2,4-di0X0-1,2,3,4-tctrahydr0-pyrimidinccarb0xylic acid [4-(6,7-
dimcthoxy-quino1iny10xy)fluor0-phcny1]—arnidc;
1 ,3 -Bis-(3 -rncthy1—butcnyl)-2,4-di0xo-1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -
carboxylic acid [4-(6,7-dimcthoxy-quino1iny10xy)fluor0-phcnyl]-arnidc;
2,4-Di0X0-1,3-di-prop-2—yny1-1,2,3 ,4-tctrahydro-pyrimidinccarb0xy1ic acid [4-
(6,7-dimcthoxy-quinolinyloxy)fluoro-phcny1]—arnidc;
2,4-Di0X0-1 ,2,3 ,4-tctrahydro-pyrirnidinccarb0xy1ic acid [4-(6,7-dirncthoxy-
quinolinyloxy)flu0ro-phcnyl]-arnidc;
1—2,4-di0X0phcny1—1,2,3 ,4-tctrahydr0-pyrirnidinc-5 -carb0xy1ic acid [4-
imcthoxy-quinolinyloxy)fluoro-phcny1]—arnidc;
l-Isopropyl-2,4-dioxophcny1-1 ,2,3 ,4-tctrahydro-pyrimidinc-5 -carb0xy1ic acid
[4-(6,7-dirncthoxy-quino1iny10xy)—3-fluor0-phcny1]—arnidc;
3 -(4-F1u0ro-phcnyl)-2,4-diox0pr0py1—1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -
carboxylic acid 7-dimcthoxy-quino1inccarb0nyl)flu0ro-phcny1]—arnidc;
luoro-phcnyl)isopropyl-3 ,5 -2,3 ,4,5 -tctrahydr0-[1,2,4]triazinc
carboxylic acid [4-(6,7-dirncthoxy-quinolinyloxy)flu0r0-phcny1]—arnidc;
4-(4-Fluorophcnyl)rncthyl-3 ,5 -di0X0-2,3 ,4,5 -tctrahydr0-[1 ,2,4]triazinc
carboxylic acid [4-(6,7-dimcthoxy-quino1iny10xy)fluor0-phcnyl]-arnidc;
2-Ethy1—4-(4-fluor0-phcnyl)-3 ,5 -di0X0-2,3 ,4,5 -tctrahydr0-[1,2,4]triazinc
carboxylic acid [4-(6,7-dimcthoxy-quino1iny10xy)fluor0-phcnyl]-arnidc;
4-(4-Fluorophcnyl)isopr0py1—3,5-di0xo-2,3,4,5-tetrahydr0-[1,2,4]triazinc
carboxylic acid [4-(2,3-dihydr0-[1,4]di0xin0[2,3-g]quinoliny10xy)—3-flu0r0phcny1]—
amide;
4-(4-F1u0ro-phcny1)-3,5-diox0-2,3,4,5-tetrahydro-[1 ,2,4]triazinccarboxylic acid
[4-(6,7-dirncthoxy-quino1iny10xy)—3-fluor0-phcny1]—arnidc;
4-(4-F1u0r0phcny1)(2-hydr0xycthy1)—3,5-di0X0-2,3,4,5-tetrahydro-
[1,2,4]triazinccarboxylic acid [4-(6,7-dirncth0xyquinoliny10xy)—3-fluor0phcny1]—
amide;
WO 74633
2-Ethy1(4-fluor0pheny1)-3 ,5-di0X0-2,3 ,4,5 -tetrahydr0 [1 ,2,4]triazine
carboxylic acid [4-(6,7-diethoxy-quino1iny10xy)fluor0-pheny1]—amide;
4-(4-Fluoro-pheny1)isopropy1-3 ,5 -di0X0-2,3 ,4,5 -tetrahydr0-[1,2,4]triazine
ylic acid [5-(6,7-dimethoxy-quino1iny10xy)-pyridiny1]-amide;
4-(4-Fluorophenyl)isopr0py1-3,5-di0xo-2,3,4,5-tetrahydr0-[1,2,4]triazine
carboxylic acid [3-flu0r0(7-meth0xyquin01iny10xy)-pheny1]-amide;
4-(4-F1uoropheny1)-3 ,5 -di0X0(2-0X0-pr0py1)-2,3 ,4,5 -tetrahydr0-[1,2,4]triazine-
6-carb0xy1ic acid [4-(6,7-dimethoxyquino1iny10xy)flu0r0pheny1]—amide;
4-(4-F1uoro-pheny1)-3 ,5-dioxopr0pyny1-2,3 ,4,5 -tetrahydr0-[1,2,4] triazine
carboxylic acid [4-(6,7-dimethoxy-quino1iny10xy)fluor0-pheny1]-amide;
2-Methy1-3,5-di0X0-2,3,4,5-tetrahydr0-[1,2,4]triazinecarb0xy1ic acid [4-(6,7-
oxy-quino1iny10xy)—3-fluor0-pheny1]—amide;
2-Methy1-3 ,5-diox0pr0pyny1-2,3 ,4,5 -tetrahydr0-[1,2,4]triazinecarb0xy1ic
acid [4-(6,7-dimethoxy-uino1iny10xy)fluor0-pheny1]—amide;
2-Methy1(5-methy1-isoxaz01y1methy1)-3,5-di0X0-2,3,4,5-tetrahydro-
[1,2,4]triazinecarboxy1ic acid [4-(6,7-dimeth0xy-quin01iny10xy) fluor0-pheny1]—
amide;
2-Methy1-3 ,5 -di0xopentyny1-2, 3 ,4,5 -tetrahydr0-[1,2,4]triazinecarb0xy1ic
acid [4-(6,7-dimethoxy-uino1iny10xy)fluor0-pheny1]—amide;
4-(4-Hydr0xy-but—2-yny1)—2-methy1-3 ,5-di0X0-2,3 ,4,5 -tetrahydro-[1 ,2,4] triazine-
0xy1ic acid [4-(6,7-dimethoxy-quino1iny10xy)—3-fluor0-pheny1]—amide;
4-(1 ,5 hy1-1H-pyraz01y1methy1)—2-methy1-3 ,5 -di0X0-2,3 ,4,5 -tetrahydr0-
[1,2,4]triazinecarb0xy1ic acid [4-(6,7-dimeth0xyquin01iny10xy)—3-fluor0pheny1]—
amide;
2-Methy1-3 ,5 -di0xo(2—pyraz01y1-ethy1)-2,3 ,4,5 -tetrahydr0- [1 ,2,4] triazine
carboxylic acid [4-(6,7-dimethoxyquino1iny10xy)fluor0pheny1]—amide;
2-Methy1(1-methy1-1H-[1,2,4]triaz01y1methy1)-3 ,5-di0X0-2,3 ,4,5 -tetrahydr0-
[1,2,4]triazinecarboxy1ic acid [4-(6,7-dimeth0xy-quin01iny10xy)fluor0-pheny1]-
amide;
omethy1methy1-3 ,5-dioxo-2, 3 ,4,5 -tetrahydr0- [1 ,2,4]triazine
carboxylic acid [4-(6,7-dimethoxy-quino1iny10xy)fluor0-pheny1]-amide;
4-Ethy1methy1-3 x0-2,3 ,4,5-tetrahydr0-[1,2,4]triazinecarb0xy1ic acid [4-
(6,7-dimeth0xyquino1iny10xy)—3-fluor0-pheny1]—amide;
4-A11y1—2-mcthy1—3,5-di0X0-2,3,4,5-tetrahydro-[ 1 ,2,4]triazinccarboxylic acid [4-
(6,7-dimcthoxy-quinolinyloxy)fluoro-phcny1]—arnidc;
opropylmcthyl-Z-rncthy1—3 ,5-di0X0-2,3 ,4,5 -tctrahydro-[1 ,2,4]triazinc
carboxylic acid [4-(6,7-dirncthoxy-quinolinyloxy)flu0r0-phcny1]—arnidc;
y1—3,5-dioxo(tctrahydr0-pyrany1rncthyl)-2,3,4,5-tetrahydr0-
[1,2,4]triazinccarboxy1ic acid [4-(6,7-dirncth0xy-quinoliny10xy)- 3-flu0ro-phcnyl]—
amide;
4-Isobuty1rncthyl-3,5-diox0-2,3,4,5-tetrahydro-[1 ,2,4]triazinccarboxylic acid
7-dirncthoxy-quino1iny10xy)—3-fluor0-phcny1]—arnidc;
4-Cyc10buty1rncthy1—2-rncthyl-3 ,5 -di0X0-2,3 ,4,5 -tctrahydr0- [1 ,2,4]triazinc
carboxylic acid [4-(6,7-dimcthoxy-quino1iny10xy)fluor0-phcnyl]-arnidc;
4-(2,2-Dirncthy1propy1)rncthy1—3 , 5 -di0X0-2,3 ,4,5 -tctrahydr0-[1 ,2,4]triazinc
carboxylic acid [4-(6,7-dirncthoxyquino1iny10xy)fluor0phcny1]—arnidc;
:2-Methyl(2-rncthy1—butyl)-3 ,5 -di0X0-2,3 ,4,5 hydr0-[1,2,4]triazinc
carboxylic acid [4-(6,7-dirncth0xy-quinolinyloxy)fluoro-phcnyl] -arnidc;
3 -(4-F1u0r0-phcnyl)-1 -rncthy1—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -
carboxylic acid [4-([1,3]di0x010[4,5 -g]quin01iny10xy)fluoro-phcnyl] -arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -carb0xy1ic
acid [4-(2,3 -dihydro-[1 dioxino [2,3 n01iny10xy)-3 -flu0r0-phcny1]—arnidc;
, 4]
2-Cyclopr0pylmcthyl(4-fluorophcnyl)—3 ,5-di0X0-2,3 ,4,5 -tctrahydr0-
[1 ,2,4]triazinccarboxylic acid [4-(6,7-dirncth0xy-quino1inyloxy)flu0r0-phcny1]—
amide;
1-Ethy1—3-(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -carb0xy1ic
acid [4-(6,7-dirncthoxy-quinolinylamino)-phcnyl]-arnidc;
3 -(4-F1uor0phcnyl)—1-isopr0py1—2,4-diox0-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -
carboxylic acid [4-(6,7-dimcthoxyquino1iny1amino)-phcny1]-arnidc;
4-(4-Fluoro-phcnyl)isopropyl-3 ,5 -di0X0-2,3 ,4,5 hydr0-[1,2,4]triazinc
carboxylic acid [4-(6,7-dimcthoxy-quino1inylamin0)-phcnyl]-arnidc;
1-cthy1—3 -(4-flu0r0-phcnyl)-2,4-di0x0-1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -carb0xylic
acid [4-(6,7-dirncth0xy-quinolinylsu1fany1)-phcnyl]-arnidc;
3 u0r0-phcny1)isopr0py1—2,4-di0xo-1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -
ylic acid [4-(6,7-dirncthoxy-quinolinylsu1fanyl)-phcnyl]-arnidc;
3 -(4-F1uor0phcnyl)—1-isopr0py1—2,4-diox0-1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -
carboxylic acid {4-[(6,7-dirncth0xy-quino1iny1)-rncthy1—arnino]-phcny1} -arnidc;
- 1 5 4-
1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -carb0xy1ic
acid {4-[(6,7-dimcthoxy-quinoliny1)-rncthylarnin0]-phcny1}-arnidc;
3 -(4-F1u0r0-phcny1)isopr0py1—2,4-di0xo-1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -
carboxylic acid [4-(6,7-dimcthoxy-quinazo1iny10xy)—phcnyl]-arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -carb0xy1ic
acid [4-(6,7-dimcthoxy-quinazo1iny10xy)—phcnyl]-arnidc;
1-Ethy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0pyrirnidinc-5 -carb0xy1ic
acid [4-(6,7-dirncth0xy-quinoliny10xy)rncthoxyphcny1]-arnidc;
1-Mcthy1—3-(4-flu0r0-phcnyl)-2,4-di0X0-1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -
carboxylic acid [4-(6,7-dimcth0xy-quinoliny10xy)mcthoxy-phcnyl]-arnidc;
1 -Isopr0py1—3 -(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -
carboxylic acid [4-(6,7-dimcth0xy-quinoliny10xy)mcthoxy-phcnyl]-arnidc;
1-Mcthy1—3-(4-flu0rophcnyl)-2,4-di0xo- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xy1ic
acid [4-(6,7-dirncthoxy-quino1inyloxy)-2,3-diflu0ro-phcny1]—arnidc;
1-Ethy1—3-(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xy1ic
acid [4-(6,7-dirncthoxy-quino1inyloxy)-2,3-diflu0ro-phcny1]—arnidc;
1—3-(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xy1ic
acid 7-dirncth0xy-quinolinyloxy)rncthy1—phcnyl]—arnidc;
3 -(4-F1uor0-phcnyl)-2,4-di0x0-1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -carb0xy1ic acid [4-
(6,7-dirncthoxy-quinolinyloxy)-3 -rncthy1—phcny1]—arnidc;
3 -(4-F1uor0-phcnyl)-2,4-di0x0-1 ,2,3 ,4-tctrahydro-pyrirnidinc-5 -carb0xy1ic acid [4-
irncthoxy-quino1iny10xy)rncth0xy-phcny1] -arnidc;
1-Ethy1—3-(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xy1ic
acid [4-(6,7-dimcthoxy-quinolinyloxy)mcthoxy-phcnyl]-amidc;
1-Ethy1—3-(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xy1ic
acid [3 -ch10r0(6,7-dirncth0xy-quinolinyloxy)mcth0xy-phcny1] -arnidc;
1—3-(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xy1ic
acid [4-(6,7-dimcthoxy-quinolinyloxy)dimcthylarnino-phcnyl]-arnidc;
3 -(4-F1u0r0-phcny1)isopr0py1—2,4-di0xo-1 ,2,3 ,4-tctrahydr0-pyrirnidinc-5 -
carboxylic acid 7-dimcth0xy-quinoliny10xy)dirncthy1arnino-phcnyl]-arnidc;
1-Ethy1—3-(4-flu0ro-phcny1)—2,4-di0x0- 1 ,2,3 ,4-tctrahydr0-pyrimidinc-5 -carb0xy1ic
acid [4-(6,7-dimcthoxy-quinolinyloxy)isopropy1—phcnyl]-arnidc;
3 -(4-F1u0r0-phcny1)isopr0py1—2,4-di0xo-1 ,2,3 ,4-tctrahydr0-pyrirnidinc
ylic acid [4-(6,7-dimcth0xy-quinoliny10xy)isopropy1—phcnyl]-arnidc;
- 1 5 5 -
2012/065019
l-Ethyl(4-fluoro-phenyl)—2,4-dioxo- l ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)-2,3-dimethyl-phenyl]-amide;
3 -(4-Fluoro-phenyl)- l opyl-2,4-dioxo-l ,2,3 ,4-tetrahydro-pyrimidine
carboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)-2,3-dimethyl-phenyl]-amide;
l-Ethyl(4-fluoro-phenyl)—2,4-dioxo- l ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)trifluoromethyl-phenyl]-amide;
3 -(4-Fluoro-phenyl)- l -isopropyl-2,4-dioxo-l ,2,3 ,4-tetrahydro-pyrimidine
carboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)trifluoromethyl- phenyl]-amide;
l-Ethyl(4-fluoro-phenyl)—2,4-dioxo- l ,2,3 ,4-tetrahydro-pyrimidine-5 -carboxylic
acid [4-(6,7-dimethoxy-quinolinyloxy)-3,5-dimethyl-phenyl]-amide;
3 -(4-Fluoro-phenyl)- l opyl-2,4-dioxo-l ,2,3 ,4-tetrahydro-pyrimidine
carboxylic acid 7-dimethoxy-quinolinyloxy)-3,5-dimethyl-phenyl]-amide;
3 -(4-Fluoro-phenyl)- l -isopropyl-2,4-dioxo-l ,2,3 ,4-tetrahydro-pyrimidine
carboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)methyl-phenyl]-amide;
2-Ethyl(4-fluoro-phenyl)—3 ,5-dioxo-2,3 ,4,5-tetrahydro- l ,2,4-triazine- 6-
carboxylic acid [5-(6,7-dimethoxy-quinolinyloxy)-pyridinyl]-amide;
2-Ethyl(4-fluoro-phenyl)—3 xo-2,3 ,4,5-tetrahydro- l riazine- 6-
carboxylic acid [4-(6,7-dimethoxy-quinolinyloxy)isopropyl-phenyl]-amide; or
4-(4-Fluoro-phenyl)isopropyl-3 ,5 -dioxo-2,3 ,4,5 -tetrahydro-l ,2,4-triazine- 6-
ylic acid [4-(6,7-dimethoxy-quinolinyloxy)methoxy-phenyl]-amide; or
a pharmaceutically acceptable salt thereof.
19. A method of treating a subject suffering from an AXL- or c-MET-mediated
disorder or condition comprising administering to the t a eutically effective
amount of a compound according to any one of preferred Embodiments l to 18.
. A method according to preferred Embodiment 19 wherein the AXL- or c-MET-
mediated disorder or condition is the development of resistance to cancer therapies.
21. A compound according to any one of preferred Embodiments l to 18 for use in the
treatment of a subject suffering from an AXL- or c-MET-mediated disorder or condition.
22. The method of preferred Embodiment 19 wherein the AXL- or c-MET-mediated
disorder or condition is cancer.
- 1 5 6-
23. A compound according to preferred Embodiment 21 wherein the AXL- or c-MET-
mediated disorder or condition is cancer.
24. The method of preferred Embodiment 19 wherein the AXL- or c-MET-mediated
disorder is ed from chronic myelogenous leukemia, chronic myeloproliferative
disorder, lung cancer, prostate cancer, esophageal cancer, ovarian cancer, pancreatic
, gastric cancer, liver cancer, thyroid cancer, renal cell carcinoma, glioblastoma,
breast cancer, acute myeloid ia, colorectal cancer, uterine cancer, malignant
glioma, uveal melanoma, osteosarcoma and soft tissue sarcoma.
. A compound according to preferred Embodiment 21 wherein the AXL- or c-MET-
mediated disorder is selected from chronic myelogenous leukemia, chronic
myeloproliferative disorder, lung cancer, prostate cancer, esophageal cancer, ovarian
cancer, pancreatic cancer, c cancer, liver cancer, thyroid , renal cell carcinoma,
glioblastoma, breast cancer, acute d leukemia, colorectal cancer, uterine cancer,
malignant glioma, uveal melanoma, osteosarcoma and soft tissue sarcoma.
26. A method of treating a proliferative disorder in a t in need thereof,
comprising administering to the subject a therapeutically effective amount of a compound
ing to any one of preferred Embodiments l to 18.
27. A compound according to any one of preferred Embodiments l to 18 for use in the
treatment of a subject suffering from a proliferative disorder.
28. A method according to red Embodiment 26 wherein the proliferative
disorder is .
29. A nd according to preferred Embodiment 27 wherein the erative
disorder is cancer.
. A method according to preferred Embodiment 26 wherein the proliferative
disorder is ed from chronic myelogenous leukemia, chronic roliferative
disorder, lung cancer, prostate , esophageal cancer, ovarian cancer, pancreatic
- l 5 7-
WO 74633
cancer, gastric cancer, liver cancer, thyroid cancer, renal cell carcinoma, glioblastoma,
breast cancer, acute myeloid leukemia, ctal cancer, uterine cancer, malignant
glioma, uveal melanoma, osteosarcoma and soft tissue sarcoma.
3 l. A compound according to preferred ment 29 wherein the proliferative
disorder is selected from chronic myelogenous leukemia, chronic myeloproliferative
disorder, lung , prostate cancer, esophageal cancer, ovarian cancer, pancreatic
cancer, gastric cancer, liver cancer, thyroid cancer, renal cell carcinoma, glioblastoma,
breast cancer, acute myeloid leukemia, colorectal , uterine cancer, malignant
glioma, uveal melanoma, osteosarcoma and soft tissue sarcoma.
32. A pharmaceutical composition comprising a compound according to any one of
preferred Embodiments l to 18 and a pharmaceutically able carrier, diluents or
excipient therefor.
33. A compound of Formula I or a salt therof,
R3 X/N O
R l I T
Rd \ Y O O
Ra R13
Rb N)
wherein:
E is chosen from H, C1_6alkyl ally substituted by 1-6 R19, C2_6alkenyl
optionally substituted by 1-6 R19, C2_6alkynyl optionally substituted by 1-6 R19,
phenyl optionally substituted by 1-6 R19, and C3_6cycloalkyl optionally
substituted by 1-6 R19;
G is chosen from H, C1_6alkyl optionally substituted by 1-3 R19, C2_6alkenyl
optionally substituted by 1-3 R19, C2_6alkynyl optionally substituted by 1-3 R19 u
phenyl optionally substituted by 1-3 R19, C3_6cycloalkyl optionally substituted
by 1-3 R19, and 3-6 membered heterocyclyl optionally substituted by 1-3 R19;
X is N or C-R4;
Y is N or C-Rld;
R3 is H or C1_6alkyl;
D is O S CHOH NH or
, , C(—O) , , CH2 , NC1_6alkyl—;
W is CH or N;
Ra, Rb, RC, and Rd are independently chosen from H, kyl optionally
substituted by 1-6 R119, —CN, and —OR110; or Ra and Rb can, together with the
atoms linking them, form a 3-6 membered heterocyclyl optionally substituted
by 1-6 R119;
Rla, Rlb, R10, and Rld are ndently chosen from H, C1_6alkyl optionally
substituted by 1-6 R119, C3_6cycloalkyl optionally substituted by 1-6 R119, 3-6
membered heterocyclyl optionally substituted by 1-6 R119, halogen, —CN, —
NRmRm, and —OR110;
R4 is chosen from H and C1_6alkyl;
R19 at each occurrence is independently chosen from C1_6alkyl ally
tuted by 1-6 R39, phenyl optionally substituted by 1-6 R39, C3_6cycloalkyl
optionally substituted by 1-6 R39, 3-6 membered heterocyclyl optionally
substituted by 1-6 R39, 5-6 membered heteroaryl ally substituted by 1-6
R39, halogen, —CN, —C(=O)OR3°, —C(=O)NR32R33, —NR32R33, —0R3°, and =0;
R30, R32 and R33 at each occurrence is ndently chosen from H, C1_6alkyl, C1-
6halolkyl, phenyl, benzyl, C5_6cycloalkyl, 5-6 membered heterocyclyl, and 5-6
membered heteroaryl; or R32 and R33 may form, together with the nitrogen
atom to which they are ed, a 5-6 membered heterocyclyl or a 5-6
membered heteroaryl;
R39 at each occurrence is independently chosen from kyl, C1_6haloalkyl, and
benzyl;
R110, R112, and R113 at each occurrence is independently chosen from H and C1-
6alkyl ally substituted by 1-3 R129;
-lS9-
R119 at each occurrence is independently chosen from C1_6alkyl optionally
substituted by 1-3 R159 5-6 membered heterocyclyl optionally substituted by
l-3 R159, and n;
R129 and R159 at each occurrence is independently chosen from C1_6alkyl, C1_6-
haloalkyl, benzyl, and halogen; and
n at each occurrence is independently chosen from 0, l, and 2.
34. A compound according to preferred Embodiment 33, wherein E is chosen from H,
C1_6alkyl ally substituted by 1-3 R19, C2_6alkenyl, C2_6alkynyl optionally tuted
by —OH, phenyl optionally substituted by halogen, and C3_6cycloalkyl.
34. A compound according to preferred Embodiment 33, wherein E is chosen from H,
kyl optionally substituted by 1-3 R19, C2_6alkenyl, C2_6alkynyl optionally substituted
by —OH, phenyl optionally substituted by halogen, and cyclohexyl.
. A compound according to preferred Embodiment 33, wherein E is chosen from C1_
6alkyl ally substituted by R19, , and p-fluorophenyl.
36. A compound according to preferred Embodiment 33, wherein E is p-fluorophenyl.
37. A compound ing to any of preferred Embodiments 33-36, wherein G is
chosen from H, C1_6alkyl optionally substituted by 1-3 R19, C2_6alkenyl optionally
substituted by 1-3 n, kynyl, phenyl optionally substituted by 1-3 halogen, C3-
6cycloalkyl, and 3-6 membered heterocyclyl.
38. A compound according to any of preferred Embodiments 33-36, wherein G is
chosen from H, C1_6alkyl optionally substituted by 1-3 R19, C3_6alkenyl optionally
substituted by 1-3 fluoro, C3_6alkynyl, phenyl optionally substituted by 1-3 fluoro, C3-
6cycloalkyl, and 6 ed heterocyclyl.
39. A compound according to any of preferred Embodiments 33-36, wherein G is
chosen from H, C1_6alkyl optionally substituted by R19, C3_6alkenyl optionally substituted
by 2 fluoro, C3_6alkynyl, phenyl optionally tuted by fluoro, C3_6cycloalkyl, and
tetrahydropyranyl.
- l 60-
40. A compound according to any of preferred Embodiments 33-36, wherein G is C1-
6alkyl optionally substituted by cyclopropyl or —OH.
41. A compound according to any of preferred Embodiments 33-40, wherein X is N.
42. A compound according to any of preferred Embodiments 33-40, wherein X is C-
43. A compound according to any of preferred Embodiments 33-42, wherein Y is N.
44. A compound according to any of preferred Embodiments 33-42, wherein Y is CH.
45. A compound according to any of red Embodiments 33-42, wherein Y is C-
Rld.
46. A compound according to any of red ments 33-45, wherein R3 is H.
47. A compound according to any of preferred Embodiments 33-46, wherein D is —O—,
—S—, —C(=O)—, —CHOH—, or —CH2—.
48. A compound according to any of preferred Embodiments 33-46, wherein D is —O—,
—, —CHOH—, or —CH2—.
49. A compound according to any of preferred Embodiments 33-46, wherein D is —O—.
50. A compound according to any of preferred Embodiments 33-49, wherein W is CH.
51. A nd according to any of red Embodiments 33-50, wherein Ra, Rb,
RC, and Rd are independently chosen from H, C1_6alkyl optionally substituted by 1-6 R119,
—CN, and —OR110; or Ra and Rb can, er with the atoms linking them, form a 5-6
membered heterocyclyl.
-l6l-
52. A compound according to any of preferred Embodiments 33-50, wherein Ra is
chosen from H, —CN, and —OC1_6alkyl; Rb is chosen from H, C1_6alkyl optionally
substituted by 1-6 R119, and ; RC is chosen from H and —OC1_6alkyl; and Rd is
chosen from H and alkyl; or Ra and Rb can, together with the atoms linking them,
form a 5-6 membered heterocyclyl.
53. A nd according to any of preferred Embodiments 33-50, wherein Ra is
chosen from H, —CN, and alkyl; Rb is chosen from H, C1_6alkyl optionally
substituted by 6-membered heterocyclyl, —OH, —OC1_6alkyl, —OCH2phenyl, —OC1_6alkyl-
O-C1_6alkyl; RC is chosen from H and —OC1_6alkyl; and Rd is chosen from H and —OC1_
; or Ra and Rb can, er with the atoms g them, form a 5-6 membered
heterocyclyl.
54. A compound according to any of preferred Embodiments 33-50, wherein Ra is
chosen from H, —CN, and —OC1_6alkyl; Rb is chosen from H, C1_6alkyl optionally
substituted by morpholinyl, —OH, —OC1_6alkyl, —OCH2phenyl, —OC1_6alkyl-O-C1_6alkyl; RC
is chosen from H and —OC1_6alkyl; and Rd is chosen from H and —OC1_6alkyl; or Ra and Rb
O O
< E
together form 0or O.
55. A compound according to any of preferred Embodiments 33-50, wherein Ra is
chosen from H and —OC1_6alkyl; Rb is chosen from H and —OC1_6alkyl; Rc is H; and Rd is
<0 E0
0 O
chosen from H and —OC1_6alkyl; or Ra and Rb together form or .
56. A compound according to any of preferred Embodiments 33-50, wherein Ra is
chosen from H and —OC1_6alkyl; Rb is chosen from H and —OC1_6alkyl; RC is H; and Rd is
O O
< E
H; or Ra and Rb together form 0or 0.
-l62-
2012/065019
57. A compound according to any of preferred ments 33-50, wherein RC and Rd
<0 [0
O O
are H, and Ra and Rb are —OC1_6alkyl; or Ra and Rb together form or .
58. A compound according to any of preferred Embodiments 33-50, wherein Ra is —
OC1_6alkyl; Rb is —OC1_6alkyl; Rc is H; and Rd is H.
59. A compound according to any of preferred Embodiments 33-40 or 42-58, wherein
R4 is H.
60. A compound according to any of preferred Embodiments 33-59, wherein Rla, Rlb,
R10, and Rld are independently chosen from H, C1_6alkyl, C1_6haloalkyl, cloalkyl,
halogen, —NH2, —NHC1_6alkylz, 6alkyl)2, —OH, and —OC1_6alkyl.
61. A compound according to any of preferred Embodiments 33-59, wherein Rla, Rlb,
R10, and Rld are independently chosen from H, C1_3alkyl, C1_3haloalkyl, ropyl,
halogen, and —OC1_3alkyl.
62. A compound according to any of preferred Embodiments 33-59, wherein Rla, Rlb,
R10, and Rld are independently chosen from H, halogen, and —OC1_3alkyl.
63. A compound according to any of preferred Embodiments 33-59, wherein Rla, Rlb,
R10, and Rld are independently chosen from H and halogen.
64. A compound according to any of preferred Embodiments 33-59, wherein Rla, R10,
and Rld are H and Rlb is chosen from H, C1_3alkyl, C1_3haloalkyl, cyclopropyl, halogen,
and —OC1_3alkyl.
65. A compound according to any of red Embodiments 33-59, wherein Rla, R10,
and Rld are H and Rlb is chosen from H, halogen, and —OC1_3alkyl.
66. A compound according to any of red Embodiments 33-59, wherein Rla, R10,
and Rld are H and Rlb is fluoro.
67. A compound according to any of preferred ments 33-66, wherein R19 at
each occurrence is independently chosen from kyl, phenyl optionally substituted by
l-3 halogen, C3_6cycloalkyl, 5-6 membered heterocyclyl, 5-6 membered heteroaryl
optionally substituted by l-3 C1_6alkyl, halogen, —CN, —C(=O)OH, —C(=O)OC1_6alkyl, —
C(=O)N(C1_6alkyl)2, —C(=O)pyrrolidinyl, —C(=O)morpholinyl, 6alkyl)2, —OH, —
OC1_6alkyl, —Obenzyl, and =0.
68. A compound according to any of preferred ments 33-67, wherein R30, R32
and R33 at each occurrence is independently chosen from H and C1_6alkyl.
69. A compound according to any of preferred Embodiments 33-68, wherein R39 at
each occurrence is C1_6alkyl.
70. A nd according to any of preferred Embodiments 33-69, wherein R110,
R112, and R113 at each occurrence is independently chosen from H and C1_6alkyl.
71. A compound according to any of preferred Embodiments 33-70, wherein R at
each occurrence is independently chosen from 6 membered heterocyclyl and halogen.
72. A compound according to any of preferred Embodiments 33-70, wherein R119 at
each occurrence is independently chosen from morpholinyl and fluoro.
73. A compound ing to any of preferred Embodiments 33-72, wherein R129 and
R159 at each occurrence is ndently chosen from C1_6alkyl and halogen.
74. A compound according to any of preferred Embodiments 33-73, wherein n at each
occurrence is 2.
75. A compound according to red Embodiment 33, wherein E is p-fluorophenyl;
G is C1_4alkyl optionally substituted by cyclopropyl, —OH, or -OC1_3alkyl; X, Y, and W are
WO 74633
CH; R3, R0, Rd, Rlb and R10 are H; D is —O—; Ra and Rb are —OCH3 or together form
[:f3
or ; and Rla is fluoro.
Claims (1)
1. A compound of Formula I or a salt form thereof, Ric T3 Xl/NYO R1b NWN / \ Rd \ IY O 0 R3 \ W Rla Rb N/J 5 Re Formula I wherein: E and G are independently chosen from H, C1_6alkyl optionally substituted by 1-6 10 R19, C2_6alkenyl optionally substituted by 1-6 R19, C2_6alkynyl optionally substituted by 1-6 R19, €6-11an optionally substituted by 1-6 R19, c3- 11cycloalkyl optionally substituted by 1-6 R19, 3—15 membered heterocyclyl optionally substituted by 1-6 R19, 5-15 ed heteroaryl optionally substituted by 1-6 R19, —C(=O)R20, —C(=O)OR2°, —C(=O)NR22R23, — 15 R2°, and —S(=O)2NR22RZ3; X is N or C-R4; Y is N or C-Rld; R3 is H or C1_6alkyl; D is O S SO CHOH , , , SOZ , C(—O) , , CH2 NH or , NC1_6alkyl—; 20 W is CH or N; Ra, Rb, RC, Rd, Rla, Rlb, R10, Rld, and R4 are independently chosen from H, C1- 6alkyl optionally substituted by 1-6 R119 substituted by , kenyl optionally 1-6 R119, kynyl optionally substituted by 1-6 R119, C6_11aryl optionally substituted by 1-6 R119, C3_11cycloalkyl optionally substituted by 1-6 R119, 3-15 25 membered heterocyclyl optionally tuted by 1-6 R119 5-15 membered -l66-
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ712194A NZ712194B2 (en) | 2011-11-14 | 2012-11-14 | Uracil derivatives as axl and c-met kinase inhibitors |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161559312P | 2011-11-14 | 2011-11-14 | |
| US61/559,312 | 2011-11-14 | ||
| PCT/US2012/065019 WO2013074633A1 (en) | 2011-11-14 | 2012-11-14 | Uracil derivatives as axl and c-met kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ624945A NZ624945A (en) | 2015-09-25 |
| NZ624945B2 true NZ624945B2 (en) | 2016-01-06 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9745283B2 (en) | Uracil derivatives as AXL and c-MET kinase inhibitors | |
| KR102075886B1 (en) | Novel pyrazolo [3,4-d] pyrimidine compounds or salts thereof | |
| US20070208053A1 (en) | Fused heterobicyclic kinase inhibitors | |
| CA2888480C (en) | Heteroaryl linked quinolinyl modulators of ror.gamma.t | |
| CA2558278A1 (en) | Diaryl-substituted five-membered heterocycle derivative | |
| KR20140051944A (en) | 4-piperidinyl compounds for use as tankyrase inhibitors | |
| CN107835811A (en) | Aniline derivatives and uses thereof | |
| JP5063708B2 (en) | Quinolone compounds and pharmaceutical compositions | |
| JP2005511760A (en) | New compounds | |
| JP2018087173A (en) | Malignant brain tumor drug | |
| NZ624945B2 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| NZ712194B2 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| HK1227035A1 (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| HK1227035A (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| HK1202528B (en) | Uracil derivatives as axl and c-met kinase inhibitors | |
| US20250353831A1 (en) | Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same | |
| JP2013234123A (en) | 3-pyrazolyl-2-pyridone derivative |